












EVALUATION OF NOVEL ANTIMALARIAL AND 






Department of Chemistry 
University of Cape Town 
 























The copyright of this thesis vests in the author. No 
quotation from it or information derived from it is to be 
published without full acknowledgement of the source. 
The thesis is to be used for private study or non-
commercial research purposes only. 
 
Published by the University of Cape Town (UCT) in terms 
of the non-exclusive license granted to UCT by the author. 
 
 





I, Natasha Strydom, declare that: 
i) this thesis is my own unaided work, both in conception and execution, and that apart from the 
normal guidance of my supervisors, I have received no assistance apart from that acknowledged; 
ii) neither the substance nor any part of the thesis has been submitted in the past, or is being, or is 
to be submitted for a degree in the University of Cape Town or any other University. 
I grant the University of Cape Town free licence to reproduce the thesis in whole or in part for the 
purpose of research. 

















Preclinical pharmacokinetic evaluation of novel antimalarial and anti-tuberculosis 
drug leads 
Natasha Strydom 
Preclinical pharmacokinetics relies on efficient and accurate screening to select clinical candidates 
from early leads. Poor pharmacokinetic interpretation can disadvantage drug discovery by 
promoting inadequate compounds and expelling potential drug candidates. 
Objectives of this project included pharmacokinetic evaluation of antimalarial and 
anti-tuberculosis lead compounds with techniques aimed at improving preclinical pharmacokinetic 
outcomes. 
This included mechanistic pharmacokinetic approaches such as non-linear mixed effects (NLME) 
modelling in comparison with traditional non-compartmental analysis. Where appropriate, 
pharmacokinetic methods were expanded to include organ distribution and capsule dosing in mice 
to bridge techniques from discovery to early development. 
Three benzoxazole amodiaquine analogues possessing equipotent in vitro antiplasmodial activity 
and showed diverse in vivo efficacy in a malaria mouse model. Evaluation of their respective 
pharmacokinetics in mice showed their in vivo exposures could translate to in vivo efficacy. 
Retrospective PK/PD simulations point to a time above IC50 drive in efficacy. 
Pharmacokinetic evaluation of an aminopyridine antimalarial compound in its cyclodextrin 
inclusion complex revealed a pH dependent increase in solubility that reduced variance, likely due 
to favoured intestinal absorption. 
Investigation of two novel fusidic acid C-3 ester prodrugs aimed at repositioning fusidic acid for 
tuberculosis, showed high concentrations of the rodent specific 3-epifusidic acid metabolite that 
greatly reduced exposure of fusidic acid in mice. Further organ distribution studies showed a 
prodrug strategy is still viable for repositioning fusidic acid for tuberculosis, but that rodent models 
are inappropriate for further evaluation. 
NLME modelling successfully provided unique mechanistic and mathematical insight of 
pharmacokinetic profiles of new leads. The level of interpretation on pharmacology parameters 
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1 INTRODUCTION 
1.1 Project introduction  
Drug discovery has taken immense strides to improve the pharmacokinetics of drug leads through 
compound optimisation. Attrition rates of compounds due to poor pharmacokinetics decreased 
from 40% in 1991 to 10% in 2010.1,2 However, the translational gap from drug discovery to clinical 
trials still remains devastating with thousands of compounds lost to the “Valley of Death,” causing 
a stagnation in approval rate, while research and development expenditure continues to increase,3–
5 Figure 1-1. The aim of this thesis was to evaluate the pharmacokinetics of novel antimalarial and 
anti-tuberculosis drug leads with an emphasis on improving pharmacokinetic techniques. These 
techniques included non-linear mixed effects modelling and the practicality of its implementation 
to improve pharmacokinetic outcomes and bridge the gaps in screening cascades. 
 
Figure 1-1: Translational gap in drug discovery6 
Schema of the drug discovery and development showing the attrition of compounds from drug discovery to approval, 
requiring 5000 – 10000 compounds to have one successful candidate requiring up to 15 years of development. 
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1.2 Drug discovery and preclinical pharmacology 
AstraZeneca reviewed their drug attrition rates from 2010 to 
2015 and found efficacy and safety to be major factors, Figure 
1-2.3 Importantly the compounds lost due to preclinical 
pharmacokinetics/pharmacodynamics (PK/PD) was 3%, while 
Phase 1 trials showed an increased loss of 15%. This highlights 
an important issue in preclinical pharmacokinetics regarding 
animal translation to human response.7 The drugs that do make 
it to market also often need additional dosing changes, 
suggesting that our current pharmacokinetic and 
pharmacodynamics practices show large inefficiencies.8 
The lack of animal translation and the stagnation of drug 
approval prompted the Food and Drug Administration (FDA) 
of the United Sates to introduce the Critical Path Initiative in 
2004. A key objective stated in Article 30 of the FDA Critical 
Path Opportunities (2006)9 is: 
 
30. Improving Extrapolation from Animal Data to Human Experience.  
We urgently need new methods to bridge from animal data to predicted human 
experience, for both product efficacy and for product safety ..... Establishing reliable 
correlations between animal pharmacokinetic/pharmacodynamic data and human 
outcomes would dramatically improve the safety of human testing and treatment and 
the ability of sponsors to invest in only those candidate products most likely to be 
effective in humans. Conversely, re-examination of existing data could identify 
features of preclinical studies that were not predictive of human response. 
 
This objective is of great importance to preclinical pharmacokinetics that requires confident 
decision making in compounds to progress.10,11 Inadequate interpretation and prediction leads to a 
two-fold failure where inadequate compounds are advanced, and promising leads are lost due to 
an insufficient screening cascade. Model-based simulations to improve success rates and to 
improve the efficiency and probability of obtaining informative results from preclinical 
experiments could aid in this objective.12–16 The project aimed to assess the murine 
Figure 1-2: AstraZeneca project 
closures.3 
Summary of project failures from 
AstraZeneca, classified by shortcomings 
in Safety, Efficacy, PK/PD and strategy, 
and stratified according to their respective 
phase of development dropout.  
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pharmacokinetics of antimalarial and antituberculosis compounds of interest and compare them to 
their relevant murine efficacy. These studies were used as the basis to assess the use of the 
population pharmacokinetic tool; non-linear mixed effects modelling (NLME) in our screening 
cascade and evaluate the practicality of its implementation. 
 
1.3 Comparison of pharmacokinetic methods and their limitation 
1.3.1 Non-compartmental analysis 
Non-compartmental analysis (NCA) has become the most popular tool for pharmacokinetic 
parameter calculation at the preclinical stage.17 It is an efficient technique to calculate important 
decision-making properties of new lead compounds, including, maximum concentration (Cmax), 
time to maximum concentration (Tmax) and area under the curve (AUC) suggestive of drug 
exposure.11,17–20  
In a practical setting, NCA’s dependency on calculating pharmacokinetics from AUC is both its 
greatest advantage and limitation.21 Pharmacokinetic parameters, and summary parameters 
including volumes and clearance calculated by NCA are all derived from the initial calculation of 
AUC (see section 2.4.4, page 38  for complete example of NCA calculations) and therefore are 
assumption free and objectively applied with ease, which is in contrast to compartmental 
modelling.18,19,21,22 However, if the directly observed concentration-time profile used for empirical 
NCA calculations is incomplete, the resulting AUC can be mistaken and the derived parameters 
imprecise and inaccurate.17,19  
The parameter determining AUC calculation of NCA is not the only numeric limitation that exists 
for the method. From a mathematical view, the methodology of NCA is built on linear first-order 
models, which often is not the function that would best describe a particular drug’s ADME 
processes.23 Also from a statistics perspective, pharmacokinetics is a multivariate phenomenon, 
and NCA cannot account for longitudinal pharmacokinetic datasets that inevitably suffer from 
unbalanced designs, time-varying covariates, missing data and other statistical considerations.24  
NCA exists as an abstraction of drug processes and its original development was meant to be 
supplemental to compartmental modelling.22 Despite this secondary nature, the NCA method has 
proved itself to be efficient, unbiased, and when the drug-concentration profile of a compound is 
well observed, is an excellent method to determine pharmacokinetic parameters.17–19,25 
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1.3.2  Compartmental methods 
Where NCA predicts drug exposure by AUC of the observed concentration-time profile of a drug, 
compartmental methods use regression to describe the concentration-time profile and extrapolate 
exposure.19 The use of compartmental models preceded non-compartmental modelling with work 
established in the early 20th century,26,27 and popularised in the 70s and 80s, leading to 
compartmental modelling being deemed the “standard” of pharmacokinetic analysis.22,28 Many of 
the equations used for NCA are derived from the descriptions and principles of pharmacokinetics 
provided by compartmental models.22,29,30 The hypothesis behind compartmental modelling was 
implemented to account for the non-linear nature of drug elimination by regression.25–27 To best 
capture the non-linear shape of the plasma-concentration-time curve, hypothetical 
“compartments” were implemented to account for the absorption, distribution and elimination of 
drug.22,29,31–33 This hypothesis is of course an oversimplification of complex physiology, and the 
untrue assumption that the body is made up of few homogenous compartments with equivalent 
kinetic properties should always be kept in mind.25  
There are excessive doubts surrounding compartmental analysis due to the discourse on how to 
determine the most appropriate model for a dataset. In fact, if considering the mathematical 
regression related to describing a pharmacokinetic curve, several models of comparable 
complexity can fit the same data, with no way of deeming which one is correct.34 Even more 
concerning, is that certain parameters considered crucial to pharmacokinetics can be entirely left 
out of some models without consequence to the final conclusion,35 questioning the validity of the 
method. 
This consequently subjective nature of compartmental models thus inevitably faces the limitation 
of great bias. Additionally, compartmental modelling is considered difficult to implement and 
require supplementary skills and experience to become proficient in the field. 
 
1.3.3 Non-linear mixed effects modelling 
Building on compartmental models and using additional statistical methods adopted from 
econometrics, Lewis Sheiner is credited with developing, applying and popularising NLME 
modelling for estimating population pharmacokinetics.36–42 Sheiner first introduced the method in 
197239 and successfully applied it to digoxin pharmacokinetics where the computer model of 
Sheiner more accurately predicted patient response than physicians predicted.25,28,43 Together with 
Arthur Beal, Sheiner released the computational NONMEM (contraction of non-linear mixed 
effect modelling) platform in 1980, written in the scientific program language FORTRAN.40 Beal 
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and Sheiner continued to refine the platform and provide continued instruction to establish the 
utility and standardisation of NLME modelling to pharmacology.36–38,42,44 
The efforts of Beal and Sheiner were readily welcomed into the discipline of pharmacometrics 
which aimed at developing mathematical models that could translate the relationship between dose 
to exposure (pharmacokinetics), and resulting exposure to response (pharmacodynamics),28,45,46 




Figure 1-3: Translation of pharmacokinetic (PK) dose to pharmacodynamic (PD) response 
The addition of mix effects to compartmental models provided a robust method to examine 
population pharmacokinetics, their relation to drug response and finally more standardised 
methods to affirm the most appropriate model.42 The application of NLME modelling has been 
greatly beneficial to drug development, with 250 applications to the FDA between 2000 and 2010 
using pharmacometric approaches.47  
 
The success of NLME modelling rests on the mathematical description of both the mechanism 
behind the pharmacokinetic profile (structural model) and the variability in the experimental data 
(stochastic/variability model) with the option of adding covariates to search for trends in 
pharmacokinetic estimates and subject demographics,31,48,49 Figure 1-4. 
 
PK PD exposure Response Dose 
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Figure 1-4: Elements of a non-linear mixed effects model 
A non-linear mixed effects approach uses three models to describe population pharmacokinetics and/or 
pharmacodynamics. The structural model describes observed data by regression with mechanistic principles. The 
covariate model includes individual characteristics allowing for relationships between a patient clinical outcomes and 
demographics. The statistical model accounts for the distribution of observations. 
 
The structural model describes the pharmacokinetic profiles using the same regression analysis 
established by compartmental modelling methods. The statistical model allows the parameters of 
this model to change according to a mixed-effects approach, where some of the variability is 
fixed/accountable, and the remaining variability described as random/unexplained.31,36,37,39,46 The 
analysis then proceeds to estimate the pharmacokinetic parameter values that best describe the 
data, the size of the random variability between individuals, and the measurement of 
uncertainty.31,39 A NLME approach is especially advantageous when there are limited data points 
available in each individual profile13,31,42 Pooling data across individuals can together provide a 
more complete profile and allows the model to complete lacking information in absorption, 
distribution, and elimination phase data.13,31,50 
Even though NLME is mathematically a much more successful tool for analysing 
pharmacokinetics, an important consideration of its application is to restrain from complexity. As 
described for compartmental models, models are based on the assumptions of researchers and are 
vulnerable to bias.16,31,49,51 George Box52 eloquently described the trouble of excessive modelling 
attempts: 
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Since all models are wrong, the scientist cannot obtain a "correct" one by excessive 
elaboration. On the contrary, following William of Occam he should seek an 
economical description of natural phenomena. Just as the ability to devise simple but 
evocative models is the signature of the great scientist, so overelaboration and 
overparameterization is often the mark of mediocrity. 
 
This was an important consideration for the pharmacokinetic evaluation, and included as an 
objective to assess the correct level of complexity that can be practically applied to preclinical 
research.  
Important advantages and disadvantages of NLME that was considered for this project are 
summarised in Table 1-1. 
Table 1-1: Advantages and disadvantages of non-linear mixed effects modelling 
Advantages Disadvantages 
Fewer data per individual required Complex mathematics 
Simulation capabilities Time consuming implementation 
Hypothesis testing Requires higher level of training  
Facilitates mechanistic interpretation Results sensitive to poor assumptions 
Easier to integrate different sources of 
information 
Excessive elaboration to fit objectives is 
possible  
 Software can be costly 
 
To address some of the predicted disadvantages, Monolix® software, which is an open source 
NLME modelling program, aimed at population pharmacokinetics was used in this project. It has 
a user-friendly graphical interface and built in models to promote NLME modelling as an 
accessible tool. 53–55 For compartmental pharmacokinetic analysis, three fundamental structural 
models based on one-, two- and three-compartment models able to describe both oral and 
intravenous administration were built with the assistance of Dr Paolo Denti, Division of Clinical 
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Pharmacology, University of Cape Town (South Africa). For an example of how these models 
were applied, refer to section 2.4.5, page 39 describing the model building process with an 
amodiaquine analogue as example. The models used for each compound evaluated and their 
respective application are discussed further within each study chapter and supplementary 
information is provided in Chapter 7: Experimental, page 197. 
 
1.4 Aim, objectives and thesis outline 
This thesis aimed to evaluate the pharmacokinetics of antimalarial and antituberculosis drug leads 
and compare their exposures to their in vivo efficacy. The studies were used to critically assess 
traditional methods with refined techniques to improve discovery outcomes that can feedback into 
compound optimisation and bridge the translational gap of potential leads that should be 
progressed to development. 
 
Key objectives included: 
1. Developing bioanalytical methods using LC/MS/MS quantification to evaluate the 
pharmacokinetics of antimalarial and antituberculosis drug leads in mice. 
 
2. The use of modelling techniques to gain better insight into preclinical drug discovery 
outcomes as compared to an empirical non-compartmental analysis approach. 
 
3. Expanding and refining pharmacokinetic methods used as better screening tools including 
capsule dosing, organ distribution studies for mechanistic-based pharmacokinetics, and 
simulating model results to evaluate PK/PD relationships and mouse to human translation. 
 
The objectives were approached as follows: 
The pharmacokinetic evaluation of three benzoxazole antimalarial drug leads with additional 
emphasis on PK/PD relationships using modelling and simulation to predict PK/PD drivers, 
presented in Chapter 2. 
In Chapter 3 is discussed a bioequivalence study aimed at evaluating the improved in vivo efficacy 
of a cyclodextrin formulation of an aminopyridine analogue using capsule dosing. 
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In Chapter 4 is presented the pharmacokinetic evaluation of fusidic acid and novel fusidic C-3 
ester prodrugs aimed at repositioning fusidic acid for tuberculosis. The evaluation included 
metabolite pharmacokinetics of the compounds and discrepancy in translation of mouse to human 
pharmacokinetics. 
In Chapter 5, investigation of the organ distribution of fusidic acid C-3 prodrugs aimed at 
improving tissue distribution is discussed. 
The highlights, limitations and future suggestions of these studies are discussed in Chapter 6: 
Conclusion. 
Experimental reports on the final mouse experiments, LC/MS/MS quantification settings and 
statistics, and modelling outputs are described in Chapter 7: Experimental. 
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2 ANTIMALARIAL BENZOXAZOLE 
AMODIAQUINE ANALOGUES 
2.1 Introduction 
Amodiaquine is a 4-aminoquinoline antimalarial and an anti-inflammatory drug related to 
chloroquine and acts similarly by targeting the host haemoglobin degradation pathway through 
inhibition of hemozoin formation, which is an essential detoxification process of the plasmodium 
parasite.56,57 Amodiaquine exhibits greater accumulation and activity in Plasmodium falciparum 
than chloroquine and has a reduced cross-resistance pattern than other quinolines, likely due to 
poor affinity for the resistant mechanism that prevents accumulation of quinolines in the 
plasmodium parasite.58,59 It is rapidly metabolised by CYP2C8 to desethylamodiaquine (DEAQ).60 
The DEAQ metabolite is approximately 3.5 times less active in vitro than amodiaquine61 but has 
a much longer half-life of up to 200 hours compared to the 5 – 12 hour half-life for 
amodiaquine.56,62 The major challenge facing amodiaquine remains its unpredictable 
hepatotoxicity, myelotoxicity and agranulocytosis, attributed to the formation of reactive 
metabolites; quinone imine and aldehyde quinone imine via the CYP1A1/1B1 pathway, Figure 
2-1.63  Pharmacokinetic parameters between patients vary as greatly as 20 fold56,64 leading to 
erratic half-lives and plasma concentrations, and irregular drug and metabolite exposures that can 
lead to suboptimal dosing that elicits resistance in some patients, while causing toxicity in others. 
This variance is not surprising as the CYP enzymes responsible for reactive metabolite formation 
have known diverse distribution patterns in different populations.63,65 However, due to prevailing 
chloroquine resistance, amodiaquine still holds value in combination therapies with other 
antimalarials such as the short acting artesunate, that partners well with the slow elimination of 
DEAQ, to eradicate residual parasites.66–68 
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Figure 2-1: Metabolic pathway of amodiaquine63 
Bioactivation of amodiaquine to less potent, but more pharmacokinetically attractive desethylamodiaquine (DEAQ) 
metabolite. Toxic metabolite formation of amodiaquine quinone imine likely via oxidation by cytochrome P450 (P450 
[O]), amodiaquine aldehyde and aldehyde quinone imine by cytochrome P1A1 or cytochrome P1B1. 
 
Attempts to address amodiaquine toxicity have led to preparation of several analogues with the 
most promising being isoquine, a regioisomer in which the formation of the toxic metabolites is 
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Figure 2-2: Amodiaquine regioisomeres that cannot form toxic quinoneimine metabolites 
Amodiaquine compared to its regioisomeres isoquine and tert-butyl isoquine that have the metabolic soft spots to toxic 
metabolites blocked show similar efficacy, but increasing hERG activity. Note: P. berghei ED50; effective dose for 
median 50% of cohort against Plasmodium berghei infected mice, hERG IC50; concentration showing 50% inhibition 
of Ether-à-go-go-Related Gene (hERG) channel activity. 
 
Isoquine showed promising in vivo efficacy in Plasmodium berghei infected mice. Further 
optimisation identified tert-butyl isoquine as a promising drug lead that was subsequently 
progressed to phase 1 human trials. However, this candidate did show a potential cardiotoxicity 
risk due to its in vitro activity against the human Ether-à-go-go-Related Gene (hERG) channel and 
was ultimately discontinued due to inadequate drug exposure in humans.69,70  
Our research group has continued similar investigation into synthesising improved amodiaquine 
analogues aimed at preventing the formation of toxic reactive metabolites. Chemical series to 
circumvent metabolism have included benzoheterocyclic 4-aminoquinolines, with the most 
promising being based on the benzoxazole amodiaquine scaffold, Figure 2-3.71,72 
 
 

















P. berghei ED50 = 2.1 mg/kg
hERG IC50 = 2.4 µM
Isoquine
P. berghei ED50 = 3.7 mg/kg
hERG IC50 = 3.9 µM
Tert-butyl isoquine
P. berghei ED50 = 2.8 mg/kg
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2.2 Rationale 
The benzoxazole amodiaquine analogues shown in Figure 2-4, displayed good antiplasmodial 
activity and the most active compounds with favourable selectivity indexes were carried forward 
for Plasmodium berghei efficacy evaluation in mice, carried out by Dr Sergio Wittlin and 
colleagues at the Swiss Tropical and Public Health Institute (Basel, Switzerland). In Table 2-1 are 
displayed the results of three dosing regimens. These in vitro equipotent compounds showed 
greater diversity in vivo with compound DS23B having the best efficacy and showing complete 
cure at 4 x 10 mg/kg oral dosing. It was hypothesised that this diversity in efficacy could be due 
to differences in pharmacokinetic properties of the series, resulting in different exposures. The 
pharmacokinetics of these analogues were therefore investigated with the aim of explaining the 
observed differences in efficacy and accordingly compared these results to the pharmacokinetics 
of amodiaquine to evaluate if they were more beneficial. 
Preclinical pharmacokinetic evaluation of novel antimalarial and antituberculosis drug leads 
30  Natasha Strydom - April 2018 
 
Figure 2-4: Benzoxazole amodiaquine analogues and their respective activity and 
cytotoxicity values 
Note:  NF54 IC50; antiplasmodial activity showing 50% inhibition in drug sensitive Plasmodium falciparum strain 
NF54, K1 IC50; antiplasmodial activity showing 50% inhibition in multi-drug resistant Plasmodium falciparum K1 
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NF54 IC50 : 10.0 nM
 K1 IC50 : 275 nM
DS48B
NF54 IC50 : 10.0 nM
K1 IC50 : 39.0 nM
CHO IC50 : 671 nM
DS23B
 NF54 IC50 : 15.0 nM
 K1 IC50 : 56.0 nM
CHO IC50 : 4900 nM
DS50B
NF54 IC50 : 11.5 nM
 K1 IC50 : 41.9 nM
CHO IC50 : 7590 nM
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Table 2-1: Efficacy of benzoxazole analogues of amodiaquine in vivo against Plasmodium 
berghei infected mice 
Compound 
% Reduction in parasitemia (MSD) 
4×50 mg/kg 1×50 mg/kg 4×10 mg/kg 
DS23B 99.83 (>30) 99.54 (23.3) 99.82 (>30) 
DS48B 99.76 (>30) 99.54 (14.0) 99.76 (15.7) 
DS50B 99.82 (29.3) 99.54 (13.7) 99.88 (24.0) 
Amodiaquine 99.88 (>30) n.d. 100 (>30) 
Chloroquine73 99.70 (9.00) n.d. 99.90 (16.0) 
Efficacy experiments performed by Dr Sergio Wittlin and colleagues at the Swiss Tropical and Public Health Institute 
(Basel, Switzerland) using an adapted method based on the Peter’s 4 day suppressive test.72,74 MSD = mean survival 
time (in days); n.d. = not done.  
 
2.3 Methodology overview 
Figure 2-5 shows the approach and experiments undertaken for the pharmacokinetic evaluation of 
the three amodiaquine analogues. LC/MS/MS method development for accurate quantification of 
the compounds in mouse blood preceded animal experiments. An initial 7 hr pharmacokinetic 
experiment for DS50B and DS23B showed slow elimination and that the compounds had not yet 
reached their terminal half-life, making pharmacokinetic calculations inaccurate. A 24 hr 
experiment for DS48B showed a complete profile and calculated parameters are shown in Section 
2.5.1. The 56 hr repeat experiments for DS50B and DS23B showed variability in the internal 
standard that appeared to be a result of ion suppression from the dosage formulation. The 
LC/MS/MS method was reassessed and improved. The unaffected final time points of this 
experiment were used to design a 15-day experiment for both DS50B and DS23B. This experiment 
showed acceptable pharmacokinetic profiles with parameters calculated by NCA and NLME 
modelling. Mouse pharmacokinetic data for amodiaquine from a previous experiment was 
reanalysed using the same NCA and compartmental approach to compare with the novel series. 
Additional in vitro assays including blood plasma partitioning, plasma protein binding, kinetic 
solubility and permeability (logPe) and lipophilicity (logD7.4) to describe the observed 
pharmacokinetic differences and fully characterise the compounds are shown in section 2.4.8. 
Section 2.4.6 contains additional simulations to examine potential PK/PD relationships.  
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Results 2.5.1 DS23B and DS50B 
7 hr PK experiment 
20 mg/kg P.O. (n = 3) 






24 hr PK experiment 
20 mg/kg P.O. (n = 3) 
5 mg/kg IV (n = 3) 
Results 2.5.3.2 
Repeat DS23B & DS50B 
56 hr PK experiment 
20 mg/kg P.O. (n = 3) 
2.5 mg/kg IV (n = 3) 
Results 2.5.2 
Repeat DS23B & DS50B 
15 day PK experiment 
10 mg/kg P.O. 
2.5 mg/kg IV (n = 3) 
Results 2.5.3 
Analytical Animal 





Blood plasma partitioning 
Results 2.5.8 
ADME 
NCA & NLME modelling 
to obtain pharmacokinetic 
parameters 
Results 2.5.2 
Simulation in Berkeley 
Madonna using final 
obtained model parameters 
Results 2.5.6 
NCA & NLME modelling 
to obtain pharmacokinetic 
parameters 
Results 2.5.3 
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2.4 Methods 
2.4.1 In vivo antimalarial efficacy testing 
In vivo antimalarial efficacy testing was carried out by Dr Sergio Wittlin and colleagues at the 
Swiss Tropical and Public Health Institute (Basel, Switzerland) and followed a similar protocol 
recommended by Fidock et al.75 This includes the adapted method of the classical 4-day 
suppressive test of Peters74,76 to evaluate initial efficacy of compounds. Specific modifications 
included; experimental groups of three mice instead of five and a GFP-transfected P. berghei 
ANKA strain (donated by A. P. Waters and C. J. Janse, Leiden University, The Netherlands) to 
easily determine parasitaemia using flow cytometry with a detection limit of 1 parasite in 1000 
erythrocytes instead of Giemsa stained blood smears that require manual counting. Additionally, 
intravenous infection was used as opposed to intraperitoneally for improved and more consistent 
infection rates.  
The procedure was as follows; on day one, experimental groups (n = 3) NMRI Swiss-type mice 
were inoculated intravenously in the tail vein with 2 x 107 GFP-transfected P. berghei ANKA 
parasitised red blood cells. Treatment with a dose of 50 mg/kg commenced 4 hrs after infection. 
The experimental mice were orally administered with the selected compound first dissolved or 
suspended in 70% Tween 80 and 30% ethanol (v/v), and then further diluted ten times in water, 
while the untreated control group received the suspension vehicle alone. Treatment occurred 4, 24, 
48 and 72 hrs after infection. Blood samples for the quadruple-dose regimens were collected 96 hrs 
after infection. Activity expressed as percentage reduction in parasitaemia was calculated as the 
difference between the mean percent parasitaemia for the untreated control and treated groups 
expressed as a percent relative to the untreated control group.  




Mice were monitored for 30 days post-infection and survival days recorded. Mice that survived to 
30 days are considered completely cured. As is the norm for this specific screening protocol, 
compounds exhibiting a cure at 4 x 50 mg/kg were carried forward to examine lower dosing of 4 
x 10 mg/kg and 1 x 50 mg/kg regimes.72,77  An exception was made for compound DS50B which 
showed a cure in 2 out of the 3 mice, with the third mouse surviving to 29 days. It was decided 
that its inclusion remained relevant in this series considering its initial reduction in parasitaemia 
was more than DS48B that managed to cure all 3 mice. These published results shown in Table 
2-1 warranted further in vivo pharmacokinetic investigation as discussed in Section 2.2 Rationale. 
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2.4.2 Final LC/MS/MS quantification 
An LC/MS/MS quantification method preceded animal studies and showed accuracy within 93.6 
– 108%. As discussed in the methodology overview, after this validation and animal work the final 
whole blood sample analysis encountered unforeseen column expiration and ion suppression on a 
differently selected column, leading to a repeat animal experiment. The LC/MS/MS 
reinvestigation is presented in the results and discussion section 2.5.1, page 67 of this chapter.  
Briefly, the final reinvestigated LC/MS/MS method used for the final samples were performed as 
follows. Whole blood concentrations of the compounds were quantified by an LC/MS/MS assay 
developed for a range of 10 – 5000 ng/ml. The samples were extracted by protein precipitation 
using 20 µl whole blood and 240 µl acetonitrile containing a structurally similar internal standard. 
Gradient chromatography was performed on a Waters Xterra™ MS C18 (2.1 x 30 mm, 3.5 µm) 
reverse phase column at a flow rate of 600 µl/min with mobile phases 0.03% ammonium hydroxide 
(v/v) in water and acetonitrile. Transition 436.3→351.2 was monitored for DS48B on an AB Sciex 
API 3200® mass spectrometer operated at unit resolution in multiple reaction-monitoring mode. 
Similarly, transitions 408.1→98.0 and 382.2→72.0 were monitored for DS23B and DS50B 
respectively, on an AB Sciex API 4000Q® for increased sensitivity. Chromatograms showing 
retention times of each analyte according to the described methods are shown in Figure 2-6. 
Column carry-over was present for these compounds. A carry-over peak below 20% of a blank 
control sample after injecting a high-quality control sample is considered acceptable. Injecting 10 
µl of blank methanol solvent between each sample reduced total carry-over to the accepted criteria. 
The highest carry over was 12.3% observed for DS23B. DS48B and DS50B showed carry-overs 
of 8.41% and 5.30% respectively. The accuracies (%Nom) for low (10 ng/mL for DS48B, and 
19.3 ng/ml for DS23B and DS50B), medium (2000 ng/mL) and high (4000 ng/mL) quality controls 
ranged between 95.1 – 117%, 90.0 – 102.0% and 99.0 – 113%, and percentage coefficient (%CV) 
below 28.0, 33.6 and 12.0% for DS48B, DS23B and DS50B respectively. In depth final 
quantification statistics, expended extraction method, mass spectrometer conditions, mobile phase 
gradient, integrated peaks of low quality controls, blank samples and their respective internal 
standards for each compound are presented in Chapter 7: Experimental, section 7.2, page 197.  
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Figure 2-6: Representative chromatogram of benzoxazole analogues of amodiaquine. 
Chromatograms for medium quality controls (4000 ng/ml) for A: DS48B, B: DS23B and C: DS50B. 
 
2.4.3 In vivo pharmacokinetic experiment 
2.4.3.1 Animals 
All animal studies and procedures were conducted with prior approval of the Ethics Committee of 
University of Cape Town, approval number 013/028, in accordance with the National Code for 
animal use in research, education, diagnosis and testing of drugs and related substances in South 
Africa. The pharmacokinetic animal experiment used healthy 8-week-old C57BL/6 mice 
maintained at the University of Cape Town animal facility. Mice were housed in 27 x 21 x 28 cm 
cages under controlled environmental conditions including a maintained temperature of 26 ± 1°C 
and 12 hr light/dark cycle. Food and water were available ad libitum. 
2.4.3.2 Compound preparation and administration 
The author of this thesis prepared compounds for administration. Mr Trevor Finch from the 
Division of Pharmacology, University of Cape Town (South Africa) performed all animal 
handling, administration of compounds and blood collection under direct supervision of the author, 
with the author always present.  
On the day of the experiment, a predetermined mass of the test compound was weighed for oral 
and intravenous groups based on the average mass of the animal experimental groups determined 
C: DS50B 
Retention time:  
3.22 min 
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that morning. Initial experiments used a 2.5 mg/kg intravenous dose and 20 mg/kg oral dose. The 
second repeat experiment for DS23B and DS50B was reduced to an oral dose of 10 mg/kg.  
For each compound, the intravenous groups consisted of three males and weighed approximately 
30 g, while oral groups consisted of three females and weighed approximately 25 g.  
For oral administration, the weighed compound was suspended in 1000 µl of aqueous 0.5% 
hydroxypropyl methylcellulose (HPMC) (w/v) and vortexed for 1 minute. Drug administration 
followed by oral gavage of 250 µl total volume of suspension. Based on previous experience this 
excess is needed to accurately draw up and administer the required volume during the animal 
procedure. Administration occurred within 30 minutes of suspension preparation.  
For intravenous administration, the weighed compound was prepared in an organic vehicle of 10% 
dimethyl sulfoxide (DMSO), 10% ethanol, 50% polypropylene glycol and 30% polyethylene 
glycol 400. The compound was dissolved in DMSO first, vortexed, followed by addition of other 
vehicle constituents and vortexing for at least 1 min. Solubility was confirmed by visual inspection 
of the dosage solution before administration. Intravenous injection into the penile dorsal vein of 
60 µL total volume was performed under microscope. The organic vehicle required a slow push 
over 1 minute to prevent shock to the mice. The approximate final dose for the males weighing 
approximately 30 g contained 0.2 ml/kg DMSO, 0.2 ml/kg ethanol, 1 ml/kg polypropylene glycol 
and 0.6 ml/kg polyethylene glycol 400, which is considered safe in mice.78 
Formulation stability could be performed to ensure the expected dose considering the compound 
could be unstable, but formulation preparation right before administration was found to be 
sufficient at this preclinical stage. 
Whole blood samples were collected via tail bleeding at predetermined time points in 0.5 ml 
lithium microvials and vortexed for 30 seconds to prevent coagulation. The samples were stored 
at -80°C. For the first DS23B and DS50B experiment whole blood collection occurred at time 
intervals predose, and 0.5, 1, 3, 5 and 7 hrs for the oral and intravenous groups. Additionally, the 
intravenous group included sample collection at 5 minutes after dosing. As discussed in the 
methodology overview, the time-concentration profiles of DS23B and DS50B showed incomplete 
pharmacokinetic profiles. This led to additional whole blood sample collections of DS48B at 24 
hrs for both groups. The animal experiments for DS23B and DS50B were repeated and sample 
collection extended to include 24, 32, 48 and 56 hrs. Experimental error during analysis of the 
blood samples unfortunately required another repeat experiment. Time intervals for the second 
DS23B and DS50B repeat experiment were extended for the oral group to include daily sample 
collection after the 48 hr sample for an additional 13 days. 
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The animal experimental record containing specific mouse weights, exact sample times and 
compound weights are included in Table 7-5 to Table 7-7, in Chapter 7: Experimental Records. 
 
2.4.4 Non-compartmental analysis 
Non-compartmental analysis was performed using PK Solutions, version 2.0 (Summit Research 
Services, Montrose, CO, USA). The analysis used individual whole blood concentrations vs 
sample times. Parameters calculated from the intravenous data included clearance (Cl) in 
ml/min/kg, initial central compartment volume (Vc) and volume at steady state (Vss) in L/kg, and 
elimination half-life (t1/2) in hrs. Maximum concentration (Cmax) in µM and time to maximum 
concentration (Tmax) were taken directly from the individual oral profiles. Area under the curve 
from time zero to infinity (AUC0-∞) was calculated for both intravenous and oral profiles and used 
to calculate absolute oral bioavailability (F) expressed as a percentage. Parameters were 
normalised by individual mouse weights. 
AUC for oral and intravenous data was calculated as the sum of the observed area under the curve 
(calculated by the trapezoidal rule) and extrapolated area (calculated by C/ke where ke is the 
elimination rate constant). The ke was estimated as the log-linear slope of the final time points that 
were manually chosen to represent terminal phase. Half-life was calculated according to t1/2 = 
ln2/ke. 
Clearance was calculated according to fraction of dose absorbed divided by AUC0-∞. For 
intravenous administration fraction absorbed is equal to 1. To calculate Vc, the initial intravenous 
whole blood concentration (C0) is calculated by extrapolation of the concentration-time curve to 
time zero. The equation then follows that Vc equals the dose amount divided by C0. Vss was 
calculated according to dose multiplied by the area under the first moment curve (AUMC0-∞) 
divided by AUC0-∞ squared. This equation is commonly expressed as 
8// = 96	7	:#; 
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Results are reported as the mean of the final individual parameters and standard error of the mean 
(s.e.) estimated by the sample estimate of the population standard deviation divided by the square 
root of the sample size. 
 
2.4.5 Non-linear mixed effects modelling 
Modelling was performed using Monolix® version 4.3.0 (LIXOFT, Antony, France). To aid in 
understanding the model-building process and criteria that was followed, an in-depth example of 
the approach is explained here with criteria results from compound DS50B. In subsequent 
chapters, brief overviews of the methods are given, but the same fundamental methodology 
applies.  
2.4.5.1 The data input 
The analysis used the same individual whole blood concentrations vs sample times used for NCA 
with the addition of time points that were measured below the lower limit of quantification (BLQ). 
The extra time points were input as their concentrations being unknown and censored as BLQ with 
the BLQ concentration stipulated. The model could then estimate the likelihood that the 
concentration was somewhere between zero and the BLQ. 
Intravenous and oral group data were pooled in the same model and the data file specified the 
compartment of dose input as either the absorption compartment for oral data or central 
compartment for intravenous data. All units used were converted to mg/L for concentration and 
hrs for time. These are the units that would be used for human data from pharmacokinetics, which 
simplified the output data and the final parameters were converted to the same units as NCA for 
comparison. 
The masses of the individual mice were included as a covariate in kg and transformed to log 
centred around the median. The transformed mass values were fixed within the covariate model 
using allometric scaling of volume and clearance.79 This allowed the model to normalise clearance 
and volumes to the mass of individual mice and the final values were calculated and then reported 
for the median value of weight in the cohort.  
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2.4.5.2 The structural models 
Three pharmacokinetic models were developed sequentially to be used as a “library” of one-, two-, 
and three- compartment models. The models were adapted for intravenous or oral administration, 
with an intravenous dose considered as instantaneous into the central compartment, and an oral 
dose absorbed via a fist-order process, possibly preceded by an absorption delay (Tlag) if 
applicable. Model building was guided by physiological plausibility, significant improvements in 
-2 the log-likelihood (-2LL), and evaluation of goodness of fit plots, including visual predictive 
plots (VPC) and individual plots. 
In this sequential approach models were built up from the simplest model and complexity added 
stepwise. Development started with a one-compartment model and parameter data and diagnostics 
collected. The order of complexity was then increased to a two-compartment model. If the 
additional complexity was deemed statistically significant when reviewed with the simpler model 
(described in more depth in sections 2.4.5.2.1- 2.4.5.2.3), the model was again progressed to a 
more complex model and similarly reviewed.  
The one-compartment model in the designed library where all model attempts started is shown in 
Figure 2-7. 
 
Figure 2-7: One-compartment model 
Structurally the model follows that the compound can be introduced P.O. (per os, by oral administration) into the 
absorption compartment. An absorption rate (ka) following first order kinetics allows one-way transfer of the 
compound from the absorption compartment to the central compartment. The central compartment is defined as the 
whole blood concentrations observed and where intravenous (IV) input occurs via instantaneous bolus introduction. 
Clearance (CL) occurs from the central compartment defined as rate of elimination (ke) multiplied by volume of the 
central compartment (Vc). 
 
For this model, the input of the dose administered in mg was defined using the assumption that the 
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administration, the dose was introduced into an absorption compartment, with dose amount in mg 
represented by Aa. The rate of absorption followed first-order kinetics (ka) into the Vc, where the 
amount of drug is described by Ac in mg. Whole blood concentration (Cc) is equal to Ac divided 
by Vc. Whole blood clearance (CL) was measured in L/h and followed CL = ke x Vc where ke is 
the rate of elimination. Initialisation of all compartments were set to zero i.e. no compound was 
present in circulation.  Bioavailability (Foral) was also calculated, described in Monolix® as the 
proportion of the oral dose that reached Vc.  







For an intravenous dose: 
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For an oral dose, the addition of the absorption compartment results in the following modification: 
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After modelling reached satisfactory parameters, the next sequential step was to increase 
complexity of the model to a two-compartment model and review if the diagnostics showed a 
significant statistical improvement. In Figure 2-8 is shown the two-compartment model used. 
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Figure 2-8: Two-compartment model 
Structurally the model follows the same input and clearance as the previous one-compartment model with the addition 
of a peripheral compartment. Transfer between the central and peripheral compartments are defined by the inter-
compartmental clearance (Q1) allowing redistribution of the compound. Q1 is defined by the rate of transfer from the 
central compartment to the peripheral compartment (kcp) multiplied by the volume of the central compartment (Vc). 
The volume of the peripheral compartment is calculated by the rate of transfer from central to peripheral compartments 
divided by the rate of transfer back to the central compartment (kcp/kpc) multiplied by Vc. 
 
The two-compartment model follows the same principles as described for the one-compartment 
model with the addition of a peripheral compartment where drug amount Ac can move in and out 
of the secondary compartment, becoming Ap1 in mg with volume of distribution Vp1, described via 
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After modelling, the diagnostics for the test compound are compared to that of the 
one-compartment model and if found statistically more significant by the addition of the 
parameters Q1 and Vp1, a three-compartment model was then attempted, Figure 2-9. 
 
Figure 2-9: Three compartment model 
Structurally the model follows the same input and clearance as the previous one-compartment model with the addition 
of two peripheral compartments. Transfer between the central and peripheral compartments are defined by the inter-
compartmental clearances, Q1 and Q2, allowing redistribution of the compound. Q1 and Q2 are defined by the rate of 
transfer from the central compartment to the peripheral compartments, kcp1 or kcp2 respectively multiplied by the 
volume of the central compartment (Vc). The volumes of the peripheral compartments are then calculated by the rate 
of transfer from central to respective peripheral compartments divided by rate of transfer back to the central 
compartment kcp1/kp1c or kcp2/kp2c, multiplied by Vc. 
 
The same principles as the two-compartment model apply and similarly, drug amount Ac can now 
move in and out of a third compartment, becoming Ap2 in mg with volume of distribution Vp2, 
described via inter-compartmental clearance Q2 (L/h). The differential equations to describe this 
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If the dose is oral: 
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After modelling the -2 the log-likelihood (-2LL), evaluation of goodness of fit plots, including 
visual predictive plots (VPC) and individual plots were reviewed again against the simpler 
two-compartment model. 
A brief overview of the -2LL and goodness of fit plots’ purpose and interpretation are described 
below. 
2.4.5.2.1 A description of -2 the log-likelihood value 
The -2LL, also often referred to as the objective function value (OFV), and is the sum of the 
squared residuals, and a mathematical optimisation tool that aims to quantify how well the 
observed data fits with the model. It considers fixed effects parameters, inter-individual variability 
and unexplained variability. In Figure 2-10 is shown a 3D graphic representation of the objective 
function surface (or the sum of the squared residuals surface) for a model exploring the best values 
of two parameters. As the software explores the optimal parameters of the model, it is guided by 
this surface to find the lowest point considered convergence of the best fitting parameters. The 
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minimum or lowest -2LL value is the maximum likelihood of the parameters fitting to the observed 
data.  
 
Figure 2-10: Objective function surface of two parameters 
The -2 log likelihood (-2LL) or objective function value illustrated as a surface which the model can trace to the lowest 
point of convergence to obtain the best-fit values of two parameters. 
 
The -2LL is therefore a vital criterion to determine which model parameters from the structural, 
covariate and statistical models are best for the observed data. However, as stated in Chapter 1, 
simplicity in model building is key, and to quote economist Ronald Coase80:  
 
“If you torture the data long enough, it will confess (sic) to anything” 
 
Adding a parameter to the model will often result in a lower -2LL due to the added variability 
allowing an additional degree of freedom in the model. In other words, the more complex a model 
is, the more flexible it becomes at fitting data. It is therefore necessary to have a threshold in the 
decrease of -2LL to justify the inclusion of additional complexity and prevent 
over-parameterisation. The criteria stated a decrease of at least 3.84 points as the threshold of 
significance for the inclusion of one additional parameter. This correlates to a p-value of 0.05 
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based on the assumption that the residuals are chi-square distributed.81 This criteria is well 
accepted in model building.51,82–91 
A large concern when dealing with the -2LL is the occurrence of a local minima, Figure 2-11. This 
occurs when the model explores the objective function value surface and finds a decreasing -2LL 
pocket that does not correlate to the global optimised values. This occurs when the initial starting 
estimates of the model are out of place and allows the model to get “lost”. This occurs more 
frequently in complicated models. To prevent this, it is the responsibility of the modeller to input 
feasible initial parameter values where the model will start searching for the optimised parameters. 
It is also the modeller’s responsibility to understand the final parameters and whether they are 
plausible, and re-estimate the initial parameters to guide the model out of a local minima, when 
the parameters are nonsensical or implausible.92 
 
Figure 2-11: Local vs global minima92 
A limitation in modelling when using the -2 log likelihood surface is that the exploration of the surface can be caught 
in a cavity of the surface known as a local minimum. This cavity is not the optimised parameters and is a result of the 
model diverting into this surface due to the initial estimated parameters being too far away from the global minima. 
In the figure the blue dots represent convergence and final parameter estimates. The red dots represent the initial 
parameter estimates. 
 
For DS50B and all other analyses, model building started with the parameters obtained from NCA. 
In Figure 2-12 is shown a screenshot of the graphical feedback in Monolix® using observed data 
from DS50B in a two-compartment model as an example when predicting initial parameters. 
Global minima 
Local minima 
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Figure 2-12: Selecting initial parameters 
Initial parameter selection for DS50B defined by a two-compartment model with parameters; bioavailability (Foral), 
absorption rate (ka), central volume (V), clearance (Cl), inter-compartmental clearance (Q) and peripheral volume 
(Vp) manually chosen. The graphic feedback allows visualisation of the best population fit (represented by the red 
line) to the observed data (blue crosses) and below limit of quantification time points (triangular blue crosses). The 
plot for individual mouse “3” is a mouse from the oral group and has been zoomed in as example to confirm if the 
rate of absorption (ka) and bioavailability (Foral) is a close approximation. 
 
The model is run and the -2LL examined for improvement. If a significant improvement in -2LL 
occurs with the same model, but different initial parameter estimates occur, a local minimum was 
likely present. 
An important consideration when dealing with -2LL values is that the values are abstract when 
viewed by themselves. They can only be used to compare models and support whether one model 
is statistically more significant than the other. This comparison must also only occur for nested 
models that fit within each other. A nested model is considered as a smaller, simpler model fitting 
into a larger more complex model, described by their structure and equations. The structural 
models are nested as can be seen from the structure diagram and their differential equations. For 
example, comparing the two-compartment to the one compartment model, if the inter-
compartmental clearance (Q) were fixed to zero, it would again be a one-compartment model. The 
-2LL values themselves differ greatly between non-nested models and are not an indication of 
their importance. The -2LL value therefore only serves to guide the backwards and forwards 
development of the inclusion and exclusion of parameters. 
2.4.5.2.2 A description of the visual predictive check graphic 
A visual predictive check (VPC) is a simulation-based diagnostic used to visualise how the 
distribution of the experimental data compares with the model predictions. In a VPC, simulations 
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from the model are used to obtain confidence intervals for where the model predicts several 
percentiles of the incomplete data to be. The corresponding percentiles from the original data are 
then checked for consistency against the model-based confidence intervals, highlighting data 
points or sections of the profile that are not well represented by the model.93–97 In the studies that 
use three subjects per group, only the 50th confidence percentile was used to assess whether the 
model could account for the observed data. In Figure 2-13 is shown the A: intravenous and B: oral 
VPC of the DS50B model respectively. 
 




Figure 2-13: Visual predictive check of A: DS50B intravenous data and B: DS50B oral data. 
The graphical diagnostic plot shows the simulated output of the A: intravenous observed data vs the B: oral observed 
data (blue dots) of the DS50B in vivo pharmacokinetic experiment modelled as a two-compartment model. The red 
dots represent simulated concentration time points below the limit of quantification (BLQ = 10 ng/ml) data. The data 
input consisted of pooled oral and intravenous data. The oral and intravenous visual predictive checks were stratified 
to compare the two experimental groups. The green line represents the empirical percentile of the observed data and 
the shaded pink area represents the median of the population estimate. Ideally, this empirical percentile should fit 
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In the oral profile, the BLQ data represented by red dots are simulated BLQ data, meaning the 
values that the model estimated are shown and can be seen decreasing to zero. The red vertical 
lines represent bins, which correspond to the data distribution. In this case, a minimum bin number 
was set to the experimental group number of three i.e. every bin as denoted by the space between 
the red vertical lines contain at least three data points. Where the red lines are closer, more 
sampling occurred and, for example, as can be seen for the intravenous data between 8 and 24 hrs, 
sampling was sparser. Importantly, the empirical percentile represented by the green line and the 
median percentile represented by the pink shaded area changes according to the bin number to best 
represent the distribution of the data and should be appropriately changed. Setting a high bin 
number can manipulate a VPC to appear better than the actual observed data and all presented 
VPC’s were set to a minimum bin number of three, except for amodiaquine that evaluated a group 
size of 10.  
2.4.5.2.3 A description of the individual fits 
Additionally, individual fits were used to assess if there were major outliers in the group and if the 
model could approximate well for all individuals in the cohort. Figure 2-14-A and B show the 
individual fits for the most deviating individual oral and intravenous mice in the DS50B 
experiment respectively.  
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Figure 2-14: Individual fit of DS50B experiment A: Oral mouse "3" and B: Intravenous 
mouse “4” 
The graphical diagnostic individual fit output of individual mouse “3” that was in the oral experimental group and 
individual mouse “4” that was in the intravenous group. The blue crosses represent the observed concentration data 
points from the experiment, the red stars represent the “censored” or below limit of quantification (BLQ) data and the 
green line represents the individual fit after parameter variability for respective individual mice are included. The 
population fit represented by the red line, is the median of the cohort of both the oral and intravenous groups. The 
individual parameters of each mice are shown in the yellow legend. 
 
The Foral and ka for the intravenous plot is not factored in the final simulation, and represents the 
median values as determined by the population model. In these plots, outlying data points at 56 
hrs for the oral group, and 25 hrs for the intravenous group can be seen. These were likely due to 
experimental error during extraction, and explain these individual plots resulting in the most 
deviation.  
2.4.5.3 Example of DS50B structural model results 
Starting with the one-compartment model, initial fixed effects equal to the NCA results were 
introduced and the model allowed to optimise the values. Optimisation struggled and results and 
diagnostic outputs proceeded with errors, meaning the model could not accurately find 
convergence of the parameters. The final -2LL was recorded as -22.47. As stated previously, this 
is an arbitrary value and can only be used in comparison with another nested model. In Figure 2-15 
and Figure 2-16 is shown the intravenous VPC and the individual fit of intravenous mouse “4” 
Time (hr) Time (hr) 
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respectively. The difficulty in modelling was unsurprising considering the linear-log plot of 
DS50B’s intravenous data showed non-linearity that a one-compartment model would likely not 
be able to account for. Nevertheless, in modelling it is important to build up from the simplest 
foundation and not allow bias in observational data. 
 
 
Figure 2-15: DS50B one-compartment model intravenous visual predictive check 
The graphical diagnostic plot shows the simulated output of the intravenous observed data of the DS50B in vivo 
pharmacokinetic experiment modelled as a one-compartment model. The data input consisted of both the oral and 
intravenous data. The visual predictive check (VPC) was divided to see how the two experimental groups compare to 
the model and the intravenous plot shown here. The green line represents the empirical percentile of the observed data 
and the shaded pink area represents the median of the population estimate. Ideally, this empirical percentile should fit 
within the pink shaded area. As can be seen in this VPC, the structural model could not account for the rapid decrease 
in concentration to hour 8 and then slower elimination over time. The prediction interval that falls out of the simulation 
is represented by the red area and individual observed data points that cannot be predicted for circled in red. 
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Figure 2-16: DS50B one-compartment model individual fit 
The graphical diagnostic individual fit output of individual mouse “4” that was in the intravenous group. The blue 
crosses represent the observed concentration data points from the experiment and the green line represents the 
individual fit after parameter variability for the individual mouse is included. The population fit represented by the 
red line, is the median of the cohort of both the oral and intravenous groups. The individual parameters of each mice 
are shown in the yellow legend. The population fit is unable to account for the individual data and the individual fit 
poorly corresponds to the observed data. 
 
Next a two-compartment model was attempted and initial fixed parameters from the previous one-
compartment model used and parameters altered significantly according to the graphical output, 
shown previously in Figure 2-12 to find the best starting point for parameter optimisation. The 
model could converge and find the optimised parameters and a reduction in -2LL of 105.26 points. 
Considering the two additional degrees of freedom due to parameters, Vp and Q would require a 
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Figure 2-17: DS50B two-compartment model intravenous visual predictive check 
The graphical diagnostic plot shows the simulated output of the intravenous observed data of the DS50B in vivo 
pharmacokinetic experiment modelled as a two-compartment model. The data input consisted of both oral and 
intravenous data. The visual predictive check (VPC) was divided to see how the two experimental groups compare to 
the model, with the intravenous VPC shown here. The green line represents the empirical percentile of the observed 
data and the shaded pink area represents the median of the population estimate. Ideally, this empirical percentile 
should fit within the pink shaded area. Individual observed data points that cannot be predicted for are circled in red. 
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Figure 2-18: DS50B two-compartment individual fit 
The graphical diagnostic individual fit output of individual mouse “4” that was in the intravenous group. The blue 
crosses represent the observed concentration data points from the experiment and the green line represents the 
individual fit after parameter variability for the individual mouse is included. The population fit represented by the 
red line, is the median of the cohort of both the oral and intravenous groups. The individual parameters of each mice 
are shown in the yellow legend. The population and individual fit lines are better able to correspond to the observed 
data. 
 
A three-compartment model was then attempted to observe if it could provide significantly better 
estimates of the parameters. Again, the initial fixed effects results from the previous model were 
used and adapted to best fit the graphical output. The model could converge on optimised 
parameters and the reduction in -2LL was 2.43 points. This was deemed an insignificant statistical 
improvement on the previous structural model and the graphical outputs confirmed improved 
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Figure 2-19: DS50B three-compartment model intravenous visual predictive check 
The graphical diagnostic plot shows the simulated output of the intravenous observed data of the DS50B in vivo 
pharmacokinetic experiment modelled as a three-compartment model. The data input consisted of both oral and 
intravenous data. The visual predictive check (VPC) was divided to see how the two experimental groups compare to 
the model, with the intravenous VPC shown here. The green line represents the empirical percentile of the observed 
data and the shaded pink area represents the median of the population estimate. Ideally, this empirical percentile 
should fit within the pink shaded area. Individual observed data points that cannot be predicted for are circled in red. 
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Figure 2-20: DS50B three-compartment individual fit 
The graphical diagnostic individual fit output of individual mouse “4” that was in the intravenous group. The blue 
crosses represent the observed concentration data points from the experiment and the green line represents the 
individual fit after parameter variability for the individual mouse is included. The population fit represented by the 
red line, is the median of the cohort of both the oral and intravenous groups. The individual parameters of each mice 
are shown in the yellow legend. The population and individual fit lines are better able to correspond to the observed 
data, but shows no significant improvement on the two-compartment model. 
 
Structural model choice then regressed back to the more appropriate two-compartment model. In 
the simulations, it could be seen that the ka value was able to accurately account for absorption. 
To satisfy expectations, a Tlag function was added to the two-compartment model to review if it 
could significantly improve model outputs. In Figure 2-21 is shown the structural model used. 
The -2LL increased by 0.10 point and the Tlag was estimated to be 0.0062 hrs with relative 
standard error recorded at 117171%, meaning the model could not make sense of this parameter. 
This additional parameter was not only statistically insignificant, but caused great difficulty for 
the model to predict as the absorption amount by the rate of absorption needed to be present 
instantaneously in the absorption compartment as the concentration in the central compartment 
shows. Physiologically this fits due to the oral gavage that is used on the mice. The dose amount 
is instantaneously deposited in the absorption compartment (gut) in suspension form where the 
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dosing where a lag in transit time to the absorption compartment is expected, such as transit to the 
absorption site, disintegration of a tablet or capsule, deaggregation of particles and dissolution in 
the surrounding environment to be available for absorption.21,98 
 
Figure 2-21: Two-compartment model with Tlag function 
 
The Tlag function was therefore excluded and with the structural model firmly established, the 
statistical model could be addressed. 
2.4.5.4 Statistical model 
Each fixed effect parameter of the two-compartment model DS50B (Foral, ka, CL, Vc, Q and Vp) 
has its own variability parameter in the model described as omega parameters. This encompasses 
between subject variability, distribution variance and any variability found specific to the 
parameter in question. Additionally, there is also the residual or unexplained variability that cannot 
be accounted for and form the sigma parameters. The same process of simplifying the model as 
much as possible applies to these statistical models as well. Originally, during the model building 
process, all omega and sigma variables were included, meaning each fixed parameter had its own 
omega value and the sigma model allowed combined residual variability allowing constant or 
proportional error on the concentration values. The significance of these parameter inclusions to 
the final model was assessed by removing the parameters stepwise and similarly as explained for 
the structural model, observing notable decreases in -2LL, VPC and individual plots. For DS50B, 
omega parameters of clearance and volume fixed effects were low enough to be eliminated, and 
constant sigma variability was deemed statistically insignificant in the final model.  Elimination 
of all these parameters resulted in a mere increase in -2LL of 1.44, showing they did not add value 
to the final model. 
In Table 2-2 is shown the final parameters of the DS50B model. 
Tlag 
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Table 2-2: DS50B two-compartment model results 
 Parameter s.e. (lin) r.s.e.(%) 
Fixed effects:    
Foral 0.46 0.074 16 
ka (hr-1) 0.24 0.06 25 
V (L) 0.0186 0.0028 15 
Cl (L/h) 0.00251 0.00016 6 
Q (L/h) 0.0072 0.0017 23 
Vp (L) 0.102 0.007 7 
    
Covariate model:    
Beta Vp (tWEIGHT) 1 - - 
Beta V (tWEIGHT) 1 - - 
Beta Cl (tWEIGHT) 0.75 - - 
    
Parameter variability:    
Omega Foral 0.253 - - 
Omega ka 0.0603 0.65 1.09E+03 
Omega V 0 - - 
Omega Cl 0 - - 
Omega Q 0.461 - - 
Omega Vp 0 - - 
    
Sigma model    
Proportional 0.308 0.0094 3 
Constant 0 - - 
Note: Foral; bioavailability, ka; rate of absorption, V; central volume, Cl; clearance, Q; inter-compartmental clearance, 
Vp; peripheral volume. Standard error (s.e.) and relative standard error (r.s.e) expressed as a percentage of the 
population estimate were estimated by linearization of the Fisher information matrix. The covariate tWEIGHT is 
defined as the transformed log individual mass of each mouse centred around the median of the cohort mass. Parameter 
values equal to 0, such as Omega V are parameters that were excluded from the model based on their statistical 
insignificance as determined by -2LL. 
 
The beta parameters denoted results from the covariate model as explained in the data input 
section, where clearance and volumes were allometrically scaled by the transformed weight of 
each individual mouse. 
Standard error values were calculated by linearization of the Fisher Information Matrix. This is a 
way of measuring the amount of information that all observable random variables carry around the 
distribution of the population models. It includes the fixed effect parameters, the covariate model, 
omega variables and sigma variables.  
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Subsequent compound NLME modelling fixed parameters and statistical model results, such as 
that shown in Table 2-2 are presented in Chapter 7, page 197. 
In subsequent chapters the results of only the VPC without bins marked are shown. As stated 
previously all VPC output settings were described as a minimum bin number of 3, except 
amodiaquine which used 10 animals per group and therefore used a minimum bin number of 10. 
All individual fits are presented in the experimental chapter. The -2LL values are not included 
because as described they are abstract values and only guide model building and specific reduction 
or increase are quoted in the results section. 
2.4.5.5 Comparing methods 
To compare NLME results to NCA, all parameters and standard errors were converted to the units 
commonly used for preclinical pharmacokinetic data. Additionally for the NLME parameters, Cmax 
values were estimated from the individual plots and the half-life calculated by the PK Parameter 
Conversion Excel spreadsheet from S.L Shafer.99 AUC for the oral profiles were determined using 





Standard error in the case of AUC and half-life, were estimated by the square root of the summed 
squared relative standard errors of the relevant parameters. The new calculated relative standard 
errors were then converted to standard error. 
In subsequent chapters, the NLME data alongside the NCA parameter estimation with their 
respective standard errors is tabulated. The parameter estimates should be compared, but the 
standard errors cannot be compared. The NCA standard errors are merely calculated as the 
deviation from the mean divided by the square root of the group number. As mentioned the 
standard error calculation for NLME includes the structural model, the covariate model, the omega 
model and sigma model around the population fit. The standard error has no bearing on the quality 
of the model or parameter estimated, but rather just the data as observed in the final model. 
When comparing NCA and NLME results it is important to remember that the NLME results are 
fundamentally more appropriate than NCA on both physiological and mathematical grounds. In 
the case of DS50B, the fact that non-linear elimination occurred means modelling will obtain the 
best parameter estimates. The objective of comparing the NCA and NLME results is to observe 
how significant the deviations are in a preclinical setting. Here the school of thought remains that 
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the ease of NCA implementation compared to NLME is more valuable than accuracy gained in 
pharmacokinetic parameters at this early screening stage. 
Additionally, to refine the project objectives and evaluate the least amount of days that would 
result in an accurate estimation of the pharmacokinetic results, the data sets were reduced to 1, 2 
and 5 days and the model allowed to predict the parameter estimates. 
 
2.4.6 PK/PD simulation 
To compare the modelling pharmacokinetic results to the efficacy results obtained by the Swiss 
Tropical and Public Health Institute (Basel, Switzerland), additional simulations were run in 
Berkeley Madonna version 8.3.18 (Berkeley Madonna Inc., Berkeley, CA, USA).  Berkeley 
Madonna is a differential equation solver that allows simulations to be performed in milliseconds. 
It is a very useful tool that allows instantaneous feedback for pharmacometric analysis requiring 
simplicity and ease of implementation.100 The pharmacokinetic population parameters calculated 
by the most appropriate model, were input with coded differential equations describing the 
structural model.  
The dose amount and frequencies were changed according to the efficacy experiment and their 
respective AUC, Cmax and time above antiplasmodial NF54 IC50 (T>IC50) values extracted for a 
30 day simulation, equal to that of the efficacy experiment. 
 
2.4.7 Data subset analysis 
While NCA could not calculate the pharmacokinetic parameters of the compounds that had 
incomplete elimination data, NLME modelling might. To investigate the robustness of NLME 
modelling for extrapolating parameters from incomplete data, the final 15-day dataset was reduced 
to 24 hrs, 48 hrs and 120 hrs and input in Monolix® and re-estimated. The same model building 
progression as previously described was used to assess the smallest dataset for which NLME could 
still accurately predict parameters.  
 
2.4.8 In vitro ADME methods 
Following the pharmacokinetic results obtained, investigation of the in vitro absorption, 
distribution, metabolism, elimination (ADME) properties of the compounds were performed with 
the aim to clarify the great differences in clearance, and volumes observed for DS48B in relation 
to those of DS50B and DS23B.  
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Under supervision of the author of this thesis, the compounds were submitted to the Drug 
Discovery and Development Centre (H3D), University of Cape Town (South Africa). Ms Nina 
Lawrence and colleagues at H3D, performed the technical portion of the parallel artificial 
membrane assay (PAMPA), kinetic solubility [evaluated at pH 2 and pH 6.5 in phosphate-buffered 
saline, and pH 6.5 in fasted state simulated intestinal fluid (FaSSIF) buffer], lipophilicity assay 
and a 5-point microsomal stability assay for each compound. The author of this thesis performed 
the blood plasma partitioning assay. 
2.4.8.1 Parallel artificial membrane assay (PAMPA) 
For the PAMPA assay, the permeation of the test compounds across an artificial hexadecane 
membrane first introduced by Kansy et al (1998)101 was examined as quantified by LC-MS/MS. 
The assays were performed in triplicate in 96-well MultiScreen Filter plates (Millipore, 0.4µM 
PCTE Membrane). Membrane filters were pre-coated with 5% hexadecane in hexane and allowed 
to dry prior to the assay. A membrane integrity marker, Lucifer yellow was added to the pre-coated 
MultiScreen plate donor/drug solution wells meant to measure integrity of the membrane. 
Phosphate buffer at a pH of 7.4 was added to the 96-well acceptor plate. The test compound 
previously dissolved in DMSO at a concentration of 10 mM, and stored at -20°C prior to use was 
spiked into the donor buffer at physiologically relevant pH's (pH4, 6.5 and 8) at a final 
concentration of 1 µM. The donor plate was then slotted into the acceptor plate and incubated for 
4 hours at 25°C with gentle shaking (40 – 50 rpm). Following the incubation, samples from the 
acceptor wells and theoretical equilibrium wells were transferred to the analysis plate and the 
matrix matched with donor buffer. Acetonitrile containing the internal standard carbamazepine at 
a concentration of 0.0236 µg/mL was added to all samples. The samples were analysed by 
LC/MS/MS (Agilent Rapid Resolution HPLC, AB SCIEX 4000 QTRAP MS). The instrument 
response of analyte to internal standard peak areas were used to calculate the apparent permeability 
(Papp) in cm/s as follows: 
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The analyte to internal standard peak area ratio of the test compound in the acceptor compartment 
represents the instrument response for the acceptor compartment test compound amount (Iacceptor) 
and similarly the test compound to internal standard ratio of the combined total donor and acceptor 
compartments represent the Instrument response for samples at equilibrium (Iequilibrium). 
The constant used is calculated by the acceptor compartment volume equal to 0.25 cm3 (VA) and 
the donor compartment volume (VD) equal to 0.15 cm3. The accessible filter surface area (A) is 
equal to 0.24 cm2 and time is equal to the total incubation time represented in seconds. 
Membrane integrity was assessed by calculating the Papp of Lucifer Yellow with acceptable criteria 
values  less than 50 nm/s evaluated by a Modulus microplate reader with excitation 490 
nm/emission 510 – 570 nm values used.102 
2.4.8.2 Kinetic solubility 
Kinetic solubility assays were performed using the miniaturised shake flask method.103,104 The 
same 10 mM stock solutions of each of the test compounds prepared in DMSO described 
previously were used to prepare calibration standards ranging from 10 to 220 µM in DMSO. The 
10 mM stock solution was spiked at a volumetric ratio of 1 to 50 in phosphate buffered saline at 
pH 6.5, 0.01M hydrochloric acid equal to pH 2 and FaSSIF at a pH of 6.5. This was done in 
duplicate and resulted in a final DMSO concentration of 2%. The samples were slowly shaking 
for 2 hours at 25°C and were then filtered and analysed by means of HPLC-DAD (Agilent 1200 
Rapid Resolution HPLC with a diode array detector). The aqueous samples’ solubility 
concentrations were calculated by the best fit calibration curves constructed using the calibration 
standards. 
2.4.8.3 Metabolic stability assay 
The metabolic stability assay used a 5-point liver metabolic stability method. The assays were 
performed in duplicate in 96-well micro titre plates. The test compounds diluted from their stock 
solution to 0.1 µM were incubated individually in mouse, rat and pooled human liver microsomes 
(0.4 mg/mL) at 37 °C in the presence and absence of the cofactor nicotinamide adenine 
dinucleotide phosphate (NADPH) at a concentration of 1 mM. The predetermined time wells were 
quenched by adding 300 µL of ice cold acetonitrile containing internal standard (carbamazepine, 
0.0236 µg/mL) at either 0 min, 5 min, 10 min, 30 min or 60 min. Test compounds in the supernatant 
were quantified by means of LC/MS/MS (Agilent Rapid Resolution HPLC, AB SCIEX 4000 
QTRAP MS). 
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The quantified concentrations vs time points were used to determine the Obach intrinsic clearance 
(Clint) using the substrate depletion approach.105,106 The rate of elimination (k) was determined 
from the negative linear regression of the log concentration profile. Intrinsic clearance could then 
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The incubation volume for these experiments were 0.1 ml, while the mass of microsomal protein 
per well was 0.036 mg. The expression Z refers to the liver organ mass in mg per species body 
weight in kg, which used the following constants from Richmond et al (2010) shown in Table 
2-3.107 
Table 2-3: Constant Z that represents liver organ mass in mg per kg of species body weight 





The in vitro half-life could then also be calculated by the negative elimination rate constant (k), 
t1/2 = ln(2)/k. 





With hepatic blood flow in ml/min/kg (Q) determined by constants calculated from Davies & 
Morris (1993), shown in Table 2-4.108 
 
 
Preclinical pharmacokinetic evaluation of novel antimalarial and antituberculosis drug leads 
64  Natasha Strydom - April 2018 
Table 2-4: Q constant representing hepatic blood flow 






The lipophilicity assays were performed using a shake-flask procedure from a modified method 
from Alelyunas et al (2010).109 The previously mentioned 10 mM stock solutions of each test 
compound were spiked into a 1:1 mixture of phosphate buffer (pH 7.4) and n-octanol to a final 
concentration of 100 µM. The solutions were shaken vigorously (1500 rpm) on an orbital shaker 
for 3 hours at 25°C. Thereafter the samples were centrifuged in order to fully separate the aqueous 
and organic layer. The samples were analysed by HPLC-DAD (Agilent 1200 Rapid Resolution 
HPLC with a diode array detector) and the peak areas used to determine the partition coefficient, 





2.4.8.5 Plasma protein binding 
Plasma protein binding was measured using an ultracentrifugation method. The assays were 
performed in a 96-well microtiter plate with pooled human plasma, spiked with the previously 
mentioned stock solutions of test compound to a final concentration of 1 µg/ml and the assays 
performed in duplicate. A volume of 40 µl of the spiked plasma was immediately removed and 
quenched using 200 µl of ice-cold acetonitrile, containing 0.0236 µg/ml internal standard 
carbamazepine and stored at -20°C. This served as the total compound amount reference samples. 
After incubating the remaining plasma samples at 37°C for 1 hr, the samples were transferred to 
ultracentrifugation tubes and ultracentrifuged for 4 hrs at 37°C (42,000 rpm) (Optima L-80XP; 
Beckman). A volume of 40 µL supernatant was extracted and quenched with the internal standard 
containing ice-cold acetonitrile. Analyte concentrations of all compounds and sample types were 
determined by means of LC/MS/MS (Agilent Rapid Resolution HPLC and AB Sciex 4000 
QTRAP MS). The peak area ratios of compound to internal standard were used to determine 
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instrument response for the reference and supernatant samples. Plasma protein binding could then 





Where: Iref = Instrument response from the total compound amount; and ISN = Instrument response 
from the supernatant. 
2.4.8.6 Red blood cell to plasma partitioning coefficient 
Blood plasma partitioning was evaluated by the author of this thesis. Using a LC/MS/MS based 
depletion method adopted from Yu et al. (2005)110 with slight modification. Atenolol, propranolol, 
and chloroquine were used as controls and a structurally similar compound from the DS series was 
used as internal standard.  
Blood plasma partitioning ratio was determined by measuring the concentration of the drug from 
centrifuged whole blood plasma after equilibration to a carefully defined plasma control incubated 
at the same time (reference plasma), thus eliminating the use of different matrices. Since both the 
equilibrating plasma and reference plasma are identical, the instrument response factors from both 
aliquots were the same. Therefore, the analyte peak area ratio to the internal standard could be 







− 1 + 1	
Where: KRBC/PL = Blood plasma partitioning, H = haematocrit; IRefPl = Instrument response from 
the reference plasma; and IPl = Instrument response from the equilibrating plasma. 
Briefly the assay was performed as follows; freshly drawn heparinized human whole blood was 
divided into a reference plasma control group and an equilibrating group. The reference plasma 
control volume was centrifuged, haematocrit measured and the plasma collected. The whole blood 
and reference plasma groups were divided into appropriate aliquots per compound. A 1 mg/ml 
DMSO primary stock solution of each compound was serially diluted in water to obtain a final 
spiking solution that resulted in less than 0.1% DMSO in the final sample, ensuring haemolysis 
did not take place. Both the whole blood and plasma reference groups were spiked with this diluted 
test compound solution to obtain a final concentration of 500 nM and mixed gently. The samples 
were then incubated at 37°C for 1 hr. After incubation the whole blood samples were immediately 
centrifuged and 50 µl plasma collected. The same volume of the reference plasma control group 
aliquots was taken and the plasma samples extracted with 200 µl ice-cold acetonitrile containing 
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the structurally similar internal standard. The samples were analysed by LC/MS/MS (Agilent 
Rapid Resolution HPLC and AB Sciex 4000 QTRAP MS) and the peak areas obtained. All 
controls passed within 20% of the literature values from Yu et al. (2005).110 
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2.5 Results & Discussion 
2.5.1 Reinvestigation of the LC/MS/MS method 
Analysis of the repeat 56 hr experiments of DS23B and DS50B showed a rapid increase in pressure 
on the HPLC system while injecting the initial system check samples to measure instrument 
response. The peaks of the internal standard DS48B had started to tail, Figure 2-22, and showed 
the column was no longer viable for the extracted batch. 
 
Figure 2-22: Internal standard peak tailing  
Internal standard response on Waters Xterra™ MS C18 column used for previous method development showed severe 
peak tailing, probably due to expiration.  
 
Replacing the Waters Xterra™ MS C18 column with a Phenomenex® Kinetex C18 (2.1 x 50 mm, 
2.6 µm) column showed better chromatography and suitable pressure and the final batch was 
analysed. Quantitation showed a severe drop in internal standard response for 5 minute intravenous 
samples in both the DS23B and DS50B batches, and a mismatch between experimental, and 
calibration samples was observed.  The calibration standards did have acceptable accuracy and 
precision statistics, but the inconsistent internal standard response required further investigation. 
Figure 2-23 shows the internal standard peak area over the course of sample injection for the 
DS50B batch. 
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Figure 2-23: Internal standard drop  
A drop in internal standard peak area was observed for intravenous(IV) samples in the DS50B batch and a general 
mismatch between experimental and calibration samples. 
 
Following the trend in Figure 2-23, the internal standard response decreased for intravenous 
samples from injection number 60 as pharmacokinetic sample time increased and was lowest for 
the 5 minute intravenous samples. The samples were reinjected to ensure the instrument did not 
lose sensitivity during the batch, but the same trend was observed and the samples were discarded. 
The oral dosage formulation which hydroxypropyl methylcellulose and intravenous oral 
formulation, which contained polyethelyne glycol, polypropylene glycol, dimethyl sulfoxide and 
ethanol, could cause ion suppression of the analytes and internal standard, and would explain the 
observed trend of increased suppression occurring at the time of dosing and decreasing as the 
formulation vehicle was eliminated. Excluding the internal standard showed that the intravenous 
group’s concentration increased over time, meaning that the internal standard did compensate for 
the suppression and had to be included. However, the pharmacokinetic results presented in section 
2.5.3 showed that the analyte and internal standard were not suppressed proportionally resulting 
in DS23B being overcompensated and had higher concentrations than expected, namely 5 uM 
higher intravenous concentration at half the dose of the 7 hr experiment. DS50B was 
undercompensated resulting in a 2-fold lower Cmax at the same 20 mg/kg oral dose. Table 2-5-A 
shows reinvestigation of the chromatography using quality control samples spiked with the 
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intravenous formulation had a lower response than quality controls spiked with Millipore water to 
the same expected concentration of the dosage formulation. Redeveloped chromatography that 
avoided this suppression on a new Waters Xterra™ MS C18 (2.1 x 30 mm, 3.5 µm) column with 
slight modifications to the gradient used in the initial 7 hr pharmacokinetic showed acceptable 
precision of the peak areas, Table 2-5-B. 
Table 2-5: Improving chromatography after discovering ion suppression 








    
 DS23B DS23B  DS50B DS50B  
Peak area 9540 2840 6620 1120 








    
 DS23B DS23B  DS50B  DS50B  
Peak area:     4960 5150 5240 4920 
A: Using the same chromatography as the failed 56 hr pharmacokinetic batch, ion suppression from competing 
formulation background decreased peak area significantly, 29.8% and 16.9% of expected response for DS23B (green 
line) and DS50B (red line) respectively. B: Changing to a new Xterra column showed improved precision of 96.3% 
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2.5.2 Incomplete pharmacokinetic profiles 
In Figure 2-24 is shown the incomplete pharmacokinetic profiles of DS23B A; 7 hour 
pharmacokinetic experiment after an intravenous dose, B; 7 hour experiment after an oral dose, C; 
repeat intravenous experiment and D; oral experiment over 56 hrs. Similarly, Figure 2-25 shows 
the incomplete profiles for DS50B. The repeat 56 hrs experiments showed ionisation interference 
as described in previous Results Section 2.5.1, page 67. 
 
 
Figure 2-24: Incomplete pharmacokinetic profiles of DS23B 
Whole blood concentrations (µM) against time profiles of compound DS23B after A: 3 mg/kg intravenous (IV) dose, 
B: 20 mg/kg oral dose evaluated over 7 hours. C: 2.5 mg/kg intravenous dose evaluated over 32 hours and D: 20 
mg/kg oral dose evaluated over 56 hours with loss of LC/MS/MS signal and unreliable concentration results for these 























A: DS23B IV (3 mg/kg)
Individual IV data

























B: Oral DS23B (20 mg/kg)
Individual P.O. data





















C: DS23B IV (2.5 mg/kg)
Individual IV data





















D: Oral DS23B (20 mg/kg)
Individual P.O. data
Mean P.O. (20 mg/kg)
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Figure 2-25: Incomplete pharmacokinetic profiles of DS50B 
Whole blood concentrations (µM) against time profiles of compound DS50B after A: 3 mg/kg intravenous (IV) dose, 
B: 20 mg/kg oral dose evaluated over 7 hours. C: 2.5 mg/kg intravenous dose evaluated over 32 hours and D: 20 
mg/kg oral dose evaluated over 56 hours with loss of LC/MS/MS signal and unreliable concentration results for these 
two profiles. Open circles and the red line respectively represent individual data and the mean concentration data. 
 
Unfortunately, the loss in ionisation described in section 2.5.1, page 67, necessitated another repeat 
experiment. Linear extrapolation of the natural log concentrations on the final 3 samples of DS23B 
and DS50B was done to plan an experiment with the objective of obtaining a full pharmacokinetic 
profile after a 10 mg/kg dose that could be followed to the lowest level of quantification (LOQ) of 
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B: Oral DS50B (20 mg/kg)
Individual P.O. data

























C: DS50B IV (2.5 mg/kg)
Individual IV data

























D: Oral DS50B (20 mg/kg)
Individual P.O data
Mean P.O. (20 mg/kg)
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Figure 2-26: Extrapolated concentration data of DS23B and DS50B 
Extrapolated semi-log plots of the terminal phase points of A: DS23B and B: DS50B from their respective 56 hr 
experiments. Filled circular data points (green for DS23B and red for DS50B) represent the mean of the last three 
measured concentrations and the dashed line represents the extrapolated concentration from these three points. The 
blue line in both plots represent the lowest level of quantification (LOQ = 10 ng/ml). 
 
The extrapolated data predicted that DS23B would reach an LOQ concentration after 
approximately 360 hrs or 15 days, and for DS50B it was predicted that LOQ would be reached at 
approximately 384 hrs or 16 days. In a rigorous drug discovery setting, a 15 day pharmacokinetic 
experiment would be impractical. Nevertheless, in this academic setting, it was of interest to see 
how accurate the extrapolation would be. The repeat experiment, though unfortunate, provided an 
appealing opportunity to assess if simulated extrapolations were valid. Rarely on a preclinical level 
is there the opportunity to plan a prospective study of this nature. A 15 day pharmacokinetic study 
was therefore pursued for the oral groups with sampling occurring every day. 
 
The final results showed that compound DS50B was over predicted and reached LOQ at day 10, 
not 15, and compound DS23B reached a concentration of 9.02 ng/ml (s.e. 0.376) on day 15 
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2.5.3 Final pharmacokinetic results 
2.5.3.1 Amodiaquine 
In Figure 2-27 is shown the raw data of amodiaquine with observed concentration-time points for 
10 mice represented by open circles and a mean solid line added for A: Intravenous and B: Oral 
experiments. In Table 2-6 is shown the final calculated parameters of Amodiaquine for both NCA 
and NLME analysis for a side-by-side comparison. A visual predictive check of the final model 
used is shown in Figure 2-28 and stratified by oral and intravenous groups. The model best fit a 2-
compartment model as described in section 2.4.5. 
 
 
Figure 2-27: Observed pharmacokinetic data for amodiaquine in mice 
Individual observed concentration-time points from the amodiaquine pharmacokinetic experiment in 10 mice for 
A: Oral and B: Intravenous experiments. Observed data are represented by purple open circles and the mean data 























































B: Oral Amodiaquine (20 mg/kg)
Individual data
Mean data
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Table 2-6: Calculated pharmacokinetic parameters for amodiaquine in mice 
Amodiaquine 
Parameter a. Oral NCA b. IV NCA c. Two compartment 
Blood Cl 
(ml/min/kg) 
- 54.3 (6.54) 55.9 (7.27) 
Vc (L/kg) - 3.34 (0.483) 4.40 (0.572) 
Vss (L/kg) - 12.1 (2.14) 14.0 (1.82) 
t1/2 (hr) 3.88 (0.434) 2.95 (1.50) 3.78 (0.619) 
AUC0-inf (µM.min) 514 (26.6) 109(16.0) 489 (80.2) * 
Tmax (hr) 1.35 (0.429) - - 
Cmax (uM) 1.42 (0.127) - 1.35 (0.001) * 
F (%) 47.2 (2.45) - 48.6 (6.03) 
ka (hr-1) - - 0.735 (0.140) 
Standard error of parameters is represented in parenthesis next to final median value for 10 mice. F; bioavailability, 
ka; rate of absorption, Vc; central volume, Blood Cl; whole blood clearance, Q; inter-compartmental clearance, Vss; 
steady state volume. Standard error (s.e.) of the population estimate were estimated by linearization of the Fisher 
information matrix. The parameters calculated by NCA used SummitPK solutions™ and the NLME modelling was 
performed in Monolix®. Individual mouse weights were included as a covariate and allometrically scaled for clearance 
and volumes. Individual plots and final parameters with variability values are presented in Chapter 7: Experimental, 
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Figure 2-28: Visual predictive check of the final model used for Amodiaquine 
The graphical diagnostic plot shows the simulated output of the amodiaquine two-compartment model for the A: 
intravenous and B: oral pharmacokinetic experiments. The final model was established from the pooled oral and 
intravenous data and the diagnostic plots stratified according to dosing. Observed data above the limit of quantification 
is represented by blue dots and concentrations measures below the limit of quantification represented by red dots. The 
green line represents the empirical percentile of this observed data and the shaded pink area represents the median of 
the population estimate. Ideally, this empirical percentile should fit within the pink shaded area.  
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2.5.3.1.1 Summary of amodiaquine results 
Amodiaquine showed non-linear elimination hinting that a possible two-compartment model 
would be more appropriate. This was confirmed with a significant 74 point drop in objective 
function compared to a one-compartment model. In mice, the half-life of amodiaquine was a 
moderate 3.75 hrs after oral dosing. Whole blood clearance was moderate at 55.9 ml/min/kg and 
amodiaquine showed a high steady state volume of 14 L/kg. Amodiaquine has good bioavailability 
greater than 70% in mice. Unfortunately, the more active DEAQ metabolite of amodiaquine was 
not included during the original analysis of the pharmacokinetic experiment, because it was not 
available to us.  
The final two-compartment model of amodiaquine captured the observation well as seen by the 
visual predictive checks for both the oral and intravenous experiment. Comparing NLME results 
to NCA showed indiscernible results for all parameters, concluding that NCA captured the 
pharmacokinetic parameters very well for this dataset. 
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2.5.3.2 DS48B 
In Figure 2-29 is shown the raw data of DS48B with observed concentration-time points for 3 mice 
represented by open shapes representing each individual mouse and a mean line of the 3 mice 
added for A: Intravenous and B: Oral experiments. In Table 2-7 is shown the final calculated 
parameters of DS48B for both NCA and NLME analysis for a side-by-side comparison. A visual 
predictive check of the final model used is shown in Figure 2-30 and stratified by oral and 
intravenous groups. The model best fit a 2-compartment model. 
 
 
Figure 2-29: Observed pharmacokinetic data for DS48 in mice 
Individual observed concentration-time points from the DS48B pharmacokinetic experiment in 3 mice for A: 
Intravenous and B: Oral experiments. Each individual animal is represented by its respective open blue shape, and the 
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Table 2-7: Pharmacokinetics of amodiaquine analogue DS48B in mice 
DS48B 
Parameter a. Oral NCA b. IV NCA c. Two compartment 
Blood Cl 
(ml/min/kg) 
- 31.1 (1.45) 38.1 (3.43) 
Vc (L/kg) - 5.68 (1.21) 7.12 (1.57) 
Vss (L/kg) - 24.2 (0.122) 28.4 (3.98) 
t1/2 (hr) 10.5 (0.498) 9.51 (0.153) 9.40 (2.50) 
AUC0-inf (µM.min) 983 (122) 435 (17.2) 893 (134) * 
Tmax (hr) 2.24 (0.644) - - 
Cmax (uM) 0.983 (0.190) - 0.782 (0.004) * 
F (%) 57.6 (7.13) - 61.3 (0.066) 
ka (hr-1) - - 0.434 (0.110) 
Standard error of parameters is represented in parenthesis next to final median value for 3 mice. F; bioavailability, ka; 
rate of absorption, Vc; central volume, Blood Cl; whole blood clearance, Q; inter-compartmental clearance, Vss; 
steady state volume. Standard error (s.e.) of the population estimate were estimated by linearization of the Fisher 
information matrix. The parameters calculated by NCA used SummitPK solutions™ and the NLME modelling was 
performed in Monolix®. Individual mouse weights were included as a covariate and allometrically scaled for clearance 
and volumes. Individual plots and final parameters with variability values are presented in Chapter 7: Experimental, 
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Figure 2-30: Visual predictive check of the final model used for DS48B 
The graphical diagnostic plot shows the simulated output of the DS48B two-compartment model for the A: oral and 
B: intravenous pharmacokinetic experiments. The final model was established from the pooled oral and intravenous 
data and the diagnostic plots stratified according to dosing. Observed data above the limit of quantification is 
represented by blue dots. The green line represents the empirical percentile of this observed data and the shaded pink 
area represents the median of the population estimate. Ideally, this empirical percentile should fit within the pink 
shaded area.  
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2.5.3.2.1 Summary of DS48B results 
Like amodiaquine, DS48B showed non-linear elimination and a two-compartment model was 
found to be most appropriate with a significant 38 point drop in objective function compared to a 
one-compartment model. In mice, the half-life was high at 9.40 hrs after oral dosing, 2-fold greater 
than amodiaquine. Whole blood clearance was moderate at 38 ml/min/kg and a high steady state 
volume of 28 L/kg was observed. DS48B had good bioavailability greater than 60% in mice from 
modelling results. As mentioned the more active metabolite of amodiaquine was not included; this 
metabolite would have been more appropriate for pharmacokinetic comparison with DS48B. 
The DS48B final two-compartment model captured the oral observations better than intravenous 
observations. The model struggled to fully capture the non-linear elimination process seen at 8 
hours and over predicted the population distribution for this time point. NCA and NLME results 
were comparable and NCA captured the pharmacokinetics parameters for this dataset.  
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2.5.3.3 DS50B 
In Figure 2-31 is shown the raw data of DS50B with observed concentration-time points for 3 mice 
represented by open shapes, each representing an individual mouse and a mean line added for A: 
Intravenous and B: Oral experiments. In Table 2-8 is shown the final calculated parameters of 
DS50B for both NCA and NLME analysis for a side-by-side comparison. A visual predictive 
check of the final model used is shown in Figure 2-32 and stratified by oral and intravenous groups. 
The model best fit a 2-compartment model. 
 
Figure 2-31: Observed pharmacokinetic data for DS50B in mice 
Individual observed concentration-time points from the DS50B pharmacokinetic experiment in 3 mice for A: 
Intravenous and B: Oral experiments. Each individual animal is represented by its respective open red shape, and the 
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Table 2-8: Pharmacokinetics of amodiaquine analogue DS50B in mice 
DS50B 
Parameter a. Oral NCA b. IV NCA c. Two compartment 
Blood Cl 
(ml/min/kg) 
- 1.24 (0.256) 1.64 (0.098) 
Vc (L/kg) - 0.020 (0.011) 0.744 (0.112) 
Vss (L/kg) - 0.27 (0.216) 4.82 (0.338) 
t1/2 (hr) 39.21 (2.78) 30.1 (4.12) 41.9 (3.94) 
AUC0-inf (µM.min) 9050 (1420) 6570 (1880) 9870 (1690) * 
Tmax (hr) 3.28 (0.007) - - 
Cmax (uM) 5.02 (0.566) - 7.61 (0.029) * 
F (%) 41.0 (6.44) - 44.8 (6.90) 
ka (hr-1) - - 0.240 (0.060) 
Standard error of parameters is represented in parenthesis next to final median value for 3 mice. F; bioavailability, ka; 
rate of absorption, Vc; central volume, Blood Cl; whole blood clearance, Q; inter-compartmental clearance, Vss; 
steady state volume. Standard error (s.e.) of the population estimate were estimated by linearization of the Fisher 
information matrix. The parameters calculated by NCA used SummitPK solutions™ and the NLME modelling was 
performed in Monolix®. Individual mouse weights were included as a covariate and allometrically scaled for clearance 
and volumes. Individual plots and final parameters with variability values are presented in Chapter 7: Experimental, 
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Figure 2-32: Visual predictive check of the final model used for DS50B 
The graphical diagnostic plot shows the simulated output of the DS50B two-compartment model for the A: intravenous 
and B: oral pharmacokinetic experiments. The final model was established from the pooled oral and intravenous data 
and the diagnostic plots stratified according to dosing. Observed data above the limit of quantification is represented 
by blue dots and concentrations measures below the limit of quantification represented by red dots. The green line 
represents the empirical percentile of this observed data and the shaded pink area represents the median of the 
population estimate. Ideally, this empirical percentile should fit within the pink shaded area.  
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2.5.3.3.1 Summary of DS50B results 
Overall DS50B had an excellent pharmacokinetic profile. Clearance was calculated to be a low 
1.64 ml/min/kg resulting in a long half-life of approximately 42 hrs. A moderate 4.82 L/kg volume 
at steady state was observed. The bioavailability of DS50B, calculated to be 45%, was the lowest 
observed of the amodiaquine analogues in this series, but is still considered adequate for further 
progression. Even with the lowest bioavailability, the slow clearance of DS50B and moderate 
steady state volume resulted in a calculated oral Cmax and AUC0-inf of 5 and 10-fold more than 
DS48B and amodiaquine. 
Like all the amodiaquine series compounds, DS50B best fits a two-compartment model, apparent 
from its multi-exponential elimination and a 106 point drop in objective function compared to a 
one-compartment model. The intravenous concentration-time profile of DS50B showed an 
unexpected drop in concentration, decreasing the linearity of the profile too far reaching for NCA 
to cope with. The possibility of sample swaps or possible instrument error were investigated, but 
no error was found. Other experimental errors could still be responsible for this observation as an 
actual physiological/pharmacological explanation is not possible. Pharmacokinetic parameter 
calculations first attempted to include all sample points, but one outlier at 8 hrs was eventually 
excluded during NCA to avoid emphasis of this concentration-time point during calculation of the 
elimination phase. NLME included all observations without needing to exclude time points at 8 
hrs. It is evident from the presented visual predictive check that the proportional error and 
variability included on inter-hepatic clearance (Q) (see section 7.2.3.2, page 217 for complete 
summary table of model parameters) captured even the 8 hr observations well. NCA failed to 
accurately calculate central and steady state volumes with a 17-fold under prediction of steady 
state volume for the compound when compared to NLME, resulting in an under predicted 
intravenous half-life of 70% compared to NLME.   
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2.5.3.4 DS23B 
In Figure 2-33 is shown the raw data of DS23B with observed concentration-time points for 3 mice 
represented by open shapes representing 3 individual mice respectively and a mean line added for 
A: Intravenous and B: Oral experiments. In Table 2-9 below is shown the final calculated 
parameters of DS23B for both NCA and NLME analysis for a side-by-side comparison. A visual 
predictive check of the final model used is shown in Figure 2-34 and stratified by oral and 
intravenous groups. The model best fit a 2-compartment model as described in section 2.4.5. 
 
Figure 2-33: Observed pharmacokinetic data for DS23B in mice 
Individual observed concentration-time points from the DS23B pharmacokinetic experiment in 3 mice for A: 
Intravenous and B: Oral experiments. Each individual animal is represented by its respective open green shape, and 
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Table 2-9: Pharmacokinetics of amodiaquine analogue DS23B in mice 
DS23B 
Parameter a. Oral NCA b. IV NCA c. Two compartment 
Blood Cl 
(ml/min/kg) 
- 4.51 (2.26) 1.18 (0.083) 
Vc (L/kg) - 0.639 (0.576) 0.716 (0.122) 
Vss (L/kg) - 14.5 (4.08) 4.59 (0.322) 
t1/2 (hr) 48.9 (1.27) 82.8 (0.686) 51.4 (5.09) 
AUC0-inf (µM.min) 13000 (2120) 14100 (5190) 10400 (1721) * 
Tmax (hr) 3.17 (0.096) - - 
Cmax (uM) 5.72 (1.24) - 7.04 (0.016) * 
F (%) 30.5 (6.49) - 54.4 (8.16) 
ka (hr-1) - - 0.244 (0.085) 
Standard error of parameters is represented in parenthesis next to final median value for 3 mice. F; bioavailability, ka; 
rate of absorption, Vc; central volume, Blood Cl; whole blood clearance, Q; inter-compartmental clearance, Vs; steady 
state volume. Standard error (s.e.) of the population estimate were estimated by linearization of the Fisher information 
matrix. The parameters calculated by NCA used SummitPK solutions™ and the NLME modelling was performed in 
Monolix®. Individual mouse weights were included as a covariate and allometrically scaled for clearance and volumes. 
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Figure 2-34: Visual predictive check of the final model used for DS23B 
The graphical diagnostic plot shows the simulated output of the DS23B two-compartment model for the A: intravenous 
and B: oral pharmacokinetic experiments. The final model was established from the pooled oral and intravenous data 
and the diagnostic plots stratified according to dosing. Observed data above the limit of quantification is represented 
by blue dots. The green line represents the empirical percentile of this observed data and the shaded pink area 
represents the median of the population estimate. Ideally, this empirical percentile should fit within the pink shaded 
area.  
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2.5.3.4.1 Summary of DS23B results 
Like DS50B, amodiaquine analogue DS23B had excellent pharmacokinetic results. An extremely 
low 1.18 ml/min/kg clearance with a resulting long half-life of approximately 54 hrs was observed, 
the highest half-life of the series. The volume at steady state was a moderate 4.59 L/kg. The 
bioavailability of DS23B was approximately 54%. Similar to the slow clearance of DS50B and 
moderate steady state volume, the calculated oral Cmax and AUC0-inf of DS23B overshadowed that 
of DS48B and amodiaquine, by a 5 and 10-fold increase respectively. 
Again, like the other amodiaquine series compounds, DS23B with its non-linear elimination best 
fit a two-compartment model, and model progression showed a 136 point drop in objective 
function compared to a one-compartment model. DS23B Had the same unexpected drop in its 
intravenous concentration-time profile at 8hrs. The exact reason for this remains inconclusive, but 
an experimental error of some kind for this time point is possible. NCA calculations had to exclude 
these sample points to avoid emphasis of this concentration-time profile during calculation of the 
elimination phase. NLME included all observations without needing to exclude time points at 8 
hrs. The presented visual predictive show that the model that included proportional error and 
variability on clearance managed to capture the observations well (complete summary table of 
model parameters are presented in section 7.2.3.2, page 217). NCA over predicted steady state 
volume and whole blood clearance 4 and 3-fold respectively and the resulting intravenous half-
life was over predicted by 50%. 
 
2.5.4 Non-linear mixed effects modelling vs non-compartmental modelling 
The non-linear elimination of amodiaquine analogues showed that NLME would better calculate 
the pharmacokinetic parameters of these compounds. However, NCA could correctly capture 2 of 
the 4 compounds, namely amodiaquine and DS48B. The amodiaquine dataset of 10 mice greatly 
improved NCA calculations. Regarding compounds DS23B and DS50B that NCA could not 
accurately calculate, it is important to re-emphasise the empirical methodology of NCA that 
estimates pharmacokinetic parameters using different sections of the pharmacokinetic curve and 
calculates the values separately for each individual subject, averages the results, and expresses 
uncertainty as the standard deviation seen between final individual parameters. For DS23B and 
DS50B the drop in concentration at 8 hrs could not be solved by NCA leading to over and 
underestimation of some parameters. NLME analyses all the observations from different test 
subjects collectively to find the most appropriate pharmacokinetic parameters with their level of 
variability that best explains all the data. In this case, the variance added to selective parameters 
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and more importantly random effects that aid in estimating error could account for the likely 
experimental error encountered at the 8hr mark. Another advantage of the variability added was 
seen with samples that approached the lower range of quantification, which inherently have higher 
variability as the concentration decreases to the lowest limit of quantification. Here random effects 
can allow the concentrations to be considered with leeway as to what the actual concentration was 
with proportional and/or constant error to account for the accuracy and precision deficits a 
LC/MS/MS method may have. NCA simply cannot do this and at most observations can be deemed 
outliers and removed from the dataset if they are considered detrimental to the final parameters. 
The NLME analysis also had the advantage of being able to include samples that were below the 
limit of quantification for DS50B. The software can stipulate that at a specific time point a sample 
less than 10 ng/ml was observed rather than a data point that has no value in NCA calculations. 
 
2.5.5 Efficacy comparison 
Correlating the pharmacokinetic results with the respective efficacy evaluation in Plasmodium 
berghei infected mice, the most effective compound was DS23B with 30 mean survival days at a 
4 x 10 mg/kg oral dose. It also had the best pharmacokinetic properties with the lowest clearance 
rate and highest exposure. The intermediate half-life compound DS50B was the second most 
effective with 24 mean survival days at a 4 x 10 mg/kg oral dose, while the fastest clearing 
compound, DS48B, had the lowest survival rate of 16 days at the 4 x 10 mg/kg oral dose. DS48B 
may be more potent than DS50B as the 1 x 50 mg/kg dose showed similar efficacy, while DS48B 
had a 26-fold lower exposure than DS50B. Compounds DS50B and DS23B at multiple oral dosing 
of 4 x 10 mg/kg experienced higher accumulation, possibly increasing their concentration above 
IC50 and improving mean survival days longer and more effectively than the less successful DS48B 
compound.  
 
2.5.6 PK/PD simulation 
To assess trends in the PK/PD results of the compounds investigated, the models of each 
compound were used to simulate AUC, Cmax and T>IC50 with input dosing matching the efficacy 
experiments. An example of a simulated population average profile for DS48B following a 4 x 50 
mg/kg oral dose is shown in Figure 2-35. Table 2-10 shows the results of all compound simulations 
in comparison with their respective efficacy evaluation to observe potential PK/PD relationships. 
An important limitation to emphasise is that the C57Bl/6 mice are not the same strain as the NMRI 
Swiss-type strain used in the efficacy experiment. The NMRI Swiss-type strain was not available 
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at the University of Cape Town animal unit. As per the project’s ethics agreement C57Bl/6 mice 
were used for the pharmacokinetic evaluation and have been used by the Division of Pharmacology 
animal lab since 2008. Therefore, they were chosen as they are readily available to the lab and the 
previous amodiaquine pharmacokinetic study was performed in C57Bl/6 mice. 
 
Figure 2-35: Simulated profile of DS48B after 4 x 50 mg.kg dosing 
DS48B was simulated over 30 days or 720 hrs using typical population parameters determined from a two-
compartment model. The plot annotates area under the curve (AUC) represented in grey calculated from the integral 
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Table 2-10: PK/PD simulations of benzoxazole amodiaquine analogues  
DS48B 1 x 50 mg/kg 4 x 10 mg/kg 4 x 50 mg/kg 
AUC(µM.min): 3020 2410 12000 
Cmax (µM): 2.84 0.708 3.54 
T>IC50 (hrs):  83.3 135 158 
%P (MSD): 99.54(14.0) 99.76(15.7) 99.76(>30) 
DS50B 1 x 50 mg/kg 4 x 10 mg/kg 4 x 50 mg/kg 
AUC (µM.min): 79600 63600 318000 
Cmax (µM): 44.7 14.0 69.4 
T>IC50 (hrs): 452 478 668 
%P (MSD): 99.54(13.7) 99.88(24.0) 99.82(29.3) 
DS23B 1 x 50 mg/kg 4 x 10 mg/kg 4 x 50 mg/kg 
AUC (µM.min): 104000 83200 414000 
Cmax (µM): 38.8 14.6 73.3 
T>IC50 (hrs): 536 560 680 
%P (MSD): 99.54(23.3) 99.82(>30) 99.83(>30) 
Note: AUC; Area under curve (µM.min), Cmax; Maximum concentration (uM); T>IC50; Time above in vitro 
antiplasmodial activity NF54 IC50 (hrs), %P; Percentage reduction in parasitemia and MSD; Mean mouse survival 
days after treatment. 
Comparing simulated AUC, time above antiplasmodial NF54 IC50, and Cmax against the in vivo 
efficacy of the compounds only showed a trend between an increase in time above IC50 relative to 
an increase in mean survival days for all compounds. There was no correlation of efficacy with 
AUC and Cmax simulated values. Important limitations of this approach include that this 
experiment was not designed for PK/PD evaluation, which would require more diverse dosing 
(including dose amount and frequency) and have the final data scattered around each compound’s 
ED50. The simulation is also based on the assumption that no saturation occurs at the higher 
concentration reached with 50 mg/kg doses or repeated dosing. If these assumptions are not true, 
the simulated pharmacokinetics would underestimate the exposure and overestimate efficacy. 
However, it is interesting that at this early stage of preclinical screening, simulations using NLME 
already showed useful trends that could benefit dose optimisation in future efficacy experiments. 
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2.5.7 Robustness of NLME with subset data 
For compounds DS23B and DS50B all data subsets fit a two-compartment model. The final 
parameter results for DS23B and DS50B are shown in Table 2-11 and Table 2-12. Fixed effects 
parameter values that were greater or smaller by 30% of the 15-day experiment are highlighted in 
bold.  
Table 2-11: DS23B subset data analysis results 
 24 hrs 48 hrs 120 hrs 360 hrs 
Fixed Effects     
Foral 0.692 0.629 0.556 0.51 
ka (hr-1) 0.182 0.205 0.243 0.244 
V (L) 0.0184 0.0185 0.0184 0.0173 
Cl (L/h) 0.000541 0.000943 0.00166 0.00177 
Q (L/h) 0.0104 0.0101 0.01 0.00932 
Vp (L) 0.17 0.15 0.0971 0.0908 
Sigma     
Proportional 0 0 0 0 
Constant 0.323 0.314 0.325 0.335 
Foral; bioavailability, ka; rate of absorption, V; central volume, Cl; whole blood clearance, Q; inter-compartmental 
clearance. NLME modelling was performed in Monolix® and individual mouse weights were included as a covariate 
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Table 2-12: DS50B subset data analysis results 
 24 hrs 48 hrs 120 hrs 144 hrs 360 hrs 
Fixed Effects      
Foral 0.541 0.469 0.461 0.500 0.510 
ka (hr-1) 0.243 0.272 0.288 0.308 0.244 
V (L) 0.0190 0.0181 0.0189 0.0185 0.0173 
Cl (L/h) 0.00005  0.00286  0.00254  0.00229  0.00177  
Q (L/h) 0.0102 0.00792 0.0079 0.0103 0.0093 
Vp (L) 0.238 0.0831 0.0931 0.0894 0.0908 
Sigma      
Proportional 0.115 0.0568 0.706 0 0 
Constant 0.237 0.243 0.285 0.337 0.335 
Foral; bioavailability, ka; rate of absorption, V; central volume, Cl; whole blood clearance, Q; inter-compartmental 
clearance. NLME modelling was performed in Monolix® and individual mouse weights were included as a covariate 
and allometrically scaled for clearance and volumes. 
 
As expected the shorter terminal phase has the highest misinterpretation of the clearance parameter 
and for both 24 hrs and 48 hrs subsets of each compound MonolixÒ could not converge on the 
correct value. For DS23B a 120 hrs data subset was enough to come within a 30% margin of the 
final results. However, DS50B needed an additional 144 hr experiment. Therefore, a minimum 5- 
and 6-day experiment for DS23B and DS50B respectively could have captured the 
pharmacokinetics of these compounds. 
 
2.5.8 In vitro assay results  
Table 2-13 shows the performed in vitro ADME assays, performed by Ms Nina Lawrence and 
colleagues at H3D. The blood plasma partitioning experiment was performed by the author.  The 
results of the assays are discussed in sections 2.5.8.1 to 2.5.8.6 that follow. 
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Table 2-13: ADME results of amodiaquine analogues 
General structure  
Compound 






pH 2 198.5 (high) 198.8 (high) 195.9 (high) 200.0 (high) 
pH 6.5 179.3 (high) 174 (high) 154.5 (high) 194.2 (high) 
FASSIF pH 6.5 183 (high) 170.7 (high) 160.4 (high) 177.9 (high) 
Microsome species HLM RLM MLM HLM RLM MLM HLM RLM MLM HLM RLM MLM 
Half-life (min) 123.2 68.2 52.5 104.8 76.3 58.3 52.2 14 14.4 <10111 n.d. <10111 
CL(int) (mL/min/kg) 16.3 45.7 129.9 19.1 40.9 117.1 38.4 223.6 474.8 n.d. n.d. n.d. 
Predicted EH 0.4 0.5 0.6 0.5 0.4 0.6 0.6 0.8 0.8 n.d. n.d. n.d. 
Metabolic stability class (moderate) (moderate) (low) (low)111,112 
LogD7.4 2.56 (optimal) 1.01 (optimal) 0.93 (low) 1.57 (optimal) 
Log Pe (cm/s) -5.9 (moderate) -5.7 (moderate) -5.7 (moderate) -6.4 (moderate) 
% Plasma protein binding 98.8 (high) 98.7 (high) 98.8 (high) >90112 (high) 
Blood plasma partitioning 2.9 (high) 1.8 (high) 1.9 (high) 2.5 (high) 
ADME classification shown in parenthesis, n.d.; not done. All experiments performed under supervision of Ms Nina Lawrence and colleagues at the Drug Discovery and 
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2.5.8.1 Parallel artificial membrane assay (PAMPA) 
The PAMPA assay is based on passive diffusion across an artificial membrane. Passive diffusion 
is involved in processes such as absorption from the gastrointestinal tract, penetration over the 
blood brain barrier, and transport across cells; all important factors for predicting drug like 
properties of compounds.102 The experiment was quantified by LC/MS/MS after a 4-hr incubation 
at room temperature using PBS pH 6.5 (pH is a large factor in final LogPe results), which compares 
more closely to the pH of the small intestine where majority of passive diffusion takes place across 
the gastrointestinal wall.113–115 Permeability of the respective compounds were classified 
according to ranges per manufacturer Biofocus instructions (based on Kansy et al., 1998)101 
provided in Table 2-14. The reference compound amodiaquine had the best LogPe value of -6.4 at 
pH 6.5 and similarly all three compounds were classified as having moderate permeability which 
supports the in vivo bioavailability results, calculated greater than 40% for all compounds. This 
shows decent absorption across the gastrointestinal tract. Of course, passive diffusion is not the 
only pathway for compounds to be absorbed. Transcellular passive diffusion, as well as active and 
paracellular transport are also possible permeability pathways for drugs. Assays such as Caco-2, 
which consist of monolayer cultured human colon epithelial cancer cells to assess permeability 
with, can predict the mentioned pathways,116,117 and can provide more mechanistic detail. In this 
case, however, the PAMPA assays were sufficient to address permeability and correlated well with 
bioavailability.  
Table 2-14: PAMPA classification 
Permeability class LogPe 
High >-5.5 
Moderate -6.5 to -5.5 
Low <-6.5 
 
2.5.8.2 Plasma protein binding 
Human plasma protein binding data of compounds were obtained by incubation in human plasma. 
Plasma stability was assessed during the procedure against buffer samples to ensure correct 
interpretation of the binding data. Compound DS23B was the only compound to show a 
degradation of 1.5%.  Binding was very high for the compounds at more than 98% for all three 
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amodiaquine analogues. Literature predicts amodiaquine protein binding greater than 90%112 
much alike to the analogues.  
Plasma protein binding has continued to gain importance as the free-drug theory has proved useful 
in describing pharmacokinetic/pharmacodynamics relationships. The free-drug theory states that 
only unbound drug can interact and elicit an effect on its target receptor, and the unbound drug in 
tissue (intracellular space) is equal to the unbound drug in plasma (extracellular space).118 Plasma 
protein binding has become useful in predicting distribution, metabolism, elimination as well as 
possible toxicity and drug-drug interactions of drugs.119,120  
For distribution, tissue distribution (related to volume of distribution at steady state) was 
specifically considered to be proportional to the free fraction drug in plasma and inversely 
proportional to the tissue free fraction of a drug. To simplify, it is expected that high plasma protein 
binding will result in low steady state volume as highly plasma bound compounds are not available 
to move into tissues.118–122 However, for amodiaquine and DS48B, high steady state volume was 
observed and DS23B and DS50B showed moderate steady states volumes. Here it is important to 
consider that the plasma protein binding assay exists in an isolated environment and cannot 
account for the altered equilibrium that may exist with other binding sites. Changes in the unbound 
plasma fraction of a drug therefore do not always predict distribution of drugs as a low unbound 
drug does not mean no drug will move into tissue120 and the amodiaquine and the analogues 
presented here are a good example of this.  
The expected influence of higher plasma protein binding decreasing in vivo clearance was 
observed. This is due to less drug being available for elimination and metabolism. An example of 
this is renal excretion by glomerular filtration and/or active secretion that depend on free fraction 
drug, and metabolism that depends on an enzyme’s ability to interact with unbound 
drug.119,121,123,124 The very low clearance of this series and related long half-lives may well be due 
to their high plasma protein binding. 
There is concern for possible toxicity and drug-drug interactions when plasma protein binding is 
high. Antimalarial drugs are given in combination to prevent resistance and the high plasma 
protein binding of these compounds could have higher toxic incidents or wide population 
variability as small changes in protein binding (due to factors including drug-drug displacement 
or population factors such ethnicity) can lead to significant fluctuations in free fractions. This 
series was designed to limit toxicity due to reactive metabolite formation and this might prevent 
issues related to this type of toxicity. 
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2.5.8.3 Kinetic solubility 
Kinetic solubility at pH 2, pH 6.5 in phosphate-buffered saline and pH 6.5 in FaSSIF buffer, which 
contains a mixture of lecithins (phospholipids) and bile salts (sodium taurocholate) were evaluated 
at 25°C for 2 hrs. The different buffers were chosen to best simulate the pH gradient of the 
gastrointestinal tract environment, where a drug will encounter low pH stomach acid, to a more 
neutral environment in the small intestine.125 Table 2-15 shows solubility classification used 
according to Kerns & Di.126 
Kinetic solubility testing is important in early drug discovery screening as compounds that do not 
possess good solubility properties will have poor absorption and bioavailability as compounds 
need to be in solution to cross the gastrointestinal tract.111 Poor kinetic solubility can also 
negatively affect the quality of other in vitro ADME assays. 
Amodiaquine and its analogues all showed high kinetic solubility, measured between 155 and 200 
µM in all media. The excellent kinetic solubility results support the in vivo bioavailability values 
observed greater than 40% for all compounds. 
Table 2-15: Solubility classification 
Solubility Class Concentration (µM) 
High ≥150 
Moderate 50 – 150 
Low 5 – 49 
Very Low <5 
 
2.5.8.4 Metabolic stability assay 
Metabolic stability data of amodiaquine analogues DS23B, DS48B and DS50B in human, rat and 
mouse liver microsomes were performed in a five-time point assay over 60 minutes to establish 
predicted half-life, in vitro clearance (CL) and hepatic extraction (EH). Amodiaquine was not 
available to the lab at the time and was therefore not evaluated. 
Microsomal stability related to liver metabolism is a very advantageous assay in drug screening as 
the liver is the largest site of metabolism.127 Liver microsomes are prepared by liver 
homogenization and consists of subcellular fractions from the endoplasmic reticulum of hepatic 
cells.128 They are used specifically for phase I oxidation evaluation and contain enzymes such as 
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cytochrome P450, flavin monooxegenase, carboxyl esterase, epoxide hydrolase and Uridine 5'-
diphospho-glucuronosyltransferase (UDP glucuronyl transferase).129–131  
The metabolic stability classes for the amodiaquine analogues were classified as low for DS50B 
and moderate for DS23B and DS48B. The calculated intrinsic clearance values were not corrected 
for plasma protein or microsomal binding or blood plasma partitioning. Comparing the observed 
in vivo clearance values of the compounds there was a disconnect between DS23B and DS50B, 
which both showed very slow clearance and reasonable bioavailability’s which would suggest 
microsomal stability would be favourable.   
The high plasma protein binding discussed in section 2.5.8.2 can account for the mismatch as a 
small unbound fraction of free drug would be available for first pass effects. Additionally, non-
specific microsomal binding was not measured and can similarly account for the poor translation 
between the in vitro assay and in vivo observation.  
Amodiaquine is considered to have low metabolic stability according to literature111,112 which is 
beneficial as it is quickly metabolised to its more active metabolite DEAQ.  To ensure that the 
compounds did not have any possible concealed metabolites with similar retention times as their 
respective parent compound, the extracted mouse blood samples were sent for additional 
metabolite identification by Dr Mathew Njoroge from the Department of Chemistry, University of 
Cape Town (South Africa). No significant metabolites were detected in the final samples, showing 
that the compounds were indeed metabolically stable when administered in mice. 
2.5.8.5 Lipophilicity 
Experiments to examine the lipophilicity of the compounds were performed at physiological pH 
of 7.4. The lipophilicity of a compound is related to whether a compound favours partitioning into 
a non-polar (organic) or aqueous phase, and has a major effect on absorption, distribution, and 
pharmacological activity.132 
Ideally, the lipophilicity expressed as LogD value should be between 1 and 3, as too aqueous (<1) 
limits absorption from the gastrointestinal tract and too high (>3) can cause the compound to 
adhere to lipophilic membranes and not be available target interaction. Therefore, a moderate 
LogD between 1 and 3 is considered optimal for gastrointestinal tract absorption by passive 
diffusion after oral dosing (which the moderate PAMPA results indicate can still be an important 
route of absorption for this series) shows potential for increased oral bioavailability of a drug.109,132  
Like amodiaquine, compounds DS23B and DS48B showed optimal LogD values and all had good 
bioavailability to support this. The LogD value of 0.93 for DS50B is considered poor and 
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comparing the series bioavailability results, compound DS50B did have the lowest bioavailability 
of the compounds analysed. 
2.5.8.6 Blood to plasma partitioning 
The blood plasma partitioning value to describe distribution between red blood cells and plasma 
was determined by a modified LC/MS/MS-based depletion method.110 A blood plasma partitioning 
value great than 1 is usually a consequence of the compounds distributing into red blood cells.133 
Distribution into red blood cells for antimalarial compounds can be viewed as advantageous as 
they are able to reach their target site well. 
All three compounds showed high blood plasma partitioning values ranging from 1.8 to 2.9, in the 
same range as the reference amodiaquine that had a partitioning value of 2.5. A proportional 
relationship has been observed with blood plasma partitioning ratios and volume at steady state. 
Higher blood plasma partitioning also correlates with lower clearance as drug is not available to 
certain metabolism and elimination processes inside erythrocytes.133,134 This together with the high 
plasma protein binding observed correlates well with the low in vivo whole blood clearance 
observed for these compounds.   
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2.6 Conclusion 
The in vivo properties of the three compounds are summarized in Table 2-16. The three 
amodiaquine analogues show considerable potential as antimalarial drugs. 
Table 2-16: Summary of efficacy and pharmacokinetic parameters for benzoxazole 




DS48B DS50B DS23B Amodiaquine 
    
Oral 20 mg/kg 10 mg/kg 10 mg/kg 20 mg/kg 
Blood Cl (ml/min/kg) 38.1 1.64 1.18 55.9 
Plasma Cl 
(ml/min/kg) 
    
Vss (L/kg) 28.4 4.82 4.59 14.0 
t1/2 (hr) 9.40 41.9 51.4 3.78 
Bioavailability (%) 61.3 44.8 54.4 48.6 
AUC0-inf (µM.min) * 893 9870 10400 489 
Cmax (uM) 0.782 7.61 7.04 1.35 
NF54 IC50 nM 10.0 11.5 15.0 4.00 
P. berghei efficacy 
4 x 50 mg/kg (MSD) 
99.76 (>30) 99.82 (29.3) 99.83 (>30) 99.88 (>30) 
Note: NLME calculated pharmacokinetic parameters were obtained at a dose of 20 mg/kg for DS48B and 
Amodiaquine and 10 mg/kg for DS23B and DS50B 
 
The analogues were metabolically stable in vivo, had very attractive pharmacokinetic properties 
that coincide well with their observed efficacy. The pharmacokinetic properties of the analogues 
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trend of improved efficacy with increased concentration time above IC50. DS23B performed 
exceptionally well, rivalling the efficacy of amodiaquine and chloroquine. Analysis by NLME was 
greatly beneficial considering NCA would have incorrectly predicted better pharmacokinetic 
properties for DS50B compared to DS23B. Possible reasons for this include the lack of a 
mechanistic approach, missing elimination phase data and sample concentrations close to the 
lower limit of quantification. Accurate and precise results are vital in early drug discovery as 
compounds are progressed and eliminated through a resource limited screening cascade. NLME 
was also able to include data below the lower limit of quantification and samples affected by large 
variability, possibly due to experimental error.  
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3 ANTIMALARIAL 
AMINOPYRIDINE IN THE FORM 
OF ITS CYCLODEXTRIN 
INCLUSION COMPLEX 
3.1 Introduction 
The 3,5-diaryl-2-aminopyridine class of molecules show great promise as antimalarial drug 
candidates.135 The class was identified as promising selective antiplasmodial hits using an image-
based136 high throughput screen of the BioFocus DPI SoftFocus library.137 Through hit to lead 
optimisation, in vitro potency, absorption, distribution, metabolism and elimination (ADME) 
properties were addressed. Compound MMV017007 from this series was able to successfully cure 
mice infected with Plasmodium berghei at a dose of 50 mg/kg using the Peters test.138 This 
promising in vivo efficacy inspired hit to lead and lead optimisation campaigns, to continue 
improving activity, ADME, in vivo potency in the Plasmodium berghei infected mouse model and 
safety within the series. These efforts culminated in the discovery of the now clinical candidate 
MMV390048, Figure 2-1.135,139 To expand on viable clinical candidates and continue efforts to 
optimise this promising class, earlier leads were re-examined for risk properties that could be 
addressed. A physicochemical disadvantage associated with MMP is its poor solubility 
[0.021mg/mL in water/ethanol (99:1, v/v) at 25 °C]. One of the primary reasons high attrition of 
drugs are seen is due to the common issue with lipophilic drug candidates.140 This led to attempts 
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to improve solubility properties and rescue MMV017007 (hereafter referred to as 007) by 
supramolecular beneficiation.  
 
Hit Compound MMV017007 MMV390048 
   
K1 IC50: 0.049 µM 
NF54 IC50: 0.049 µM 
K1 IC50: 0.051 µM 
NF54 IC50: 0.051 µM 
hERG: 3.00 µM 
Cytotox (L6): >146 µM 
K1 IC50: 0.025 µM 
NF54 IC50: 0.051 µM 
hERG: >10 µM 
Cytotox (L6): 251 µM 
Figure 3-1: Selected 3,5,-diaryl-2-aminopyridines 
The original hit compound from the BioFocus DPI SoftFocus kinase library compared to optimised lead structures 
MMV017007 and MMV390048. Note: NF54 IC50; antiplasmodial activity showing 50% inhibition in Plasmodium 
falciparum drug sensitive strain NF54, K1 IC50; antiplasmodial activity showing 50% inhibition in a Plasmodium 
falciparum multi-drug resistant K1 strain, Cytotox (L6) cytotoxicity concentration in L6 muscle cell line. 
 
The benefits of crystalline forms of compounds include increased reproducibility in 
manufacturing, increased stability and less effort to purify crystalline forms.141 One of the 
approaches attempted included an extrinsic strategy of a cyclodextrin inclusion complex 
formulated between heptakis(2,6-di-O-methyl)-b-cyclodextrin (DMB) and 007. The structure of 
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Figure 3-2: Chemical structure of the host DMB molecule 
Heptakis(2,6-di-O-methyl)-b-cyclodextrin (DMB) structure as seen from the front and side to show the hydrophobic 
cavity and outer surface groups that can aid in hydrogen bonding and solubility in aqueous solutions. 
 
Cyclodextrins are oligosaccharides that have a hydrophilic exterior and lipophilic cavity that can 
form inclusion complexes with lipophilic guest molecules to improve their aqueous solubility.142 
Cyclodextrins are found as white crystalline powders. The crystal lattice is formed by hydrogen 
bonding on the secondary phase. Crystallization in aqueous medium causes some molecules of 
water to be included in the cyclodextrin cavity. Water molecules are also present as an integral 
part of the crystal structure (crystal water). The cyclodextrin-inclusion complexes are formed by 
the substitution of included water from the cyclodextrin cavity by the appropriate guest 
molecule.143,144 The guest molecule is not covalently linked with the host but associated with the 
lipophilic cavity, allowing for easy detachment. Solubility is improved by favourable hydrogen 
bonding between the outer surface hydroxyl groups of the cyclodextrin and water.145 The complex 
is in dynamic equilibrium with its guest molecule and host cyclodextrin, Figure 3-3. The 
equilibrium shifts to the free fraction by competitive displacement from endogenous bile salt and 
cholesterol in the stomach, change in temperature and drug uptake in tissues.146 Absorption of 
cyclodextrins themselves has been estimated at about 2 – 4% from the small intestine, with the 
remaining being degraded by amylase and absorbed as glucose.147,148 
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Figure 3-3: Dynamic equilibrium of DMB complex 
Simplified schematic of MMV017007 (007) represented in orange and Heptakis(2,6-di-O-methyl)-b-cyclodextrin 
(DMB) represented as the blue cone. The guest compound can move in and out of the DMB structure and an 
equilibrium takes place between these two forms. 
 
Ms. Laurelle Joseph at the Centre for Supramolecular Chemistry Research, University of Cape 
Town, (South Africa) attempted derivatisations of cyclodextrins, with namely, β-cyclodextrin, (2-
Hydroxypropyl)-β-cyclodextrin, heptakis(2,6-di-O-methyl)-β-cyclodextrin (DMB), 
heptakis(2,3,6-tri-O-methyl)-β-cyclodextrin (TRIMEB) and hexakis(2,3,6-tri-O-methyl)-α-
cyclodextrin (TRIMEA) to produce a co-crystal. Only the DMB derivatization was successful and 
yielded a 1:1 host-guest inclusion complex.  
Further examination of the apparent solubility of 007 in DMB at the highest host concentration 
employed (namely 20 mM) was 0.0592 mM, hence a 65-fold compared to 007. Using the hosts β-
CD (AN-type behaviour) and HP-β-CD (AL-type behaviour) as solubilisers yielded association 
constant values of 1620 M-1 and 2872 M-1 respectively. The solubility enhancement factors and 
respective highest concentrations employed were 17-fold for 20 mM β-CD and 49-fold for 23 mM 
HP-β-CD. The 1:1 host-guest inclusion complex between DMB and 007 (hereafter DMB·007) was 
deemed the most successful and was progressed to antimalarial screening. 
Ms. Joseph further characterised the DMB·007 complex to confirm its successful derivatisation 
and purity. This included thermogravimetric analysis (TGA) to quantify the water content as well 
as 1H NMR to determine the host-guest stoichiometry leading to the correct chemical formula for 
the inclusion complex, which could be reported with total confidence. Single crystal X-ray 
diffraction was used to solve the structure of the inclusion complex at atomic resolution, Figure 
3-4. The mode of guest inclusion, the role of the water molecules as well as the crystal packing 
could all be modelled unambiguously. Scale-up of the inclusion complex was performed to provide 
the necessary material for the antimalarial and further pharmacokinetic testing. The purity of the 
inclusion complex was confirmed using powder X-ray diffraction.149 
DMB∙007      DMB        007 
+ ⇌ 
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Figure 3-4 X-ray structure of the DMB·007 complex  
The host drawn is in stick representation and the guest is in space-filling mode (a) and a sectioned space-filling view 
to illustrate the mode of guest inclusion (b).149 
 
This DMB·007 complex and reference active ingredient, 007 were tested in vivo at 30, 10 and 3 
mg/kg in the Plasmodium berghei model, carried out by Dr Sergio Wittlin and colleagues at the 
Swiss Tropical and Public Health Institute (Basel, Switzerland). DMB·007 showed a 30% 
improvement in efficacy at 3 mg/kg over 007, Table 3-1.  
Table 3-1: Efficacy of DMB·007 complex 
Dose (mg/kg) 007 %P (MSD) DMB·007 %P (MSD) 
1 x 30 98.7 (8.33) 99.36 (9.00) 
1 x 10 97.8 (8.00) 98.6 (6.00) 
1 x 3 20.8 (3.00) 54.4 (7.00) 
Experiments using a single dose suppressive test performed by Dr Sergio Wittlin and colleagues at the Swiss Tropical 
and Public Health Institute (Basel, Switzerland). Note: Active pharmaceutical ingredient 007 as reference. heptakis 
(2,6-di-O-methyl)-β-cyclodextrin (DMB) complex with 007. %P: Reduction in percentage parasitaemia in the 
Plasmodium berghei mouse model (n = 3). MSD: Mean survival days after ending treatment.  
 
Examination of the original data from the efficacy experiment (Table 3-2) indicated that results 
from mice treated with 3 mg/kg of reference compound 007 had a much higher variance (standard 
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error 10.2) compared to the standard error of 2.20 of the DMB·007 group. Further, the mouse 
survival days were not an improvement on the control groups. 
Table 3-2: DMB·007 and 007 efficacy in Plasmodium berghei infected mice 
  Control Vehicle 007 DMB·007 
Dose (mg/kg)  - 3 3 
% Parasitaemia 
(Survival days) 
M1 8.13 (3) 41.1 (3) 58.7 (7) 
M2 8.77 (3) 12.3 (3) 53.3 (7) 
M3 33.1 (3) 9.09 (3) 51.3 (7) 
Mean 20.8 (3) 16.7 (3) 54.4 (7) 
Standard error 10.2 (0) 8.22 (0) 2.20 (0) 
Individual values for the efficacy experiment using a single 3 mg/kg dose suppressive test performed by Dr Sergio 
Wittlin and colleagues at the Swiss Tropical and Public Health Institute (Basel, Switzerland). Note: Active 
pharmaceutical ingredient 007 as reference. heptakis (2,6-di-O-methyl)-β-cyclodextrin (DMB) complex with 007. 
%P: Reduction in percentage parasitaemia in the Plasmodium berghei mouse model (n = 3). MSD: Mean survival 
days after ending treatment. 
 
Closer examination of the original efficacy experiment’s raw data showed that the 007 group had 
much higher variance (standard error 10.2) with two mice having no effect with comparable 
reduction in parasitaemia to the vehicle control group. Further, their mouse survival days were not 
an improvement on the control groups. The DMB·007 group did have low variance (standard error 
2.20) and consistent results in reduction on parasitaemia leading to improved mouse survival days 
over the control and 007 groups. 
 
3.2 Rationale 
It was hypothesised that an increase in solubility due to the complexation increased exposure and 
efficacy of 007 against Plasmodium berghei in infected mice. The kinetic solubility and 
pharmacokinetics at the lower dose range in mice were therefore examined to understand the 
improvement in efficacy. 
In a drug discovery and development setting, the 33.6% improvement in efficacy may not be 
sufficient to warrant further investigation. However, for the academic project undertaken, the 
Preclinical pharmacokinetic evaluation of novel antimalarial and antituberculosis drug leads 
108  Natasha Strydom - April 2018 
complex that showed modest improvement was the best available. The DMB·007 complex also 
showed a 65-fold increase in aqueous solubility which was deemed intriguing for further 
development. 
 
3.3 Methodology overview 
In Figure 3-5 is shown the approach and experiments undertaken for the pharmacokinetic 
evaluation of the active pharmaceutical ingredient 007 as reference and DMB·007. A LC/MS/MS 
quantification method was first developed in mouse blood for 007, section 3.4.2. The absorption 
of the DMB saccharide alone and DMB·007 are negligent due to their large size148,150 and the final 
quantification method only included 007 and a structurally similar internal standard.  A 24 hr 
pharmacokinetic experiment in mice was performed for oral DMB·007 and 007 administered 
groups (n = 3) at 5 mg/kg equivalent 007 dose in solid form using mouse sized capsules. A third 
group consisted of 007 dosed intravenously at 2.5 mg/kg as reference for clearance, volume of 
distribution and bioavailability calculations. The final concentration time points after LC/MS/MS 
quantification were analysed by NCA and NLME modelling. Two approaches of NLME 
modelling were attempted with results obtained placing different emphasis on the parameters 
responsible for the change in exposure, section 3.4.5. Additional kinetic solubility experiments 
were performed to evaluate the pH related effect of complex solubility. 
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Figure 3-5: DMB·007 evaluation methodology overview 
 
3.4 Methods 
3.4.1 In vivo antimalarial efficacy 
In vivo antimalarial efficacy testing was carried out by Dr Sergio Wittlin and colleagues at the 
Swiss Tropical and Public Health Institute (Basel, Switzerland) and followed a similar protocol 
recommended by Fidock et al.75 This includes the adapted method of the classical 4-day 
suppressive test of Peters74,76 to evaluate initial efficacy of compounds. Specific modifications 
were the same as described in section 2.4.1, page 33. The method only differed in dosing regimens 
and the animals were treated at 1 x 30 mg/kg, 1 x 10 mg/kg and 1 x 3 mg/kg of the 007 and 
DMB·007 compounds, similarly suspended in 70% Tween 80 and 30% ethanol (v/v). Analysis of 
efficacy was carried out the same as mentioned previously, with mean reduction in parasitaemia 





007 & DMB·007 
24 hr PK experiment 
5 mg/kg P.O. (n = 3) 
007 
24 hr PK experiment 
2.5 mg/kg IV (n = 3) 
3.4.3 
Analytical Animal 
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3.4.2 LC/MS/MS quantification 
Whole blood concentrations of 007 were quantified by an LC/MS/MS assay developed for a range 
of 4.1 – 3000 ng/ml. The samples were extracted by protein precipitation using 20 µl whole blood 
and 240 µl methanol containing a structurally similar internal standard. Gradient chromatography 
was performed on a Phenomenex® Kinetex PFP (2.1 x 50 mm, 2.6 µm) reverse phase column at a 
flow rate of 200 µl/min with mobile phases 0.1% formic acid (v/v) in water and acetonitrile. 
Transition 355→277 was analysed for the compound on an AB Sciex API 4000Q® mass 
spectrometer operated at unit resolution in multiple reaction-monitoring mode.  The compound 
ionised well and method development proceeded without challenges. The accuracies (%Nom) for 
low (10 ng/mL), medium (2000 ng/mL) and high (4000 ng/mL) quality controls ranged between 
95.5% – 97.3% and the percentage coefficient (%CV) was below 4.9%. In Figure 3-6 is shown the 
peak of a medium quality control. For further discussion on the analytical method used, see 
Chapter 7: Experimental, section 7.3.1, page 224. 
 
Figure 3-6: Representative chromatogram of MMV017007 
MMV017007 
Retention time: 3.20 min 
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3.4.3 In vivo pharmacokinetic experiment 
3.4.3.1 Animals 
All animal studies and procedures were conducted with prior approval of the Ethics Committee of 
University of Cape Town (approval number 013/028) in accordance with the National Code for 
animal use in research, education, diagnosis and testing of drugs and related substances in South 
Africa. The pharmacokinetic animal experiment used healthy six-week-old C57BL/6 mice 
maintained at the University of Cape Town animal facility and housed as previously described in 
Section 2.4.3.1, page 36. 
3.4.3.2 Compound preparation and administration 
All animal handling, administration of compounds and blood collection were performed by Mr 
Trevor Finch from the Division of Pharmacology, University of Cape Town (South Africa) under 
direct supervision of the author, with the author present at all procedure times. 
The nine, 6-week-old C57BL/6 mice were divided into one intravenous group consisting of three 
males weighing approximately 30 g and two oral dosage groups, each consisting of three females 
weighing between 23 and 24.5 g. For intravenous administration, test compound 007 weighed that 
morning was prepared by the author in an organic vehicle of 10% DMSO, 10% ethanol, 50% 
polypropylene glycol and 30% polyethylene glycol 400. 
The formulation was vortexed for 1 minute and solubility was confirmed by visual inspection of 
the dosage solution before administration, which took place within 30 minutes of weighing the 
compound. Intravenous injection required a slow push over 1 minute into the penile dorsal vein of 
60 µL total volume and was performed under microscope resulting in a 5 mg/kg dose. A volume 
of 20 µl of whole blood was collected from the tail tip at 0.08, 0.5, 1, 3, 8 and 24 h.  
For the oral groups the filled Torpac® capsules were prepared by Ms Laurelle Joseph at the Centre 
for Supramolecular Chemistry Research, University of Cape Town, (South Africa) under the 
guidance of the author of this thesis. The solid-state material was passed through a 100-micron 
sieve to ensure consistent particle size and surface area and filled in respective capsules using the 
Torpac® Profunnel capsule filler. The final mass coincided with a 5 mg/kg 007 dose, and DMB·007 
dose equivalent to 5 mg/kg of 007 for a 25 g mouse. 
Fasting the animals before pharmacokinetic evaluation to improve the issue of variability in 
absorption of these compounds was considered. However, this was decided against due to the 
inconvenience and discomfort of the animals, and the ability to see variability and accordingly flag 
solubility issues was deemed an advantage at this early stage in drug discovery and development.  
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The capsules, Figure 3-7, were dosed with a modified method designed by Mr. Trevor Finch. The 
dosing procedure gavaged anesthetised mice with a venous catheter, depositing the capsule in the 
oesophagus, which was then pushed into the stomach with a rounded tip stainless steel gavage 
needle. On average, the entire gavage procedure took 90 seconds, which compared well with the 
efficiency of gavaging a suspension, which averages 20 seconds in the experiments.  
 
Figure 3-7: Torpac® capsule and modified apparatus used for gavage 
Apparatus used by Mr Trevor Finch to gavage the capsules in C57/Bl6 mice. Mouse capsule size of 8.4 mm length 
and maximum 1.27 mm diameter. The capsule placed in the end of the venous catheter was gavaged in anesthetised 
mice. Measured polyetheretherketone (PEEK) tubing, not pictured here, was inserted and pushed to the end of the 
catheter, depositing the capsule. After removing the catheter and PEEK tubing, the oral gavage needle was used to 
push the capsule into the stomach. 
 
Blood samples from oral groups were collected at 0.5, 1, 3, 5, 8 and 24 h.  
All samples from the oral and intravenous groups were collected in 0.5 ml lithium heparin 
microvials and briefly vortexed to prevent blood coagulation and immediately put on ice at time 
of collection and stored at -80°C until extraction.  
The animal experimental spreadsheet listing animal weights and individual capsule masses is 
presented in Table 7-18, section 7.3.2, page 230 in Chapter 7: Experimental. 
 
3.4.4 Non-compartmental analysis 
NCA was performed using PK Solutions, version 2.0 (Summit Research Services, Montrose, CO, 
USA). The analysis used individual whole blood concentrations vs sample times and were 
analysed as described in section 2.4.4, page 38. 
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3.4.5 Non-linear mixed effects modelling 
Following the general sequential approach described in section 2.4.5, page 39, two modelling 
approaches were attempted using the same concentration-time data as the NCA calculations. 
Individual mouse weights were included as a covariate and allometrically scaled for clearance and 
volume. The first approach included first estimating the best structural model based on the 
intravenous data alone. The intravenous data of the compound best fit a one-compartment model, 
with first-order elimination. These parameters were fixed and the oral data of 007 and DMB·007 
evaluated separately. The oral dose allowed for a lag in transit (Tlag) time to the absorption 
compartment and absorption via a first-order process (ka) from this compartment to the central 
compartment. The parameters were estimated separately. The second modelling approach involved 
pooling all data from the three groups as a single data set to be analysed in the same model. The 
007 and DMB·007 groups were designated in the covariate model as a categorical variable and the 
model allowed to determine the optimised estimates from all nine mice. Again, a one-compartment 
model with first-order rate of absorption (ka) and a lag-time (Tlag) to account for the delay in the 
onset of absorption best fit the data. Model building was guided by physiological plausibility, 
significant improvements in -2 the log-likelihood (-2LL), and evaluation of goodness of fit plots, 
including visual predictive plots (VPC) and individual plots. The structure of the model is shown 
in Figure 3-8 below. Variability was included for all parameters and eliminated if statistically 
insignificant, as determined by changes in the -2LL. Individual plots and final parameters with 
statistical model parameters are presented in Chapter 7: Experimental, section 7.3.4, page 230.  
 
Figure 3-8: One compartment model with Tlag function 
Structurally the model follows that the compound can be introduced P.O. (per os, by oral administration) into the 
absorption compartment followed by a lag in transit time (Tlag). One-way transfer of the compound from the absorption 
compartment to the central compartment proceeds via absorption rate (ka) following first order kinetics. The central 
compartment is defined as the whole blood concentrations observed and where intravenous (IV) introduction of the 
dose occurs via instantaneous bolus. Clearance (CL) occurs from the central compartment defined as rate of 
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3.4.6 Kinetic Solubility 
Kinetic solubility was determined by the miniaturised shake flask method103,104 with modification. 
The experiment was performed by Mr Lloyd Tanner from the Division of Pharmacology, 
University of Cape Town (South Africa) under direct supervision of the author of this thesis. The 
method used a 10 mM stock solution of 007 and a 37.8 mM stock solution of DMB·007, equivalent 
to an equal amount of 007 in both solutions, prepared in acetonitrile. The stock solutions of 007 
were used to prepare calibration standards ranging from 11 to 220 µM in acetonitrile. The stock 
solutions were added to a 96 well plate and dried using a Mivac© drying apparatus. Respective 
buffers that included phosphate buffered saline at pH 7.4, 0.01 M hydrochloric acid equal to pH 2 
and FaSSIF buffer at a pH of 6.5 were then added to this dried material to a final concentration of 
200 µM to simulate a dissolution step as opposed to the traditional method that spikes stock DMSO 
solution in relevant buffer. The aqueous samples and calibration standards prepared in phosphate 
buffer at a range of 11 – 220 µM were then slowly shaken for 2 hours at 25°C using a plate shaker. 
The solutions were then filtered and analysed by means of HPLC-DAD (Agilent 1200 Rapid 
Resolution HPLC with a diode array detector). The aqueous samples’ solubility concentrations 
were calculated by the best fit calibration curves constructed using the calibration standards. 
 
3.5 Results and discussion 
At the time of the experiment, the capsules were still on a trial basis, but performing this 
experiment in mice rather than rats or dogs had the advantage of needing less of DMB·007 for the 
smaller animals and matching the animal species of the efficacy model. The mouse-sized capsules 
have since been introduced commercially. 
The Tocris® mouse sized capsules are designed to disintegrate within 10 minutes in the stomach. 
High variance was expected with the added disintegration and dissolution steps and per the 
approved ethics agreement it was necessary to stay within a group number of 3. 
 
3.5.1 Pharmacokinetic profiles and calculated parameters 
In Figure 3-9 is shown the observed concentration-time points raw of the aminopyridine 
intravenous and oral capsule experiments, each using n = 3. In Table 3-3 are shown the final 
calculated parameters for both NCA and NLME attempts for a side-by-side comparison. Visual 
predictive check of the final models attempted are shown and stratified by oral and intravenous 
groups in Figure 3-10. The model best fits a 1-compartment model with a Tlag function. 
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Figure 3-9: Observed pharmacokinetic data for aminopyridine experiment in mice 
Individual observed concentration-time points from the A: 007 pharmacokinetic intravenous experiment, B: DMB·007 
oral experiment and C: 007 oral experiment (n = 3). Each individual animal is represented by its respective open 
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Table 3-3: Comparison of parameter values by method 
Parameter DMB·007 007 IV 
Non-compartmental analysis 
Blood Cl (ml/min/kg) - - 1.94 (0.236) 
Vd (L/kg) - - 0.74 (0.058) 
t1/2 (hr) 6.12 (1.79) 3.82 (0.516) 4.58 (0.787) 
AUC0-inf (µM.min) 2131 (241) 1548 (715) 3666 (442) 
Tmax (hr) 4.96 (0.011) 3.93 (0.683) - 
Cmax (uM) 2.98 (0.856) 2.47(0.898) - 
F (%) 29.3 (3.53) 22.1 (9.47) - 
Conc 24 hr (µM) 0.295 (0.096) 0.061 (0.0354) 0.25 (0.135) 
NLME modelling as combined data set 
Blood Cl (ml/min/kg) - - 2.34 (0.304) 
Vd (L/kg) - - 0.82 (0.025) 
ka(hr-1) 0.815 (0.230) 1.76 (1.10) - 
t1/2 (hr) - - 4.05 (1.05) 
AUC0-inf (µM.min) 1970 (335) 1360 (585) 5330 
Tlag (hr) 2.83 (0.210) 2.76 (0.350) - 
Cmax (uM) 2.96 (0.776) 2.84 (1.11) - 
F (%) 24.9 (11.0) 21.5 (0.99) - 
NLME modelling as separate data sets 
Blood Cl (ml/min/kg) 2.68 (fixed) 2.68 (fixed) 2.68 (0.080) 
Vd (L/kg) 1.06 (fixed) 1.06 (fixed) 1.06 (0.032) 
ka(hr-1) 0.926 (0.38) 1.58 (1.2) - 
t1/2 (hr) 4.59 (fixed) 4.59 (fixed) 4.59 (0.138) 
AUC0-inf (µM.min) 1940 (279) 1310 (542) 5240 
Tlag (hr) 2.88 (0.13) 2.59 (0.47) - 
Cmax (uM) 2.91 (0.571) 2.85 (1.09) - 
F (%) 30.1 (8.70) 22.7 (13.0) - 
Standard error of parameters is represented in parenthesis next to final median value for 3 mice. F; bioavailability, ka; 
rate of absorption, Vd; volume of distribution, Blood Cl; whole blood clearance, Tmax; time of maximum 
concentration, Cmax, maximum concentration. The parameters calculated by NCA used SummitPK solutions™ and 
the NLME modelling was performed in Monolix®. Individual plots and final parameters with variability values are 
presented in Chapter 7: Experimental, section 7.3.3.1, page 232. 
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Figure 3-10: Visual predictive check of the final model used for 007 
The graphical diagnostic plots of the aminopyridine dosage forms by method used. Observed data above the limit of 
quantification is represented by blue dots and concentrations measures below the limit of quantification represented 
by red dots. The green line represents the empirical percentile of this observed data and the shaded pink area represents 
the median of the simulated population estimate. Ideally, this empirical percentile should fit within the pink shaded 
area. The combined approach is a single model using data pooled from both oral and intravenous data, and the 
diagnostic plots here are stratified according to dosing. The separate approach consists of three separate models for 
each dosing group. First a robust model for the intravenous data was established to accurately determine clearance 
and volume which was fixed in the next two respective models for each dosing form.  
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3.5.1.1.1 Comparison of results for aminopyridine dosing 
Examining the pharmacokinetic profiles of the three experiments, 007 was detectable for the entire 
duration of 24 hrs in all groups. As expected parameters calculated by NCA showed the capsule 
dosage form had higher variability in absorption due to the added variability of capsule and 
compound dissolution. The rate of absorption for DMB·007 from the concentration-time profile 
appeared slower with a significant lag in absorption and a longer time to maximum concentration 
(Tmax) of 5 hours compared to 4 hours for 007. Mean bioavailability suggests higher exposure was 
observed for DMB·007, which also showed less variability in pharmacokinetics, suggesting its 
absorption to be more consistent and predictable. Apparent terminal half-life was higher for 
DMB·007 and at 24 hours after the dose, an average concentration of 0.3 µM was observed, much 
higher than the average concentration of 007, which was only 0.06 µM.  
The pharmacokinetic profile of the 007 compound appeared to show linear elimination with an 
initial a-slope, distribution phase, of higher magnitude during the first 2 hours compared to the b-
slope, elimination phase, Figure 3-11. This initially suggested a two-compartment model may best 
fit the data. 
 
Figure 3-11: Pharmacokinetic profile of intravenous 007 
The log-scaled intravenous profile of 007 (n = 3) with observations shown in open shapes respective of individual 
animal and the mean intravenous concentration shown by solid red line. The a and b slope related to distribution and 
































-a slope (distribution) 
-b slope (elimination) 
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Model building proceeded with the general approach as described in section 2.4.5, page 39 and 
started with a one compartment model, in this case starting with just the intravenous reference 
data.  Changing the structural model to a two-compartment model with two added parameters 
namely, inter-compartmental clearance and peripheral volume resulted in the log-likelihood 
function dropping only 3 points, which was not statistically significant for the additional two 
parameters included. There was also no striking improvement in diagnostic plots showing that a 
one-compartment model was statistically relevant to capture the intravenous dataset. Whole blood 
clearance was calculated to be low at 2.68 ml/min/kg (38% higher than NCA calculations) and 
volume of distribution was low at only 0.74 L/kg confirming that the compound did not greatly 
move into peripheral space and stayed in the measured central compartment. The half-life was 
moderate at 4 hrs.  
Model building for the oral groups used these clearance and volume parameters as fixed values 
and necessary oral bioavailability and rate of absorption parameters added in each dosing groups’ 
respective oral model. A delay in absorption was clear from the oral profiles and inclusion of a 
Tlag parameter caused a significant drop in objective function, together with improved diagnostic 
plots, confirming its inclusion. Both the 007 dosing group and DMB·007 had similar lag in 
absorption times, calculated close to 3 hrs. This was different from the initial NCA impression, 
showing that NLME could “fill-in” the individual profiles compared to the empirically observed 
Tmax and Cmax values from NCA that can be misleading if sampling does not occur at exactly Tmax. 
This concluded that both dosage forms had similar transit times from capsule to compound 
available for absorption.  
Further the modelling approach using separate datasets result showed a 9% increase in 
bioavailability for DMB·007 and though variance was high in both models, DMB·007 showed less 
variance supporting the results of the NCA. When clearance and volume of distribution were 
unfixed and re-estimated to assess the stability of the model, a significant increase in objective 
function did occur for both models. Unfixing parameters should not cause an increase in objective 
function value, so this was interpreted as a sign that a local minimum of the objective function 
value was encountered during the search for the optimal parameter values, possibly indicating that 
the model was not stable and over-parameterised for such a small data set. The differences in the 
final parameter estimates of the freed models were a lower clearance of DMB·007 and 11% 
increase in bioavailability in favour of DMB·007 compared to 007.  
A joint model for both 007 and DMB·007 with separate estimates for ka, bioavailability and Tlag 
of the two compounds was also attempted and showed slightly different results compared to the 
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separate analyses. In this model, no significant increase in bioavailability was observed and the 
model showed a faster rate of absorption (ka) for 007 when compared to DMB·007 (1.7 and 0.8 
hr-1 respectively), and larger variability observed for 007 than DMB·007.  
 
3.5.2 Modelling attempts and limitations 
It is not straightforward to decide what modelling approach is the most suitable to interpret this 
data. The argument for developing a joint model is mathematical/statistical in nature as the model 
gains power in sample size and is expected to be more robust. The argument against this asserts 
that the introduced dose is fundamentally different in chemical nature, so a separate or more 
flexible structural model may be necessary to account for the complexity of the absorption and the 
differences between the two compounds. Adding complexity to the model such as using a mixed-
order absorption or transit compartment model was attempted but not feasible, as the added 
complexity could not be supported by the data and was prone to lead to more bias than solid 
answers.  
NLME relies on finding parameters that best fit all the data, and even separating the absorption 
parameters of DMB·007 and 007 as a categorical covariate could not robustly identify significant 
differences. The model could not reliably attribute the differences to either Tlag, ka, or 
bioavailability, and the results were found to be mostly driven by the choice of initial parameter 
estimates rather than solid differences in the data.  
Despite this uncertainty, results from both the separate or joint modelling approach provide similar 
results to the kinetic solubility and final efficacy results. Of course, it is an important limitation to 
note that a direct comparison between the efficacy experiment that used suspension formulations 
cannot be directly compared to the pharmacokinetic study that used a solid-state formulation in 
this case. The separate models approach suggested higher bioavailability, while the joint model 
proposed more consistent, slower absorption from the duodenum. Both results are consistent with 
increased concentration observed at 24 hours and improvement in DMB·007 efficacy in vivo over 
007.   
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3.5.3 Kinetic Solubility 
In Table 3-4 is shown the solubility experiment results performed by Mr Lloyd Tanner from the 
Division of Pharmacology, University of Cape Town (South Africa) under supervision of the 
author of this thesis. The concentration of 007 (the guest molecule able to cross the intestinal wall) 
was measured.  
Table 3-4: Kinetic solubility of DMB·007 and 007  
  Concentration of 007 measured (µM) 
 DMB·007 007 
pH 2 in 0.01 M HCl solution 198 (1.75) 170 (0.261) 
pH 6.5 in FaSSIF media 65.5 (2.24) 23.1 (0.568) 
pH 7.4 phosphate buffer 52.9 (1.36) 22.0 (0.569) 
The solubility experiment was performed by Mr Lloyd Tanner from the Division of Pharmacology, University of 
Cape Town (South Africa) under direct supervision of the author and used a miniaturised shake flask method. The 
concentration of 007 was measured for comparison. FaSSIF: 25°C for 2 hrs. n = 2 
 
Improved kinetic solubility was observed for DMB·007 at all pH’s with a two-fold increase at 
FaSSIF pH 6.5 and pH 7.8, and a slight improvement at pH 2. As expected, comparing the 
acetonitrile dried method to DMSO spiked concentrations had lower solubility results. Ideally, the 
best practice to evaluate the dissolution would be an exact mass of pre-weighed complex with 
buffer added to the solid mass, but the low yield and high effort required to produce DMB·007 
required conservative efforts in evaluation. The assays were kept at 2 hrs to best simulate transit 
times through the stomach and were in line with the final pharmacokinetic results. 
The increase in solubility at pH 2 for both DMB·007 and 007 due to partial ionisation of the amine 
group is problematic as absorption should ideally take place in the higher pH environment of the 
duodenum where there is a larger surface area and longer transit times to allow for complete 
absorption. Stomach emptying could cause great variance as early emptying after dosing could 
lead to inadequate time for dissolution and subsequent absorption, and could even lead to dissolved 
compound crashing out in the higher pH duodenum. Previous pharmacokinetic studies show that 
Preclinical pharmacokinetic evaluation of novel antimalarial and antituberculosis drug leads 
122  Natasha Strydom - April 2018 
cyclodextrins are capable of delayed release due to a pH-dependent shift in dynamic equilibrium, 
releasing the guest molecule in intestinal, rather than gastric fluid and improving absorption and 
bioavailability from the small intestine.113–115 The DMB·007 complex did show improved 
solubility of 2.8-fold at pH 6.5 FaSSIF media and 5.3-fold in pH 7.4 phosphate buffer compared 
to 007. 
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3.6 Conclusion 
Table 3-5 compares the final results of DMB·007 and 007 with the acetonitrile dried solubility 
method and separate modelling approach. 
Table 3-5: Summary of DMB·007 and 007 results 
  DMB·007 007 
Bioavailability (%)  30.1 22.7 
Tlag (hr)  2.88 2.59 
ka (hr-1)  0.926 1.58 
Solubility pH (µM) 2 198 170 
 
(Fassif)    
6.5 
65.5 23.1 
 7.8 52.9 22.0 
%P (MSD) 1 x 3 mg/kg 54.4 (7) 20.8 (3) 
Note: Pharmacokinetic parameter assessed at 5 mg/kg oral dose. %P: Reduction in parasitaemia (%), MSD: Mean Survival Days. 
 
To draw a single conclusive reason for the difference observed in efficacy of DMB·007 and 007 
remains challenging. Speculatively, a pH dependent change in dissolution for DMB·007 and 007 
resulting in increased absorption from the duodenum would explain the decreased variance and 
change in apparent half-life of the NCA results for DMB·007, and improved final exposure. Either 
the joint or separate modelling approaches that respectively showed improved bioavailability or 
improved rate and consistency in absorption support the narrative of higher and more consistent 
absorption for DMB·007. However, the emphasis on which parameter is responsible remains 
unknown. Decreasing variance in absorption supports the known drug discovery paradigm that a 
compound’s reproducibility in vivo is as significant if not more important than an improved 
increase in absorption.151 However, it is important to maintain that the experiments used to 
evaluate the expected pharmacokinetic improvements all show small and possibly insignificant 
differences.  
Criticism of the modelling used in this study rightly observe it as a “hit-and-miss” approach that 
is noteworthy. Although variance in the capsule dosing form was assumed to be higher, it was 
thought that modelling could overcome this, but this was not possible. To keep in line with the 
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objectives of the study it needed to exhaust all possible modelling options to compare NCA and 
NLMA. One school of thought believes that modelling even to ascertain variability within the 
dosing forms is a positive outcome and speaks to current knowledge of the experiment and where 
improvements need to be made Future experiments to evaluate the effect of DMB·007 
complexation on pharmacokinetics would benefit from higher animal numbers and more sample 
times at the expected absorption phase. In contrast, another school of thought believes that 
modelling already adds a level of difficulty that lacks efficiency at this preclinical stage. 
Further criticism of the technique used include the capsule use and that it is a flawed design and 
an over complication of a mouse pharmacokinetic study that was unlikely to lead to any 
meaningful results. Notwithstanding this, it is noteworthy that the quality of the material that 
showed a 65-fold increase in aqueous solubility provided by the Supramolecular group warrants 
further progression. This would ideally include dissolution studies. Therefore, progressing to 
animal studies was the simplest approach in the lab repertoire at the time. Rats and dogs are 
commonly used in capsule dosing where the material tested needs to stay in a solid-state to assess 
its improvement in dissolution.152–161 Mice capsule provided a unique advantage here as they were 
more similar to the mice used for efficacy studies and considering their smaller size their greatest 
advantage was that less of DMB·007 needed to be synthesised. 
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4 FUSIDIC ACID PRODRUGS FOR 
POTENTIAL REPOSITIONING IN 
TUBERCULOSIS 
4.1 Introduction 
Fusidic acid is a well-characterised antibacterial drug that shows favourable in vitro 
antimycobacterial activity, Figure 4-1.162–164 Introduced clinically in the 1960s for the management 
of gram-positive infections including methicillin resistant Staphylococcus aureus (MRSA),165–168 
fusidic acid possesses favourable pharmacokinetic properties and a well-tolerated safety 
profile.169,170 The naturally occurring fusidane antibiotic acts by inhibiting protein synthesis 
through stabilisation of the elongation factor G – GDP complex, preventing peptide elongation, 
Figure 4-2.171,172 
            
Figure 4-1: Structure and activity of fusidic acid 
MIC99; minimum inhibitory concentration to inhibit 99% of mycobacterial growth, CHO IC50; cytotoxicity 










Activity MIC99: 1.25 µM 
Cytotoxicity in CHO IC50: >194 µM 
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Figure 4-2: Sites of antibiotic action during protein synthesis. Adapted from Wilson, 2009.173 
During initiation, initiation factors (IF) 1, 2 and 3 assist ribosome complexation and incorporate messenger RNA 
(mRNA) at its 5’ cap position and insert coded transfer RNA (tRNA) carrying its appropriate amino acid.  Elongation 
factor thermo-unstable (EFTu) assists additional tRNA to move into the free ribosome site where peptide elongation 
can occur. Elongation factor G (EFG) assists in translocating mRNA and tRNA as the ribosome complex moves along 
the mRNA sequence to insert coded tRNA carrying amino acids that form peptide bonds with the lengthening peptide 
chain. Finally, when the mRNA reaches its terminal stage, release factor 3 (RF3) reads the stop codon, signalling 
termination where EFG and ribosome recycling factor (RFF) assist in removing mRNA and tRNA, and split the 
ribosome complex that can return to the initiation phase of a new peptide synthesis. Fusidic acid stabilises EFG-GTP 
in the ribosome complex, thereby preventing turnover, which disrupts the translocation and termination stages of this 
sequence. 
 
The antimycobacterial activity of fusidic acid, including activity against resistant clinical 
strains,163 unique mode of action and well-tolerated clinical profile made it an attractive compound 
to repurpose for the potential treatment of tuberculosis. The Global Alliance for Tuberculosis Drug 
Development initiated efficacy evaluation of fusidic acid in mice at Colorado State University in 
the laboratory of Dr Anne Leanerts. Two models were used to evaluate efficacy; an acute 
interferon-gamma knockout (GKO) mouse model to test against actively replicating bacteria 
representing early bactericidal activity, and a chronic Balb/c mouse model to test against more 
slowly replicating bacteria. Both models showed fusidic acid had no effect against tuberculosis in 
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mice at 100 mg/kg oral dosing. To increase exposure, repeat experiments using subcutaneous 
dosing at 100 and 200 mg/kg were performed, but three experiments had to be halted and animals 
sacrificed early due to severe toxicity. A cyclodextrin formulation, 30% Captisol®, was used to aid 
in buffering the acidic drug for a repeat experiment and improved tolerability, and the experiment 
could be performed to 4 week completion. All subcutaneous experiments similarly showed no 
effect in the selected tuberculosis mouse models. In Table 4-1 is shown the log colony forming 
unit (CFU) reduction results with appropriate positive controls for comparison. This lack of in vivo 
efficacy in a tuberculosis mouse model is consistent with other findings such as the study by Payne 
et al.,174 that found fusidic acid to be active in vitro, but not in vivo in mice against toxoplasmosis 
and listeria.  
Table 4-1: Tuberculosis efficacy of fusidic acid in mice 
GKO knockout mouse (fast replicating bacteria) 
  log CFU reduction 
Drug Dose (mg/kg) Route Lung Spleen 
Isoniazid 25 Oral 3.02 4.52 
Fusidic Acid 100 Oral 0.15 0.18 
Isoniazid 25 Oral 2.99 5.04 
Fusidic Acid 100 SQ -0.18 -0.25 
Fusidic Acid 200 SQ 0.78 0.62 
Chronic Balb/c (slow replicating bacteria) 
   log CFU reduction 
Drug Dose (mg/kg) Route Duration Lung Spleen 
Rifampicin 10 Oral 4 weeks 3.44 1.79 
Fusidic acid 100 PBS SQ 2 weeks* 0.21 0.14 
Fusidic acid 200 PBS SQ 2 weeks* 0.01 -0.04 
Fusidic acid 100 Captisol® SQ 4 weeks -0.13 0.05 
Anti-tuberculosis efficacy experiments performed at Colorado State University in the laboratory of Dr Anne Leanerts 
Note: * experiment halted early due to signs of toxicity. SQ; subcutaneous, PBS; phosphate buffered saline, CFU; 
colony forming units. Negative values represent an increase in mycobacterial burden compared to controls.  
 
4.2 Rationale 
It was hypothesised that the reasons for the lack of fusidic acid efficacy in mice could include poor 
exposure of fusidic acid at the site of infection. To test this hypothesis, a prodrug strategy was 
considered. The definition of a prodrug includes any compound that must undergo 
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biotransformation in vivo to exhibit its pharmacological effect.  It has become an advanced field 
with strategies that can improve a pharmacologically active compound’s physiochemical, 
biopharmaceutical or pharmacokinetic properties. Potential compound properties that can be 
improved through a prodrug approach can include:175–179 
1. Poor aqueous solubility  
2. Chemical instability 
3. Insufficient oral absorption  
4. Rapid pre-systemic metabolism  
5. Inadequate blood brain barrier penetration 
6. Poor tissue distribution 
7. Toxicity and/or local irritation 
Esters are the most common prodrugs used, accounting for approximately 49% of all prodrugs on 
the market.178 Other derivatisation options include synthesis of the compound to form carbonates, 
ethers, phosphates, amides, carbamates, N-Mannich bases, oximes and imines.180 
For this study, it was expected that fusidic acid would already have sufficient oral absorption and 
good bioavailability, based on its well documented clinical profile. The initial aim for a prodrug 
design was to see if prodrug modification could improve tissue distribution at expected drug target 
sites, which in tuberculosis pathology can be difficult to reach. Prodrugs designed to interact with 
carboxylic esterase is a common strategy as carboxylic esterase is functionally prominent and 
ubiquitously distributed.181 This is advantageous as a prodrug metabolised by carboxylic esterase 
is unlikely to become saturated or show high population variance. Carboxylic esterase is 
distributed in lungs182 and macrophages,183 which make them an attractive prodrug strategy in 
tuberculosis as they could potentially deliver compounds closer to the site of mycobacterial 
infection. Accordingly, a series of C-3 ester prodrugs of fusidic acid was designed and synthesised 
by Dr Gurminder Kaur from the Department of Chemistry, University of Cape Town (South 
Africa). In Figure 4-3 is shown the two of the prodrugs, GKFA16 and GKFA17, considered for 
further investigation due to their inherent antimycobacterial and low cytotoxicity giving a 
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GKFA16 GKFA17 
   
MIC99: 1.25 µM 
CHO IC50: 170 µM 
MIC99: 2.5 µM 
CHO IC50: 74 µM 
Figure 4-3: C-3 ester fusidic acid prodrugs, GKFA16 and GKFA17184 
The C-3 ester fusidic acid prodrugs were designed and synthesised by Dr Gurminder Kaur from the Department of 
Chemistry, University of Cape Town (South Africa). Note: MIC99; minimum inhibitory concentration to inhibit 99% 
of mycobacterial growth, CHO IC50; cytotoxicity concentration showing 50% inhibition in Chinese hamster cell 
ovarian cells. 
 
In parallel to the in vivo studies undertaken, metabolite identification studies of fusidic acid were 
being conducted by Dr Mathew Njoroge at the Department of Chemistry, University of Cape Town 
(South Africa). It showed metabolism of fusidic acid to a metabolite with a shorter retention time 
exclusively in mouse and rat liver microsomes, but this metabolism did not occur in human liver 
microsomes. This metabolite was suspected to be 3-epifusidic acid.185 To our knowledge, this 
metabolite has not been observed in a clinical setting. In Figure 4-4 is shown the selected prodrugs 
and their assumed metabolite route in rodents accompanied by individual antimycobacterial 
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Figure 4-4: Metabolic pathway of C-3 ester prodrugs GKFA16 and GKFA17 in mice 
Note: MIC99; minimum inhibitory concentration to inhibit 99% of mycobacterial growth, CHO IC50; cytotoxicity 







































MIC99: 0.156 µM 
CHO IC50: > 194 µM 
GKFA16
MIC99: 1.25 µM 
CHO IC50: > 170 µM 
GKFA17
MIC99: 2.5 µM 
CHO IC50: 74 µM 
3-Ketofusidic acid
MIC99: 1.25 µM 
CHO IC50: > 194 µM 
3-Epifusidic acid
MIC99: >160 µM 
CHO IC50: > 194 µM 
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To rationalise the lack of fusidic acid efficacy in mice, full pharmacokinetics, organ distribution 
(discussed in Chapter 5, page 167) was performed and relevant metabolites in mice were monitored 
to evaluate compound exposure closer to the site of infection for these fusidic acid C-3 ester 
prodrugs, fusidic acid and its 3-keto- metabolite.  
4.3 Methodology overview 
Figure 4-5 shows the approach and experiments undertaken for the pharmacokinetic evaluation of 
two fusidic acid C-3 ester prodrugs and their respective known metabolites as reference. A 
multiplex LC/MS/MS assay was developed to quantify the selected metabolites efficiently in one 
method, section 4.4.2. The initial pharmacokinetic experiments of GKFA16, GKFA17 and fusidic 
acid where run over 7 hours and 3-ketofusidic acid over 24 hours. An intense peak matching the 
transition and retention times of the suspected 3-epifusidic acid was observed. This information 
motivated the synthesis of 3-epifusidic acid, and a recovery experiment to retrospectively quantify 
the metabolite was performed, section 4.5.1. Quantified 3-epifusidic acid and metabolites were 
included in NCA, but NLME modelling attempts to include metabolite concentrations as separate 
compartments were unstable with the small datasets. NLME was used to exclusively model parent 
compounds for comparison with their respective NCA results. The compounds were progressed to 
organ distribution studies, discussed in Chapter 5, page 167. 
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4.4 Methods 
4.4.1 In vivo anti-tuberculosis efficacy 
4.4.1.1 Testing site 
In vivo efficacy trials were performed by Dr Anne Lenaerts at Colorado State University according 
to standardised methods186–188 approved by the Colorado State University Institutional Animal 
Care and Use Committee (IACUC). 
4.4.1.2 In vivo efficacy model of acute tuberculosis infection 
Efficacy of fusidic acid was tested by the method from Lenaert et al. (2003).187 Briefly, 8 week 
female C57BL/6-IFNγ knockout mice, also known as interferon-gamma knockout mice (GKO) 
from Jackson Laboratories were infected with a low dose aerosol of approximately 100 colony 
forming units (CFU)’s of Mycobacterium tuberculosis Erdman strain per mouse. A total of three 
mice were sacrificed on day one to verify bacterial uptake. On day 13, 5 mice were sacrificed to 
quantify pre-treatment bacterial load in lungs and spleen. Treatment by oral gavage of fusidic acid 
at 100 mg/kg in aqueous 0.5% methylcellulose commenced in the remaining five mice on the same 
day. The drug was given daily for nine consecutive days. On day 10 post-initiation of treatment, 
lungs and spleens were harvested and bacterial loads determined by enumeration of CFU. 
4.4.1.3 In vivo efficacy model of chronic tuberculosis infection 
Fusidic acid was also evaluated in a chronic infection, using female Balb/c mice (Charles River 
Labs, Wilmington, MA) infected with a low dose aerosol infection.186,189–191 Similarly on the day 
of infection three mice were sacrificed to verify bacterial uptake. At 21 days post-infection, 5 mice 
were sacrificed as controls and the remaining 5 mice per experimental group were treated with 
fusidic acid at 100 and 200 mg/kg, given in sterile phosphate buffered saline by subcutaneous 
injection for 4 weeks of treatment. Alternatively, fusidic acid was dosed at 100 mg/kg in 30% 
Captisol, also given subcutaneously. Lungs and spleens were harvested after the 28 days of 
treatment and bacterial loads determined by enumeration of CFU. 
 
4.4.2 LC/MS/MS method 
Whole blood concentrations of the compounds were quantified by an LC/MS/MS assay developed 
for a range of 2 – 5000 ng/ml. The samples were extracted by protein precipitation using 20 µl 
whole blood and 240 µl methanol containing a structurally similar internal standard. Gradient 
chromatography was performed on a Phenomenex® Kinetex C18 (2.1 x 50 mm, 2.6 µm) reverse 
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phase column at a flow rate of 400 µl/min with mobile phases 0.03% ammonium hydroxide (v/v) 
in water and acetonitrile. The ammonium adducts of all compounds ionised best and Table 4-2 
shows final transitions for the selected compounds analysed on an AB Sciex API 4500® mass 
spectrometer operated at unit resolution in multiple reaction-monitoring mode. Quantification 
accuracy and precision were measured for high (4000 ng/ml), medium (2000 ng/ml) and low (6 
ng/ml) quality controls of all analytes. The quantification statistics of each compound’s respective 
batch with highest and lowest accuracy (%Norm) and highest percentage coefficient (%CV) of all 
parent and metabolite compounds are shown in Table 4-2. 
Table 4-2: Fusidic acid analogues transition and statistics 
Compound Transition %Norm CV 
GKFA16 604 → 527 93.5 – 123 9.42% 
GKFA17 618 → 541 95.6 – 112 22.2% 
Fusidic acid 534 → 458 97.7 – 116 30.5% 
3-ketofusidic acid 532 → 455 94.6 – 104 17.8% 
 
Figure 4-6 shows a chromatogram of the multiplex method and an inset zoomed axis of the 
chromatogram with labelled peaks. The integrated peaks of low quality controls and their 
respective internal standards for each compound from selected batches, quantification statistics of 
individual analytes of each batch, expanded extraction method and mass spectrometer conditions 
are presented in Chapter 7: Experimental, section 7.4, starting on page 240. 
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Figure 4-6: Chromatogram of fusidic acid analytes 
Multiplex assay to quantify GKFA16 and GKFA17 and respective metabolites in the same method. Cut-out presents 
the zoomed in time axis between 3.82 and 4.10 min to better view the separation. 
 
4.4.3 In vivo pharmacokinetic experiment 
4.4.3.1 Animals 
All animal studies and procedures were conducted with prior approval of the Ethics Committee of 
University of Cape Town (UCT) (approval number 013/032) in accordance with the National Code 
for animal use in research, education, diagnosis and testing of drugs and related substances in 
South Africa. The pharmacokinetic animal experiment used healthy 6 - 8-week-old C57BL/6 mice 
maintained at the University of Cape Town animal facility. Mice were housed in 27 x 21 x 28 cm 
cages under controlled environmental conditions including a maintained temperature of 26 ± 1°C 
and 12 hr light/dark cycle. Food and water was available ad libitum.  
4.4.3.2 Compound preparation 
The author of this thesis prepared compounds for administration. Mr Trevor Finch from the 
Division of Pharmacology, University of Cape Town (South Africa) performed all animal 
handling, compound administration and blood collection under direct supervision of the author, 
with the author present for all animal procedures and responsible for samples and record keeping.  
XIC of +MRM (7 pairs): 534.315/423.300 Da ID: GKFA_FusidicAcid from Sample 126 (H) of 15082014_batch01_GKFA17.wiff (Turbo Spray) Max. 7231.0 cps.



























XIC of +MRM (7 pairs): 534.315/423.300 Da ID: GKFA_FusidicAcid from Sample 127 (M) of 15082014_batch01_GKFA17.wiff (Turbo Spray) Max. 3585.0 cps.
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On the day of the experiment, a predetermined mass of the test compound was weighed for oral 
and intravenous groups based on the average mass of the animal experimental groups determined 
that morning. 
For the 3-ketofusidic acid compound, the intravenous group consisted of three males that weighed 
approximately 30 g, while the oral group consisted of three females that averaged approximately 
22 g.  
For oral administration, the weighed compound was suspended in 1000 µl of aqueous 0.5% HPMC 
(w/v) and vortexed for 1 minute. Drug administration followed by oral gavage of 200 µl total 
volume of suspension. Administration occurred within 30 minutes of suspension preparation. For 
intravenous administration, the weighed compound was prepared in an organic vehicle of 10% 
dimethyl sulfoxide (DMSO), 10% ethanol, 50% polypropylene glycol and 30% polyethylene 
glycol 400. The compound was first dissolved in DMSO, vortexed, followed by addition of other 
vehicle constituents and then vortexing for at least 1 min. Solubility was confirmed by visual 
inspection of the dosage solution before administration. Intravenous injection into the penile dorsal 
vein of 60 µL total volume was performed under microscope. The organic vehicle required a slow 
push over 1 minute to prevent shock to the mice. 
For fusidic acid, GKFA16 and GKFA17, both the oral and intravenous groups consisted 
exclusively of males, averaging 26 g. Oral and intravenous dosing followed the same procedure, 
and in all experiments dosage occurred within 30 minutes of formulation preparation. 
Whole blood samples were collected via tail bleeding at predetermined time points in 0.5 ml 
lithium microvials and vortexed for 30 seconds to prevent coagulation. The samples were stored 
at -80°C. For the 3-ketofusidic acid experiment whole blood collection occurred at time intervals 
predose, and 0.5, 1, 3, 5, 8 and 24 hrs for the oral and intravenous groups. Additionally, the 
intravenous group included sample collection at 5 minutes after dosing. Fusidic acid, GKFA16 
and GKFA17 had whole blood collected at 5 min, 0.5, 1, 3, 5 and 7 hrs for intravenous groups and 
0.5, 1, 3, 5, and 7 hrs for oral groups. 
The animal experimental records are presented in Table 7-29 to Table 7-32, section 0, starting 
from page 251. 
 
Chapter 4: Fusidic acid prodrugs for potential repositioning in tuberculosis 
Natasha Strydom - April 2018   137 
4.4.4 Metabolite identification 
4.4.5 Non-compartmental analysis 
NCA was performed using PK Solutions, version 2.0 (Summit Research Services, Montrose, CO, 
USA). The analysis used individual whole blood concentrations vs sample times and were 
analysed as described in section 2.4.4, page 38. Additionally, AUC values for the metabolite data 
were calculated by the sum of the observed AUC (calculated by the trapezoidal rule) and 
extrapolated area (calculated by final concentration divided by ke where ke is the elimination rate 
constant). Individual whole blood concentration vs time data, individual NCA results are presented 
in section 7.4.3, page 264. 
 
4.4.6 Non-linear mixed effects modelling 
As previously described in section 2.4.5, page 39, model development occurred sequentially 
starting with one-, two-, and three- compartment structural models. The models were adapted for 
intravenous or oral administration, with the intravenous dose considered as instantaneous into the 
central compartment, and an oral dose absorbed via a fist-order process from an absorption 
compartment. Model building was guided by physiological plausibility, significant improvements 
in -2 the log-likelihood (-2LL), and evaluation of goodness of fit plots, including visual predictive 
plots (VPC) and individual plots. 
At the time of the design, the 3-epifusidic acid metabolite was unknown. The model would start 
with the concentration-time data for the 3-ketofusidic acid and parameter estimates recorded and 
fixed into the next model using the data obtained from fusidic acid. These estimates would then 
similarly be fixed in the prodrug models. Finally, the model would be freed to check the robustness 
of the model and again fixed where necessary and the statistical model approached sequentially. 
After discovering and quantifying the 3-epifusidic acid metabolite data, this was included as an 
extra compartment within the designed model. The accented section below represents the 
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Step 2: Fix previously obtained 3-ketofusic acid (3-kFA) clearance and volume values and 
estimate addition of intravenous fusidic acid (FA) and its metabolite values to obtain rate of fusidic 





Step 3: Fix previously obtained 3-ketofusic acid (3-kFA) and fusidic acid (FA) clearance and 
volume values and rate of fusidic acid metabolism to 3-ketofusidic acid (kFA/3-FA). Estimate 
addition of intravenous prodrugs GKFA16 and GKFA17, and its metabolite values to obtain rates 













IV dose of fusidic acid (FA) 
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Step 4: Using the last estimates, free previously fixed parameters and analyse robustness of the 
model. 
 
4.5 Results and discussion 
4.5.1 Quantification of rodent specific metabolite, 3-epifusidic acid 
Previous metabolite identification studies highlighted a possible metabolite of interest that 
appeared to be 3-epifusidic acid. This metabolite was exclusively observed in mouse and rat, but 
not human liver microsomes.185 During analysis of the pharmacokinetic samples, an intense 
chromatographic peak matching the expected transitions and retention time of the 3-epifusidic acid 
metabolite was observed in all experimental samples. A representative pharmacokinetic sample 
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Figure 4-7: Chromatogram including 3-epifusidic acid metabolite 
 
Due to the significant peak, Dr Gurminder Kaur proceeded to synthesise 3-epifusidic acid and Dr 
Mathew Njoroge confirmed that the metabolite identification correctly predicted 3-epifusdic acid. 
Since metabolite 3-epifusidic acid has the same transitions as fusidic acid, and due to their 
stereoisomerism, it was hypothesised that a recovery experiment to account for potential 
ionisation, extraction and matrix effect changes in the final instrument response, and resulting peak 
area could be used for quantification. The synthesised 3-epifusidic acid metabolite was 
subsequently used in a recovery experiment designed to obtain a suitable correction factor to 
quantify 3-epifusidic acid retrospectively with the calibration curve of fusidic acid. Equal 
concentrations of fusidic acid and 3-epifusidic acid were spiked at high (5000 µg/ml), medium 
(2500 µg/ml) and low (10 µg/ml) concentrations in appropriate matrix such as blood or organ 
tissue, and extracted under the same conditions as the pharmacokinetic and organ distribution 
studies. By comparing the peak area of 3-epifusidic acid to fusidic acid within the dynamic range 
of the quantification method, it was possible to calculate a correction factor to account for potential 
changes in ionisation, extraction and matrix effect. The results in Table 4-3 showed that protein 
precipitation extraction in blood had lower recovery and that the 3-epifusidic acid had a higher 
response than fusidic acid. This is likely due to more endogenous background being present after 
protein precipitation, interfering with ionisation at the retention time of fusidic acid. Liquid-liquid 
XIC of +MRM (10 pairs): 534.379/457.200 Da ID: GKFA from Sample 32 (spleen_B_M5) of 01052015_spleen_kinetixC18_001.wiff (Turbo Spray) Max. 1.5e5 cps.
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extractions had very consistent analyte to internal standard areas between fusidic acid and 
3-epifusidic acid in the different matrices with high recovery. Percentage recovery was compared 
to reference controls spiked in Millipore® water due to the scarce amount of organ tissue available 
as percentage recovery is usually performed in blank extracted matrix to match the background of 
the final extraction. Percentage recovery did not match across the investigated range with a lower 
extraction recovery observed at the low range and higher than expected recovery occurring at the 
medium range. This is likely due to a more linear response in Millipore® water, while the 
endogenous background of the tissue extractions caused saturation, resulting in a more quadratic 
curve that could not be accurately compared to the Millipore® water peak areas. Quantification of 
3-epifusidic acid used a final correction factor of 1.0 for liquid-liquid extracted samples and 2.3 
for protein-precipitated samples. The concentrations of 3-epifusidic acid were included in 
subsequent data analysis. 
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Table 4-3:  Recovery experiment of 3-epifusidic acid  
 Blood (Protein ppt) Blood (Liq-Liq) Spleen (Liq-Liq) Lungs (Liq-Liq) Brain (Liq-Liq) 
Chromatogram showing 
integration of one low 
conc quality control (10 
ng/ml) 
     
Quality control H M L H M L H M L H M L H M L 
FA area ratio mean 40.0 18.7 0.466 195 103 0.984 33.2 17.0 0.229 32.2 13.7 0.142 44.5 21.3 0.323 
e-FA area ratio 
mean 95.3 42.3 1.09 204 109 1.08 35.2 18.2 0.247 33.6 14.6 0.152 43.7 21.4 0.336 
FA Recovery (%) 20.5 29.0 24.9 117 166 115 108 121 44.3 92.2 99.1 39.0 116 136 58.8 
e-FA Recovery (%) 61.9 79.5 49.6 243 294 138 129 155 50.1 108 127 52.1 129 164 62.9 
Correction factor 2.34 2.27 2.38 1.09 1.06 1.05 1.08 1.07 1.06 1.07 1.06 1.04 1.04 1.01 0.981 
Note: (FA) fusidic acid, (e-FA) 3-epifusidic acid at 5000 ng/ml (H), 2500 ng/ml (M) and 10 ng/ml (L) concentrations using protein precipitation (Protein ppt) and liquid-liquid 
extraction (Liq-Liq). Calculated recovery used analytes spiked at same concentrations in Millipore water as reference.  
2.9e4 - 2.6e6 - 1.6e4 - 2.7e4 - 
2.2e4 - 
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4.5.2  Importance and limitations of retrospective quantification of 3-epifusidic acid 
Increased sensitivity and precision of LC/MS/MS technology has led to the use of microsampling in 
mice to offer the benefit of several blood samples collected from the same mouse over the course of 
a pharmacokinetic experiment. The major disadvantage is that the smaller blood volume only allows 
enough sample for one extraction, meaning if a batch fails, a repeat animal experiment is necessary.  
By applying a rational screening cascade to the study design, previous metabolite identification 
studies showed the likely transitions and retention time window of the suspected metabolite, 3-
epifusidic acid. The final samples showed that the metabolite peak was prevalent and warranted 
further investigation. Subsequent synthesis of the 3-epifusidic acid confirmed that the metabolite 
identification was correct and a recovery experiment to provide a correction factor could quantify 
3-epifusidic acid in all mouse pharmacokinetic samples.  
Some have argued that a repeat animal experiment would have provided the necessary information 
to answer this question up front, thereby avoiding the need for a retrospective analysis. However, this 
would have required an animal study and additional LC/MS/MS analysis. A simple bioanalytical 
recovery experiment only required one set of LC/MS/MS analysis.   Additionally, a very small 
amount of compound (less than 1 mg used from an existing stock solution) was necessary for the 
recovery experiment, whereas for an animal study approximately 10 mg of an already difficult to 
synthesise compound would be necessary. Finally, the LC/MS/MS batch of an animal experiment 
would also require more sample preparation and time than samples from a recovery experiment. 
A limitation of this approach is that the original LC/MS/MS method was not optimised to include 3-
epifusidic acid and matrix effects from the change in retention time could lead to a decrease in the 
accuracy and precision of this quantification. However, the data gained without a repeat animal 
experiment greatly outweighs this limitation and the results support the pharmacokinetic parameters 
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4.5.3 Pharmacokinetic profiles and calculated parameters 
4.5.3.1 Fusidic acid 
In Figure 4-8 is shown the raw data of fusidic acid with observed concentration-time points for 3 mice 
with different open shapes representing individual mice and individual colours representing 
individual analytes for A: Intravenous and B: Oral experiments. In Table 4-4 is shown the final 
calculated parameters of fusidic acid for both NCA and NLME analysis for a side-by-side 
comparison. A visual predictive check of the final model used is shown in Figure 4-9 and stratified 
by oral and intravenous groups. The model best fit a 2-compartment model. 
 
 
Figure 4-8: Observed pharmacokinetic data for fusidic acid in mice 
Individual observed concentration-time points from the fusidic acid pharmacokinetic experiment in 3 mice for A: 
intravenous and B: oral experiments. Each individual animal is represented by a respective open shape. Each metabolite 





























A: Intravenous Fusidic acid (2.5 mg/kg)
Mean fusidic acid concentration
Mean 3-ketofusidic acid concentration



























B: Oral Fusidic acid (25 mg/kg)
Mean fusidic acid concentration
Mean 3-ketofusidic acid concentration
Mean 3-epifusidic acid concentration
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Table 4-4: Pharmacokinetics of fusidic acid in mice 
Fusidic acid 
Parameter a. Oral NCA b. IV NCA c. Two compartment 
Blood Cl 
(ml/min/kg) 
- 47.9 (4.22) 58.0 (15.1) 
Vc (L/kg) - 2.99 (0.817) 2.12 (0.550) 
Vss (L/kg) - 6.38 (0.686) 5.12 (1.12) 
t1/2 (hr) 1.27 (0.106) 0.819 (0.267) 1.80 (0.644) 
AUC0-inf (µM.min) 116 (25.1) 101 (7.02) 94.5 (26.7) * 
Tmax (hr) 0.5 - - 
Cmax (uM) 1.20 (0.256) - 1.05 (0.042) * 
F (%) 12.1 (2.02) - 12.4 (0.032) 
ka (hr-1)   3.06 (1.90) 
Standard error of parameters is represented in parenthesis next to final median value for 3 mice. F; bioavailability, ka; 
rate of absorption, Vc; central volume, Blood Cl; whole blood clearance, Q; inter-compartmental clearance, Vs; steady 
state volume. Standard error (s.e.) of the population estimate were estimated by linearization of the Fisher information 
matrix. The parameters calculated by NCA used SummitPK solutions™ and the NLME modelling was performed in 
Monolix® Individual mouse weights were included as a covariate and allometrically scaled for clearance and volumes. 
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Figure 4-9: Visual predictive check of the final model used for fusidic acid 
The graphical diagnostic plot shows the simulated output of the fusidic acid two-compartment model for the A: 
intravenous and B: oral pharmacokinetic experiments. The final model was established from the pooled oral and 
intravenous data and the diagnostic plots stratified according to dosing. Observed data above the limit of quantification 
is represented by blue dots. The green line represents the empirical percentile of this observed data and the shaded pink 
area represents the median of the population estimate. Ideally, this empirical percentile should fit within the pink shaded 
area.  
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4.5.3.1.1 Summary of fusidic acid pharmacokinetics 
Fusidic acid showed non-linear elimination meaning a one-compartment may not best fit the dataset. 
Proceeding with model building from a one-compartment model to a two-compartment model had a 
significant drop in objective function of 114 points compared to a one-compartment model. 
Intravenous and oral administration of fusidic acid in mice showed a moderate clearance of 48 
ml/min/kg, low (12%) bioavailability and high levels of the inactive 3-epifusidic acid metabolite with 
a 200% higher AUC than fusidic acid. This suggests the low bioavailability was due to high hepatic 
extraction as opposed to low absorption. 
The two-compartment model of fusidic acid captured the observations well as seen by the visual 
predictive checks for both the oral and intravenous experiment. NLME and NCA results were 
comparable and showed that NCA captured the pharmacokinetic parameters well for this dataset. 
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4.5.3.2 3-Ketofusidic acid 
In Figure 4-10 is shown the raw data of 3-ketofusidic acid with observed concentration-time points 
for 3 mice represented by respective open shapes, respective colours representing different analytes 
and mean lines added for A: Intravenous and B: Oral experiments. In Table 4-5 is shown the final 
calculated parameters of 3-ketofusidic acid for both NCA and NLME analysis for a side-by-side 
comparison. A visual predictive check of the final model used is shown in Figure 4-11 and stratified 
by oral and intravenous groups. The model best fit a 2-compartment model. 
 
Figure 4-10: Observed pharmacokinetic data for 3-ketofusidic acid in mice 
Individual observed concentration-time points from the 3-ketofusidic acid pharmacokinetic experiment in 3 mice for A: 
intravenous and B: oral experiments. Each individual animal is represented by a respective open shape. Each metabolite 





























B: Intravenous 3-Ketofusidic acid (5 mg/kg)
Mean 3-ketofusidic acid concentration
Mean fusidic acid concentration


























A: Oral 3-Ketofusidic acid P.O. (20 mg/kg)
Mean 3-ketofusidic acid concentration
Mean fusidic acid concentration
Mean 3-epifusidic acid concentration
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Table 4-5: Pharmacokinetics of 3-ketofusidic acid in mice 
3-Ketofusidic acid	
Parameter	 a. Oral. NCA	 b. IV NCA	 c. Two compartment	
Blood Cl (ml/min/kg)	 -	 115 (16.6)	 155 (26.3)	
Vc (L/kg)	 -	 3.51 (0.192)	 3.59 (1.08)	
Vss (L/kg)	 -	 38.1 (3.79)	 13.5 (3.92)	
t1/2 (hr)	 2.51 (0.129)	 3.45 (0.064)	 2.74 (0.920)	
AUC0-inf (µM.min)	 752 (94.3)	 89.7 (15.1)	 867 (158) *	
Tmax (hr)	 0.520	 -	 -	
Cmax (uM)	 3.48 (1.07)	 -	 2.46 (0.033) *	
F (%)	 314 (39.4)	 -	 303 (68.0)	
ka (hr-1)	 	 	 0.408 (0.079)	
Fusidic Acid AUC (µM.min) 6.57 (1.72)	 3.10 (0.573)	 -	
Standard error of parameters is represented in parenthesis next to final median value for 3 mice. F; bioavailability, ka; 
rate of absorption, Vc; central volume, Blood Cl; whole blood clearance, Q; inter-compartmental clearance, Vss; steady 
state volume. Standard error (s.e.) of the population estimate were estimated by linearization of the Fisher information 
matrix. The parameters calculated by NCA used SummitPK solutions™ and the NLME modelling was performed in 
Monolix® Individual mouse weights were included as a covariate and allometrically scaled for clearance and volumes. 
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Figure 4-11: Visual predictive check of the final model used for 3-ketofusidic acid 
The graphical diagnostic plot shows the simulated output of the 3-ketofusidic acid two-compartment model for the 
A: intravenous and B: oral pharmacokinetic experiments. The final model was established from the pooled oral and 
intravenous data and the diagnostic plots stratified according to dosing. Observed data above the limit of quantification 
is represented by blue dots. The green line represents the empirical percentile of this observed data and the shaded pink 
area represents the median of the population estimate. Ideally, this empirical percentile should fit within the pink shaded 
area.  
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4.5.3.2.1 Summary of 3-Ketofusidic acid 
The oral and intravenous data from administration of the 3-ketofusidic acid yielded inconclusive 
results. Non-compartmental analysis and a two-compartment model estimated the bioavailability to 
be more than 300%. The metabolism of 3-ketofusidic acid had a nonsensical result showing a higher 
rate of metabolism to 3-epifusidic acid in the intravenous group compared to the oral group. 
Metabolism from the 3-ketofusidic acid to the more active fusidic acid was observed, but at negligible 
concentrations. Upon further investigation, it was noted that the genders of the oral and intravenous 
groups differed (as per agreement with the University of Cape Town Animal Research Ethics 
Committee to reduce discarded animals based on gender) and the rate of metabolism to 3-epifusidic 
acid was likely gender specific. Cempra Pharmaceuticals that developed a front loading dose for 
fusidic acid170 reported higher clearance in female rats compared to males192 and this finding should 
have been considered earlier in the design of the experiments. All other experiments exclusively used 
males. The results from this experiment were excluded from final data analysis and a repeat 
experiment decided against after careful consideration that further male vs female classification of 
rodent specific 3-epifusidic acid metabolism in mice are outside the scope of this study and 
unnecessary for the advancement of fusidic acid and its analogues in humans. 
  




In Figure 4-12 is shown the raw data of GKFA16 with observed concentration-time points for 3 mice 
graphed by open shapes representing individual animals and colours representing individual analytes 
and mean lines added for the A: oral and B: intravenous experiments. In Table 4-6 is shown the final 
calculated parameters of GKFA16 for both NCA and NLME analysis for a side-by-side comparison. 
A visual predictive check of the final model used is shown in Figure 4-13 and stratified by oral and 
intravenous groups. The model best fit a 2-compartment model. 
 
Figure 4-12: Observed pharmacokinetic data for GKFA16 in mice 
Individual observed concentration-time points from the GKFA16 pharmacokinetic experiment in 3 mice for A: 
intravenous and B: oral experiments. Each individual animal is represented by a respective open shape. Each metabolite 






























A: Intravenous GKFA16 (3 mg/kg)
Mean GKFA16 concentration
Mean fusidic acid concentration
Mean 3-ketofusidic acid concentration

























B: Oral GKFA16 (25 mg/kg)
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Table 4-6: Pharmacokinetics of GKFA16 in mice 
GKFA16 




19.2 (7.78) 40.3 (4.43) 
Vc (L/kg) - 0.611 (0.186) 1.34 (0.254)  
Vss (L/kg) - 1.28 (0.545) 2.30 (0.668) 
t1/2 (hr) 0.814 (0.209) 0.744 (0.092) 1.19 (0.368) 
AUC0-inf (µM.min) 464 (215) 166 (18.2) 426 (156) * 
Tmax (hr) 0.500 -  
Cmax (uM) 5.51 (1.66) - 11.4 (1.11) * 
F (%) 35.5 (16.5) - 43.5 (15.2) 
ka (hr-1)   3.18 (1.4) 
Fusidic Acid 
 AUC (µM.min) 
134 (65.8) 63.8 (9.28) - 
Standard error of parameters is represented in parenthesis next to final median value for 3 mice. F; bioavailability, ka; 
rate of absorption, Vc; central volume, Blood Cl; whole blood clearance, Q; inter-compartmental clearance, Vss; steady 
state volume. Standard error (s.e.) of the population estimate were estimated by linearization of the Fisher information 
matrix. The parameters calculated by NCA used SummitPK solutions™ and the NLME modelling was performed in 
Monolix® Individual mouse weights were included as a covariate and allometrically scaled for clearance and volumes. 
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Figure 4-13: Visual predictive check of the final model used for GKFA16 
The graphical diagnostic plot shows the simulated output of the GKFA16 two-compartment model for the A: intravenous 
and B: oral pharmacokinetic experiments. The final model was established from the pooled oral and intravenous data and 
the diagnostic plots stratified according to dosing. Observed data above the limit of quantification is represented by blue 
dots and concentrations measures below the limit of quantification represented by red dots. The green line represents the 
empirical percentile of this observed data and the shaded pink area represents the median of the population estimate. 
Ideally, this empirical percentile should fit within the pink shaded area.  
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4.5.3.3.1 Summary of GKFA16 results 
Like fusidic acid, GKFA16 best fit a 2-compartment model with a significant drop of 65 points in 
objective function compared to a 1-compartment model. From the observed pharmacokinetic profiles 
GKFA16 was rapidly metabolised to the more active fusidic acid. Biotransformation of GKFA16 to 
fusidic acid had similar exposure of fusidic acid compared to a single equivalent dose of fusidic acid 
with the bioavailability measured to be 43.5% compared to 12% for fusidic acid. The levels of 3-
epifusidic were still observed at high concentration, of course detrimental to the pharmacokinetic 
profile of GKFA16, but GKFA16 had much higher concentrations than 3-epifusidic acid during the 
first 3 hrs of the experiment. Clearance remained moderate for GKFA16 (40 ml/min/kg), but all 
active metabolites were below their expected MIC concentrations before reaching 3 hours after the 
initial dose. Compound GKFA16, like fusidic acid, had very low half-lives in less than 2 hours.  
Technically NCA failed to predict the pharmacokinetics of GKFA16 with clearance calculated less 
than half of NLME calculations. Volumes were out by half as well but when considering final 
classification, both NCA and NLME values would be considered moderate volumes. The 
miscalculation on clearance and volume of course led to the half-life to be predicted less than half 
compared to NLME. For this compound, however, neither NLME nor NCA would classify GKFA16 
as having favourable pharmacokinetics, so though NCA was out by some margin, the conclusions 
remained the same. 
 
  




In Figure 4-14 is shown the raw data of GKFA17 with observed concentration-time points for 
3 individual mice represented by respective open shapes and analytes represented by respective 
colours and mean lines added for A: Intravenous and B: Oral experiments. In Table 4-7 is shown the 
final calculated parameters of GKFA17 for both NCA and NLME analysis for a side-by-side 
comparison. A visual predictive check of the final model used is shown in Figure 4-15 and stratified 
by oral and intravenous groups. The model best fit a 2-compartment model. 
 
Figure 4-14: Observed pharmacokinetic data for GKFA17 in mice 
Individual observed concentration-time points from the GKFA17 pharmacokinetic experiment in 3 mice for A: 
Intravenous and B: Oral experiments. Each individual animal is represented by a respective open shape. Each metabolite 



























A: Intravenous GKFA17 (3 mg/kg)
Mean GKFA17 concentration
Mean fusidic acid concentration

























B: Oral GKFA17 (25 mg/kg)
Mean GKFA17 concentration
Mean fusidic acid concentration
Mean 3-ketofusidic acid concentration
Mean 3-epifusidic acid
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Table 4-7: Pharmacokinetics of GKFA17 in mice 
GKFA17 




71.6 (17.5) 134 (12.1) 
Vc (L/kg) - 0.903 (0.566) 3.88 (0.620) 
Vss (L/kg) - 2.10 (1.74) 8.36 (1.75) 
t1/2 (hr) 1.35 (0.206) 0.665 (0.114) 1.63 (0.373) 
AUC0-inf (µM.min) 133 (12.2) 82.9 (26.4) 130 (21.6) * 
Tmax (hr) 0.583 (0.019) - - 
Cmax (uM) 2.85 (0.640) - 2.28 (0.031) * 
F (%) 22.3 (2.04) - 44.5 (6.40) 
ka	(hr-1)	 	 	 3 (fixed) 
Fusidic Acid AUC 
(µM.min) 
165 (30.6) 39.7 (2.80) - 
Standard error of parameters is represented in parenthesis next to final median value for 3 mice. F; bioavailability, ka; 
rate of absorption, Vc; central volume, Blood Cl; whole blood clearance, Q; inter-compartmental clearance, Vss; steady 
state volume. Standard error (s.e.) of the population estimate were estimated by linearization of the Fisher information 
matrix. The parameters calculated by NCA used SummitPK solutions™ and the NLME modelling was performed in 
Monolix® Individual mouse weights were included as a covariate and allometrically scaled for clearance and volumes. 
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Figure 4-15: Visual predictive check of the final model used for GKFA17 
The graphical diagnostic plot shows the simulated output of the GKFA17 two-compartment model for the A: intravenous 
and B: oral pharmacokinetic experiments. The final model was established from the pooled oral and intravenous data and 
the diagnostic plots stratified according to dosing. Observed data above the limit of quantification is represented by blue 
dots and concentrations measures below the limit of quantification represented by red dots. The green line represents the 
empirical percentile of this observed data and the shaded pink area represents the median of the population estimate. 
Ideally, this empirical percentile should fit within the pink shaded area.  
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4.5.3.4.1 Summary of GKFA17 pharmacokinetics 
Similar to fusidic acid and GKFA16, GKFA17 best fits a 2-compartment model. The objective 
function using a two-compartment model decreased by 80 points compared to a 1-compartment 
model, deemed statistically relevant for the additional two parameters. Examining the visual 
predictive checks of the model though, the model was unable to capture the elimination of GKFA17 
well and overpredicted concentrations during the distribution phase. A three-compartment model did 
not yield a significant improvement in model building. Like GKFA16, GKFA17 was rapidly 
metabolised to the more active fusidic acid. GKFA17 resulted in a 42% increase in fusidic acid 
exposure compared to single fusidic acid administration. The bioavailability of GKFA17 was the 
same as GKFA16 and measured 44.5%. Like all fusidic acid compounds tested, 3-epifusidic levels 
were apparent and negatively affected the pharmacokinetic outcomes of the fusidic acid series. 
Clearance of GKFA17 was high at 1344 ml/min/kg with a corresponding low half-life less than 2 
hrs.  
The butyl ester GKFA17 was more rapidly metabolised to fusidic acid than the propyl ester GKFA16 
and therefore did have higher initial concentrations of fusidic acid. This, however, also led to the 
higher clearance observed for GKFA17 and exposed the fusidic acid 3-hydroxy soft spot to be 
metabolised to the inactive 3-epifusidic acid.  
NCA performed poorly against NLME and clearance and half-life were under predicted less than 
50% of NLME calculations. Bioavailability was also less than half of that predicted for NLME. 
NLME calculated central volume and volume at steady state 3-fold and 4-fold more than NCA. For 
the GKFA17 dataset NCA performed worse than the GKFA16, but again for both compounds NCA 
would not recommend further evaluation of these compounds due to poor pharmacokinetics. 
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4.5.4 Comparison of metabolite exposure 
A model to include the metabolite concentrations was attempted, but no robust model could be 
supported by the sparse data available and proved difficult and unstable in Monolix®. Comparing 
AUC of each metabolite calculated by simpler NCA was found to be a more suitable approach for 
the objectives of this study, and these results are shown in Figure 4-16. 
 
 
Figure 4-16: Parent and metabolite exposures 
Note: Area under curve to infinity (AUC∞) divided by dose given in respective experiment. Fusidic acid (FA), 3-ketofusidic acid (k-FA) and 3-epifusidic 
acid (e-FA) after oral and intravenous administration. 
 
Examining the exposure levels presented in Figure 4-8, it is again apparent that the inactive 3-
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acid exposures, showed a fast turnaround from fusidic acid to the final metabolite 3-epifusidic acid. 
It is striking to also see this and the ubiquitous nature of the 3-epifusidc acid metabolism after 
intravenous administration of male mice with 3-ketofusidic acid, which still showed 8 times higher 
levels of 3-epifusidic acid. 
There is a lack of translation of carboxylic esterase between mice and humans due to higher 
expression of carboxylic esterase in mice compared to humans and across all tissues.193 This in 
addition to the rodent-specific metabolism to inactive 3-epifusidic acid reveals that the mouse model 
is inappropriate for characterising fusidic acid and related analogues. 
 
4.5.5 Non-compartment analysis vs non-linear mixed effects modelling 
Due to the failed metabolite model, NLME modelling already showed limitations in implementation. 
The only comparisons that could be drawn were therefore between the parent compound NLME and 
parent compound NCA. This is important to consider for future preclinical studies hoping to make 
use of NLME modelling to predict metabolite profiles. In this case, better sampling would be required 
with more useful data points at the elimination phase. It would be wise to do a preliminary snapshot 
pharmacokinetic evaluation of the parent and metabolite to validate further animal studies that would 
provide more useful time points around the elimination phase. In this case, with the incredibly fast 
metabolism of fusidic acid to the 3-epifusidic acid, there was a limited elimination profile to explore. 
NLME showed that the C-3 ester prodrugs had higher bioavailability than the NCA predicted, likely 
due to the elementary trapezoidal rule calculation that NCA uses to obtain reference AUC values and 
its sensitivity to the sampling schedule. If the sampling schedule was not optimal to characterise the 
absorption phase and maximum concentration peak of the curve, the resulting AUC as estimated by 
NCA can underestimate oral profiles. In contrast, poor sample scheduling during the elimination 
phase can lead to overestimation, illustrated in Figure 4-17. Together these incorrect predictions can 
lead to poor bioavailability estimates. NLME best describes a pharmacokinetic curve around observed 
sample points and accordingly calculates bioavailability by the integrated equation that best describes 
the data. 




Figure 4-17: Trapezoidal NCA over and underestimation 
The advantage of NLME analysis in this case provided a model that could be used for simulations. 
This was done using a scaling technique of the fusidic acid parameters as reference. This is discussed 
further in the next section.  
 
4.5.6 Simulations to compare results with existing clinical data 
To assess the impact of the rodent-specific 3-epifusidic acid, the mouse parameters were scaled using 
the well accepted power allometric equation,79 Figure 4-18, to simulate what a human 










Figure 4-18: Equation used for scaling clearance and volume based on weight. 
The results comparing final parameters and simulated human pharmacokinetic plot versus actual 
observed clinical data is shown in Table 4-8. The parameter values were simulated in Berkeley 
Madonna to obtain the predicted pharmacokinetic profiles in a preclinical “translational” setting with 
a dose of 1650 mg, equivalent to the 23.6 mg/kg dose from the clinical data, which was most 
appropriate to compare with the original mouse experiments of 25 mg/kg. A possible limitation could 
include reported auto-inhibition of fusidic acid clearance in man leading to dose accumulation in 
plasma on multiple dosing.169,194 This is, however, not observed in mice and rats,192  and was therefore 
not included in the final simulation. It is doubtful that accounting for auto-inhibition could greatly 
improve the overall outcome of exposure when observing the single dose scaled parameters. 
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Knippenberg et al., 2016 reported a blood-plasma partitioning value of 0.9894195 showing that 
comparison of whole blood to plasma in this case could be done 1:1. 
Table 4-8: Simulated results compared to clinical parameters 
A: Scaled Human B: Clinical170 
  
Time (hrs) for period 1 and 2 
Parameter Mouse (25 g)  Scaled Human (70 kg) Clinical170 (>50 kg) 
Cl (L/h) 0.0865 33.3 1.10 
Vss (L) 0.102 286 23.9 
t1/2 (hr) 1.80 5.95 16.1 
Dose (mg) 0.571 1650 1650 
Bioavailability (%) 12.1 12.1 91.0 
AUC (mg.h/L) 0.818 5.95 1840 
Cmax (mg/L) 0.620 7.07 102 
Cl; clearance, Vss; volume at steady state, AUC; area under the curve, Cmax; maximum observed concentration. The two 
pharmacokinetic plots show a simulated profile from Berkeley MadonnaÔ with the MonolixÒ fusidic acid calculated 
parameters clearance and volume allometrically scaled by weight. The simulation used a 23.6 mg/kg dose to correspond 
to the clinical experiment of 1650 mg dose and input similar single dosing (Period 1) and multiple dosing over 216 hrs 
(Period 2). 
 
Period 1 Period 2
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Using this scaling technique to translate the mouse data to compare to existing clinical data, the extent 
of mismatch between species was seen. Simulated whole blood clearance compared to plasma 
clearance shows a 30-fold difference. Knippenberg et al., 2016 reported a blood-plasma partitioning 
value of 0.98 showing that comparison of whole blood to plasma in this case is appropriate. Similarly, 
the half-life of fusidic acid was 3 times faster in the simulated human outcome compared to clinical 
results.  The simulated profile plot is juxtapositioned next to actual clinically observed profile, 
highlighting the higher clearance, shorter half-life and greatly diminished Cmax that is 10 times less 
in a simulated human individual compared to observed clinical results.  
 
4.5.7 Observed variability 
The results showed high variance of all the compounds for oral and intravenous groups, likely due to 
poor solubility. Poor solubility causes two problems at a preclinical stage. Dosing becomes difficult 
as a homogenous suspension with uniform particle size is difficult to obtain and a highly organic 
intravenous vehicle, which requires a slow injection (usually 2- 3 min for 100 µl) to prevent a pH 
shock to the mice, is necessary. In a clinical setting fusidic acid is administered as a salt to aid in 
dissolution and this salt may have been more appropriate for this study. The high levels of 3-epifusidic 
acid and organ distribution studies, discussed in Chapter 5, did show that the liver concentrations 
were high and using the free base had a low impact on total absorption. Still, it is the variability in 
absorption that leads to inconsistent profiles between genetically similar mice as shown in the 
formulation study presented in Chapter 3. 
  




In Table 4-9 is shown the final pharmacokinetic parameters of the fusidic acid analogues with their 
respective fusidic acid exposures. 
Table 4-9: Final pharmacokinetic results of C-3 ester prodrugs in mice 
General structure      
 Fusidic Acid GKFA16 GKFA17 
R =  
 
  
Blood Cl (ml/min/kg) 58.0 40.3 134 
Vss (L/kg) 5.12 2.30 8.36 
t1/2 (hr) 1.80 1.19 1.63 
F (%) 12.4 43.5 44.5 
Fusidic Acid AUC 
(µM.min) 
116 134 165 
Increase in fusidic acid 
AUC 
- 15.5 % 42.2 % 
Blood Cl; whole blood clearance, Vss; steady state volume. Standard error (s.e.) of the population estimate were estimated 
by linearization of the Fisher information matrix. The parameters calculated by NCA used SummitPK solutions™ and 
the NLME modelling was performed in Monolix® Individual mouse weights were included as a covariate and 
allometrically scaled for clearance and volumes. Individual plots and final parameters with variability values are presented 
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This investigation revealed a lack of pharmacokinetic translation of fusidic acid in mice and humans. 
The formation of 3-epifusidic acid in mice greatly lowered the exposure of fusidic acid, and explained 
the poor efficacy of fusidic acid in previous mouse models, despite good in vitro activity and well 
tolerated human clinical pharmacokinetics. 
The ester prodrugs did display good fusidic acid exposure and are still promising to pursue for the 
potential repurposing and repositioning of fusidic acid against tuberculosis. Technically the two 
prodrugs, when considered without their metabolic mistranslation, do not possess the 
pharmacokinetic properties to advance to organ distribution studies in the screening cascade. 
However, the hypothesis that they could improve distribution and exposure at the site of infection by 
aiding in delivery was still intriguing enough to progress them. Chapter 5 discusses these results 
together with fusidic acid reference data. 
Application of a mechanistic model to investigate the fusidic acid metabolites and prodrug delivery 
was not possible in this case and not recommended unless considering a preliminary snapshot 
pharmacokinetic study that can be expanded on with a repeat study containing optimised sampling 
times.  NLME of the parent compound, however, improved AUC predictions and provided a tool to 
easily predict pharmacokinetic profiles using variable inputs and applying allometric scaling. This 
aided in assessing the distortion of the 3-epifusidic acid on final exposure and supports that earlier 
modelling of data can provide interesting translational capacity at a preclinical stage. 
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5 ORGAN DISTRIBUTION OF 
FUSIDIC ACID PRODRUGS 
5.1 Introduction 
The complex pathology of tuberculosis leads 
to poor drug exposure at the site of 
mycobacterial infection and is considered a 
major obstacle in current tuberculosis therapies 
and drug discovery. Drug access to the 
tuberculosis causing mycobacteria becomes 
increasingly difficult as the disease progresses 
from macrophage infection to diverse 
granuloma lesions, causing discrete 
microenvironments with poor vasculature that 
insulates the mycobacteria from the immune 
system and systemically available drugs, 
Figure 5-1.196 Pharmacokinetic profiles that 
exclusively examine drug concentrations in 
plasma or whole blood therefore become 
inadequate to predict drug effectiveness and 
need to be refined to include target site 
concentrations, Figure 5-2.197 
Figure 5-1: Tuberculosis disease progression196 
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Research into lung distribution and lesion pharmacokinetics of 
current therapies have shown diverse pharmacokinetic properties 
of tuberculosis drugs, suggesting an array of properties are 
necessary to target multiple mycobacteria environments, Figure 
5-2. First line drugs; isoniazid, pyrazinamide and rifampicin 
partition rapidly into tissues, but cellular lesion concentrations of 
these three drugs are lower than plasma concentrations. 
Rifampicin does accumulate well in uninvolved lung tissue.198,199 
Matrix-assisted laser desorption ionisation mass spectrometry 
imaging (MALDI-MSI) revealed that sterilising agents, 
rifampicin and pyrazinamide penetrate well into necrotic caseum, 
suggesting this to be the site of persisting tolerant mycobacteria 
that are responsible for resistance.200 
Tuberculosis is not exclusive to lung pathology and tuberculosis 
meningitis and pericarditis complications have high morbidity 
and mortality rates. Mortality of tuberculosis pericarditis is as 
high as one in every four patients dying within 6 months of 
diagnosis201. Tuberculosis meningitis carries morbidity higher 
than 50% with fatality rates as high as 10%.202 Research shows 
first203 and second line treatments204 have poor permeation into 
the meninges infection space. Similarly, poor exposure of 
rifampicin, ethambutol and pyrazinamide was observed in 
patients suffering from tuberculosis pericarditis.205 
 
5.2 Rationale 
The research efforts mentioned above focused on the objective 
of shortening the treatment duration, preventing resistance and 
improving sterilising effects of existing tuberculosis therapies. 
The results showed diverse pharmacokinetic profiles of the 
existing first and second line drugs and the definition of what 
good pharmacokinetics for a tuberculosis drug is becomes 
troublesome. Considering the failure of many tuberculosis 
Figure 5-2: Pharmacokinetic 
challenges of reaching 
mycobacterial target197 
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therapies and emerging research searching for drug leads based on the properties of clinical 
candidates might only lead to the same inappropriate therapies. The need for new tuberculosis drug 
candidates is therefore vital with emphasis on novelty not only placed on activity, but on improved 
pharmacokinetic properties. It was hypothesised that refining the pharmacokinetic techniques to 
include organ distribution during early preclinical screening of drug leads with the aim of improving 
tissue distribution could improve drug discovery outcomes for tuberculosis. 
Physiologically based pharmacokinetics (PBPK) provides the opportunity to build 
multi-compartment pharmacokinetic models, based on organ and tissue drug concentrations e.g. in 
Figure 5-3. They can be used to scale between species,206 adult to paediatric dosing207 and disease 
states where renal or hepatic function may be impaired.208,209 In the past PBPK methods used animal 
tissue data to extrapolate to humans.210–212 The choice of modelling approach is conditional on the 
data available, with existing observed data used in a “top down” pharmacokinetic approach and a 
broader understanding of human physiology and existing mechanisms used in a “bottom up” 
approach. These classifications have limitations on both sides, and the field has moved to a more 
“middle out” approach that utilises both paradigms.210,213–215 This “middle-out” approach is 
sometimes classified within systems pharmacology.215 Implementation of a tuberculosis aimed 
“middle out” systems model could assist in predicting drug concentrations more closely to the site of 
infection.216–218 
 
Figure 5-3: Physiologically based pharmacokinetic model 
A traditional representation of a physiologically based pharmacokinetic model that shows drug distribution in organ 
specific compartments and their relation to one another. Both intravenous and oral pathways are shown.  
 
Continuing the fusidic acid project, the prodrugs evaluated from Chapter 4 were further evaluated for 
organ distribution. However, a limitation of this study was that the C-3 ester fusidic acid prodrugs 
examined in Chapter 4, showed the rodent specific metabolite 3-epifusidic acid had the highest levels 
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of exposure and in turn negatively affected fusidic acid exposure. The C-3 ester prodrugs were still 
intriguing to assess if the C-3 ester prodrug strategy was useful in increasing exposure of the prodrugs 
and their respective metabolites in tissues compared to administration of unaltered fusidic acid. Drug 
concentrations were examined in the lungs and spleen due to the high bacterial burden at these sites, 
liver and kidneys due to their role as elimination sites, and the heart and brain due to tuberculosis 
pericarditis and meningitis complications. 
 
5.3 Methodology overview 
Figure 5-4 shows the process followed for the organ distribution evaluation of two C-3 ester fusidic 
acid prodrugs and fusidic acid as reference. Pharmacokinetic results discussed in Chapter 4 
determined sampling time points for the organ distribution experiments. Sampling points were chosen 
to best represent the elimination phase of the compounds. GKFA16, GKFA17 and fusidic acid were 
respectively dosed each at 10 mg/kg in 10 mice. Initial calibration curves of the organ homogenate 
used the same method as previously described for the whole blood pharmacokinetic experiments 
discussed in Chapter 4. Unfortunately, this method was imprecise and inaccurate with poor 
reproducibility of organ samples. LC/MS/MS methods were reinvestigated and the extraction 
improved to a liquid-liquid extraction method that likely reduced matrix effects from the complex 
organ tissue background. 
The final data showed strong trends in pharmacokinetic results, but implementing a pharmacokinetic 
model in Monolix® proved unstable with the high number of compartments. Microsoft® Excel 2013 
was used to calculate the respective AUC of the organ profiles to compare the exposure of the C-3 
ester prodrugs, fusidic acid and their metabolites. These results were found to be sufficient for this 
fusidic acid repositioning project.  




Figure 5-4: Methodology overview of organ distribution evaluation 
5.4 Methods 
5.4.1 In vivo tissue distribution experiment 
5.4.1.1 Animals 
All animal studies and procedures were conducted with prior approval of the Ethics Committee of 
University of Cape Town (UCT), approval number 013/032, in accordance with the National Code 
for animal use in research, education, diagnosis and testing of drugs and related substances in South 
Africa. The pharmacokinetic animal experiment used healthy eight-week-old male C57BL/6 mice 
maintained at the University of Cape Town animal facility. Mice were housed in 27 x 21 x 28 cm 
Fusidic acid, GKFA16 & 
GKFA17 
7 hr Organ distribution 
experiment 
10 mg/kg P.O. (n = 10) 
Methods 5.4.1 























profiles used to 
compare results 
5.5.5 
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cages under controlled environmental conditions including a maintained temperature of 26 ± 1°C and 
12 hr light/dark cycle. Food and water was available ad libitum.  
 
5.4.1.2 Compound preparation 
On the day of the experiment, a predetermined mass of the test compound was weighed for the 
experimental group consisting of 10 males weighing approximately 30 g. 
Right before oral administration the compound was suspended in 2000 µl of aqueous 0.5% HPMC 
(w/v) and vortexed for 1 minute. Drug administration followed by oral gavage of 150 µl total volume 
of suspension for a total dose of 10 mg/kg. Administration occurred within 30 minutes of suspension 
preparation. Mr Trevor Finch from the Division of Pharmacology, University of Cape Town (South 
Africa) performed the animal procedures. 
5.4.1.3 Organ harvesting 
Organ collection of 3 mice occurred at approximately 1, 3 and 5 hrs, and 1 mouse at 7 hrs to confirm 
elimination. Blood samples were collected every hour before sacrifice. Sacrifice was performed by 
cardiac puncture and removed most vascular blood, which was followed by dissection along the mid-
ventral line of the animal to expose the organs. Both femoral arteries were cut and approximately 20 
ml of saline injected into the right aorta to rinse the circulatory system of blood. This was continued 
until the organs experienced a pale colour change, and if additional rinsing was required, specific 
organs were isolated from the circulatory system to remove as much blood as possible. The organs 
were then dissected out. The author of this thesis was responsible for final inspection of blood, further 
rinsing if necessary and drying of the organs, weighing and flash freezing in liquid nitrogen, and 
sample storage at -80°C. The entire procedure was performed on average within 12 minutes. To obtain 
blank matrix for calibration curves, this process was repeated in three mice that did not receive any 
compound. 
 
5.4.2 Tissue homogenation 
The summarised procedure for tissue homogenation of each respective organ is shown in Table 5-1. 
Briefly a 1:1 or 2:1 mass of saline to mass of the thawed organ samples was added in a 2 ml reinforced 
microtube containing 5 x 2.8 mm ceramic beads. The large liver samples were first dissected into 
smaller sections and placed in different microtubes. The samples were then briefly vortexed on an 
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Omni Bead Ruptor™ instrument with settings according to the manufacturer’s website. These 
settings could be optimised to a single method that can homogenise different organ samples in one 
batch. Homogenate liver samples were pooled for analysis and all samples stored at -80°C. 
Table 5-1: Tissue homogenation settings 
 Liver Brain Kidney Lungs Spleen Heart 
Saline:Organ (m/m) 1:1 2:1 1:1 2:1 2:1 2:1 
Speed (m/s) 5.50 5.65 6.00 4.00 5.00 6.00 
Time of Cycle (s) 30 30 30 40 30 30 
Number of Cycles 2 2 1 1 1 2 
Dwell (s) 5 5 0 0 0 20 
The Omni bead ruptor has 4 adjustable settings namely the speed of pulsing/shaking (Speed), the time of sample 
shaking/pulsing (Time of cycle), the number of times the sample is pulsed (Number of cycles) and the time between pulse 
cycles (Dwell).  Each organ sample was homogenised at their optimised settings with a specified amount of saline by 
mass to provide a homogenous liquid sample for accurate pipetting. 
 
After analysis, the organ sample concentrations were corrected for by the saline dilution during 
homogenation and density of the homogenate. Table 5-2 contains the mean density values as 
determined for three different animal samples and rounded correction values used. The final 
concentration was expressed as nmol/mg. For reference, a solution of 1 nmol/mg in water would 
equal 1 uM. 
Table 5-2: Organ densities and correction factor 
 Density (g/ml) Correction 
Liver 0.954 1.0 
Spleen 0.938 0.9 
Kidney 0.853 0.9 
Heart 0.969 1.0 
Lung 0.975 1.0 
Brain 0.862 0.9 
Blood 0.985 1.0 
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5.4.3 Final LC/MS/MS method 
Initial cross-validation of the method described in Chapter 4, section 4.4.2, page 133 in blank liver 
matrix showed that the extraction method and chromatography needed to be optimised due to 
increased background interference. The detailed results from the method optimisation is presented in 
Section 7.5.1, page 277. Briefly, the final liquid-liquid extraction method used 20 µl of homogenised 
organ sample with 20 µl of pH 3 universal buffer containing a structurally similar internal standard 
and 250 µl ethyl acetate. Gradient chromatography was performed on a Phenomenex® Kinetex C18 
(2.1 x 50 mm, 2.6 µm) reverse phase column at a flow rate of 400 µl/min with mobile phases 0.03% 
ammonium hydroxide (v/v) in water and acetonitrile. The lung, brain and spleen samples were 
analysed on an AB Sciex API 4500® mass spectrometer, and the heart, liver and kidney samples on 
an AB Sciex API 5500® mass spectrometer, both operated at unit resolution in multiple reaction-
monitoring mode.  
Due to the small organ volume obtained from each mouse, conservative efforts were required for 
calibration standards and final analysis. Method development was performed in higher volume liver 
homogenate and the final method was then implemented for the other organs. Calibration standards 
for GKFA16 and GKFA17 were prepared together with their metabolites; fusidic acid and 3-
ketofusidic acid. Each respective organ batch therefore contained all three experiments with one set 
of calibration standards to quantify GKFA16 and GKFA17, and their metabolites. In Table 5-3 is 
shown the accuracies (%Nom) of each organ batch with highest and lowest accuracy of the calibration 
curves of all parent and metabolite compounds with their stipulated range.  
Chapter 7: Experimental, section 7.5.3, page 277 presents the final quantification statistics of 
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Table 5-3: Accuracy of calibration curves 
 
GKFA16 GKFA17 Fusidic acid 3-Ketofusidic acid 
Range  
(ng/ml) 
Whole blood 83.1 – 117% 85.8 – 106% 82.5 – 111% 88.5 – 110% 10 – 5000 
Liver 83.5 – 115% 96.1 – 104% 94.2 – 107% 91.8 – 107% 50 – 2500 
Lungs 86.9 – 113% 93.3 – 115% 93.5 – 115% 86.0 – 103% 10 – 2500 
Spleen 91.0 – 106% 84.4 – 108% 87.4 – 104% 84.4 – 108% 10 – 2500 
Kidney 93.8 – 112% 82.0 – 113% 90.0 – 115% 89.9 – 113% 10 – 2500 
Brain 92.4 – 112% 93.9 – 111% 92.5 – 116% 94.0 – 112% 10 – 2500 
Heart 83.3 – 115% 81 – 116% 88.0 – 111% 91.4 – 108% 10 – 2500 
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5.4.4 Area under the curve calculations 
Concentration time profiles and area under the curve to infinity (AUC0-∞) were calculated in 
Microsoft Excel® 2013 by means of the linear trapezoidal rule from time 0 to the final concentration-
time point, and to infinity estimated by assuming log-linear decline.  
 
5.5 Results & Discussion 
5.5.1 LC/MS/MS method optimisation 
Organ concentrations of the compounds were quantified by a LC/MS/MS assay developed for a range 
of 10 – 2500 ng/ml, and liver tissue calibration curve for a range of 50 – 2500 ng/ml. Initial cross-
validation of the method described in Chapter 4, section 4.4.2, page 133 in blank liver matrix showed 
that the extraction method and chromatography needed to be optimised due to increased background 
interference. A new Phenomenex® Kinetex C18 column with adjusted gradient chromatography 
decreased the run time and improved separation. The extraction method was optimised for a liquid-
liquid extraction and improved separation. Figure 5-5 shows recovery of the analytes performed in 
triplicate, comparing methanol protein precipitation, liquid-liquid extraction using ethyl acetate and 
hexane as organic solvents followed by liquid-liquid extraction using ethyl acetate with universal 
buffer at different pH values to optimise best recovery and repeatability of extraction. The extraction 
trend of the two C-3 ester prodrugs showed better extraction at acidic pH while fusidic acid and the 
3-ketofusidic acid metabolite showed higher extraction at basic pH. Liquid-liquid extraction to 
compare the best pH for extraction used pH 10 and pH 3 universal buffers and ethyl acetate as organic 
solvent. Their respective calibration curves had similar recovery rates. Figure 5-6 contains 
representative calibration curves of fusidic acid at pH 3 and pH 10. The final extractions used pH 3, 
due to slightly better regression values of the calibration curves compared to pH 10 and a lower 
background observed for blank samples. Figure 5-7 contains the blank chromatograms of the original 
protein precipitation double blank sample, and liquid-liquid extracted liver blank samples, extracted 
at pH 3 and pH 10.  
 









Figure 5-5: Organic solvent and buffer optimisation for liquid-liquid extraction  
Extraction efficiency (related to an increase in analyte peak) of analytes extracted by protein precipitation extraction by 








































Figure 5-6: Calibration curves of pH 3 and pH 10 extraction 
Area counts versus concentration of standards prepared by liquid-liquid extraction at A: pH 3 and B: pH10. 
A:  pH = 3 
 R2 = 0.9913 
B:  pH = 10 
 R2 = 0.9803 




Figure 5-7: Double blank samples of different extraction methods 
Comparison of extraction methods effect on carry over by examining the maximum observed value of a double blank 
sample after injecting a high concentration of the respective analytes. The lowest observed carry over was observed for a 
liquid-liquid extraction using a pH3 buffer. 
XIC of +MRM (7 pairs): 604.369/527.400 Da ID: GKFA16 from Sample 11 (Liver_Dblank) of 09112014_batch01_GKFA-OrganPK_liver.wiff (Turbo ... Max. 3.4e4 cps.







































6.185.50 6.356.040.74 6.95 7.19
7.481.18 3.370.38 2.75 10.809.331.961.56 2.13 7.892.87 9.539.018.50 10.048.77 10.67
XIC of +MRM (10 pairs): 618.440/541.200 Da ID: GKFA17 from Sample 25 (pH10_Blank) of 04042015_liq-liq_noIS.wiff (Turbo Spray) Max. 4550.0 cps.







































XIC of +MRM (10 pairs): 618.440/541.200 Da ID: GKFA17 from Sample 5 (pH3_Blank) of 04042015_liq-liq_noIS.wiff (Turbo Spray) Max. 2650.0 cps.




























3.321.51 2.952.39 3.27 3.49
Methanol protein precipitation 
Maximum observed value = 34000 cps 
Liquid-liquid, pH 10 
Maximum observed value = 4550 cps 
Liquid-liquid, pH 3 
Maximum observed value = 2650 cps 




5.5.2 Bioanalytical method 
Developing an accurate LC/MS/MS method for the organ samples required an improved extraction 
method. A liquid-liquid extraction method was found to be sufficient for the samples, but could be 
refined to a solid phase extraction method as high background was still observed. Original 
expectations were that sensitivity would be the major challenge in quantification, but the lowest 
standard of these compounds still showed an intense peak at 10 ng/ml from a 20 µl diluted organ 
sample. More importantly, the greatest challenge for quantification was matrix effects from the organ 
samples that decreased precision and reproducibility. A known limitation of multiplex methods that 
evaluate a diverse polarity range of analytes and/or metabolites is that the gradient required to separate 
and elute analytes in an efficient run time increases the chances of matrix effects as a similarly large 
polarity range of endogenous background elutes with the analytes. Due to the small volume of blank 
matrix, conservative preparation was required for the calibration standards and a cassette analysis 
approach that depended on a multiplex assay to analyse respective organs from different experiments 
in the same batch was necessary. The multiplex method for these samples also remained a very 
convenient approach and is still recommended for future experiments to save on blank matrix and 
decrease run time.  
Another concern in quantification was determining the range of calibration curves. The liver had 
concentrations as high as 4000 ng/ml before correcting, while the other tissues showed much lower 
concentrations ranging between 10 – 1000 ng/ml. Therefore, choosing an ideal range for calibration 
standards when the concentrations of final samples are unknown is difficult and method development 
should aim to keep the range as wide as possible without losing the integrity of the accuracy and 
precision in quantification. 
Future suggestions for bioanalytical methods aimed at organ distribution studies include persisting 
with a multiplex assay to evaluate similar compounds in the same organ batch with care taken to 
assess and limit possible matrix effects. This includes starting method development with an optimised 
liquid-liquid or solid-phase extraction that will also preserve the LC/MS/MS instrument from 
contamination of the high background. Cross-validating organ tissues with a single surrogate organ 
tissue or whole blood was considered, but was not possible for these analytes as evident by the great 
diversity in respective organ calibration curves. Method development exclusively in liver homogenate 
with final methods transferred to other organs produced adequate results and should be similarly 
applied in future experiments. When selecting a final calibration curve range, it is important to keep 
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in mind that an improved extraction method will give similar sensitivity as whole blood extractions. 
It is also important to acknowledge the greater objective of preclinical screening, which includes 
identifying promising compounds that are expected to have high exposures. Emphasis on the lower 
range of quantification therefore becomes less important and a low concentration limit related to final 
in vivo concentration rather than instrument capability should be defined. 
 
5.5.3 Animal procedure 
Rinsing the organs with saline during organ harvest was performed to remove excess whole blood as 
the whole blood concentration could greatly influence results. This procedure poses its own 
limitations though, as the equilibrium between the vascular system and tissues can shift quickly to 
allow analytes to leach out into the saline. The animal procedures to harvest organs were therefore 
performed as efficiently as possible to minimise the time from initial cardiac puncture to flash 
freezing the samples, with an average of 12 minutes. It is important to note, however, that the 
respective analytes could be lost during this procedure resulting in lower observed concentration 
values in the tissues. 
 
5.5.4 Non-linear mixed effect modelling attempt and non-compartmental analysis 
compromise 
An initial five-compartment model starting with the metabolite data input as separate compartments 
did not work in the Monolix® software. Possible reasons for this included the complexity of the 
metabolic model where metabolism between fusidic acid, 3-ketofusidic acid and 3-epifusidic acid 
appeared to be reversible. The precision of the organ concentration data was not ideal considering the 
complexity of the organ harvesting and bioanalytical methods. Overall, the sparse data did not support 
the complexity of the model. Moreover, looking at the pharmacokinetic profiles, it seems the tissues 
equilibrated reasonably quickly with the central compartment, and therefore speculatively, there 
would not be much benefit in modelling the whole kinetics as opposed to calculating their relative 
exposures. Nonlinear mixed effects modelling (and the Monolix® software) are generally applied to 
population pharmacokinetic models, which are not as complex as tissue distribution models and 
require many more compartments and parameters. Concomitant estimation of all parameters from the 
current data was not feasible, and fixing some of the parameters appeared somewhat arbitrary without 
strong supporting evidence. Other software packages tailored for systems modelling include features 
and libraries aimed at assisting the researcher to fix parameters to reasonable values, and such 
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solutions may have proved more suitable for the interpretations of these results. However, these 
software packages are costly, require ad hoc training and were deemed outside of the scope of this 
project, especially when weighed against the objectives of fusidic acid repositioning where the mouse 
model was already found inappropriate for future evaluation.   
It was therefore chosen to evaluate and compare organ distribution of the analytes exclusively by 
NCA techniques and calculate the ratio between the observed concentrations in the different organs. 
The area under the terminal log-linear phase of the curve to infinity (AUC∞) was chosen for 
comparison. As discussed in previous chapters, there are many limitations to NCA and accuracy of 
the approximated AUC∞ to true area under the curve depends on the number of concentration-time 
points, the selected time points and whether log-linear decline is appropriate. Nevertheless, in this 
comparative situation, NCA was deemed the best option to obtain AUC∞, which is used to compare 
organ distribution in similar studies.219 
The sampling schedule for this experiment was aimed at evaluating the elimination phase and 
therefore excluded initial absorption. The initial plan was to use a modelling approach to supplement 
the lack of information on absorption in this experiment using data from the original whole blood 
pharmacokinetics. Since that approach proved unfeasible, as explained above, the lack of absorption 
phase was problematic for the NCA-based estimation of total AUC. In Figure 5-8 is shown the 
original whole blood pharmacokinetic profile of GKFA16 (oral 25 mg/kg) with the organ distribution 
whole blood pharmacokinetic profile of GKFA16 (oral 10 mg/kg) and respective semi-log plot to 
illustrate the loss of the absorption phase AUC and subsequent restriction in analysis. 
 
Figure 5-8: NCA limitations of organ distribution time points 
The concentration-time profile for Experiment 1 and 2 that evaluated blood pharmacokinetics and organ distribution 
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To overcome this limitation, the results are therefore not considered for the initial concentration time 
point and the values reported are not total AUC. In this analysis, only the terminal component of the 
AUC was considered, with the assumption that this is when the distribution to the tissues has reached 
an equilibrium with the whole blood. This assumption is supported by visual inspection of the 
pharmacokinetic profiles, which in a log-plot appear parallel in this terminal phase, and by the fact 
that the concentration ratios remain reasonably constant over time in this phase, as shown in Figure 
5-8.   
While this simplified approach prevented proper characterising of the absorption phase, it provided 
insight into the equilibrium between the concentrations after the transitory absorption phase, and one 
could argue that these values are closer to the steady-state equilibrium, which is therapeutically more 
relevant. 
 
5.5.5 Organ distribution profiles 
Figure 5-9 presents the linear pharmacokinetic plots of the fusidic acid, GKFA16 and GKFA17 
experiments for each respective organ with observations represented by crosses and the mean 
concentration by organ and analyte shown by a solid line of appropriate colour. Figure 5-10 contains 
the semi-log pharmacokinetic plots with similar format, omitting brain concentrations. Figure 5-11 
shows the respective AUC∞ values to compare exposures in relevant organs. 
In Figure 5-12 is shown the natural logarithmic function of respective organ AUC∞ to whole blood 
AUC∞ to visualise the magnitude of the partitioning exposure, i.e. AUC∞ above 0 represents 
partitioning into relevant organ and below 0 shows partitioning into whole blood. 
 




Figure 5-9: Linear organ distribution profiles 
Linear concentration time plots for the fusidic acid, GKFA16 and GKFA17 experiments stratified by experiment and organ. Individual observations are represented by crosses. Each 
metabolite is represented by a different colour, namely GKFA16; green, GKFA17; purple, fusidic acid (FA); red, 3-ketofusidic acid (k-FA); blue, and  3-epifusidic acid;  e-FA (yellow). 




Figure 5-10: Log-linear organ distribution profiles 
Log scaled organ distribution plots to better compare their pharmacokinetic profiles on a more convenient scale for the fusidic acid, GKFA16 and GKFA17 experiments stratified by 
experiment and organ. Individual observations are represented by crosses. Each metabolite is represented by a different colour, namely GKFA16; green, GKFA17; purple, fusidic acid (FA); 
red, 3-ketofusidic acid (k-FA); blue, and 3-epifusidic acid; e-FA (yellow). 



















Figure 5-12: Log ratio of organ to blood exposures
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The organ distribution results showed a high first pass effect for fusidic acid, GKFA16 and GKFA17. 
This rapid metabolism increased the exposure of 3-epifusidic acid resulting in the highest exposure 
of the rodent-specific metabolite in all organs. The high concentrations observed in the liver suggest 
that the compounds were well absorbed with GKFA17 administration showing the highest observed 
concentrations of fusidic acid and the respective C-3 prodrug. However, little of this exposure made 
it into systemic circulation as hepatic elimination reduced the percentage of observed active 
compound concentrations in whole blood to a concentration less than 2 nmol/mg, compared to the 
liver concentrations that were well above 2 nmol/mg. 
It is known that fusidic acid crosses the blood brain barrier by approximately 7%220 and the C-3 ester 
prodrugs investigated were found to be similarly poorly blood brain barrier permeable. The negligible 
concentrations observed could likely be from unavoidable whole blood contamination during brain 
harvesting and future experiments should examine cerebrospinal fluid instead. Further discussions 
exclude brain distribution of the compounds. 
Heart, spleen and lung concentrations were similar for the respective compounds suggesting their 
peripheral distribution to be non-discriminatory between these sites. The kidneys had the second 
highest concentrations of 3- epifusidic acid, which fits renal extraction of the compound. This was 
true for all analytes, except 3-ketofusidic acid and GKFA16, which had higher exposure ratios in the 
blood compared to the kidneys. This does not mean that GKFA16 and 3-ketofusidic acid are not 
renally cleared as the partitioning values only represent the compound’s affinity for kidney or whole 
blood tissue, not their final interaction.  
Caution should be applied in interpreting the results, as increased distribution or partitioning into 
tissues does not necessarily translate into efficacy. Organ distribution is the first barrier in reaching 
mycobacteria sites, but the increase in distribution could be due to binding of the compound to 
unwanted membranes etc. not allowing the compound to elicit an effect. 
Generally, the prodrugs preferentially partitioned into tissues more than blood, except for the kidney 
partitioning of GKFA16. This is a positive result that the prodrugs were effective in increasing 
distribution when compared to fusidic acid administration, where fusidic acid preferentially partitions 
into blood for all organs except the liver and kidney. The prodrugs also altered the trend of fusidic 
acid partitioning and a higher ratio of fusidic acid was observed for the spleen and heart tissues 
compared to blood. This is likely due to bioactivation of the better-distributed prodrugs in the organs 
releasing fusidic acid. This finding was unfortunately not observed for the lung tissue that carries the 
highest mycobacterium burden. Total lung exposure of the C-3 ester prodrugs compared to fusidic 
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acid did not show an improvement. The concentration time curves reveal that there was an initial high 
concentration of GKFA16 and GKFA17, but their rapid elimination did not sustain exposure in the 
lung.  
Future experiments should look at bound and unbound fraction of compounds in the organ tissue, as 
it is the unbound fraction that can elicit an effect against the mycobacteria. Compounds progressed 
to animal efficacy should attempt to repeat the organ distribution studies to compare infected vs. 
uninfected tissues which could show different exposures. 
  




In Table 5-4 is shown the summarised pharmacokinetic profiles of the active analytes, fusidic acid, 
3-ketofusidic acid, GKFA16 and GKFA17 of the three organ distribution experiments. 
 
Table 5-4: Summarised lung profiles of active analytes 
 






The aim of the prodrugs to improve the pharmacokinetic properties of fusidic acid including 
distribution was successful. The C-3 ester prodrugs showed improved partitioning into peripheral 
tissues compared to fusidic acid and showed a favourable fusidic acid ratio in the peripheral tissues 
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promising to pursue towards the repositioning of fusidic acid, despite the drawback of the high rodent 
specific metabolite exposures that limited analytical interpretation. The organ distribution study 
showed that the 3-epifusidic acid metabolite was present at highest concentrations in all organs and 
again highlighted the inappropriateness of the mouse model for further fusidic acid evaluation.  
The bioanalytical method development was challenging and could be improved significantly, but the 
found method was not found to be suitable to show the trends in partitioning and exposure that was 
required from this project. Future experiments could improve on the bioanalytical outcomes and find 
the optimised balance between accuracy and efficiency at a preclinical stage. 
Implementation of a mechanistic model for these compounds proved unfeasible due to the complexity 
of the metabolism and the limited information contained in the collected data, affected by 
quantification uncertainty due to the complicated experimental procedures and limited data points. It 
is therefore not possible to comment on the benefit of adding a modelling step, but it is advised that 
the difficulty in the implementation of a mechanistic model while characterising the pharmacokinetics 
may outweigh the advantages at this early preclinical stage. Further, the ability to extrapolate these 
animal results to humans are poor due to the rodent specific metabolism. A full-fledged mechanistic 
approach, supported by dedicated software may prove more feasible and yield results that are more 
accurate. However, future assessment in the use of these models should weigh the effort of 
implementation in a drug discovery screening cascade and aim to simplify solutions that can easily 
be applied to diverse compounds. 
The distribution results are a positive step in the objective of improving compound pharmacokinetics 
for tuberculosis as the results show rational drug design with renewed pharmacokinetic objectives 
can potentially rescue compounds with poor distribution properties. Increased screening of future 
drug leads while simultaneously expanding techniques to get closer to the site of mycobacterial 
infection, will aid in increasing existing knowledge of what is the ideal pharmacokinetics of a 









6.1 General objectives 
Overall, the results from this project added a positive level of interpretation of the potential drug-like 
properties of the analysed compounds, through means of their preclinical pharmacokinetic evaluation. 
Insights were gained into the murine pharmacokinetics of four antimalarial compounds, including a 
bioequivalence study, and two antituberculosis prodrugs and their metabolites. The individual studies 
were used as a foundation to compare NLME modelling techniques with traditional NCA, and expand 
the methods of this preclinical lab to include capsule dosing and organ distribution evaluation.  
 
Reflecting on the original objectives, adequate development of bioanalytical methods using 
LC/MS/MS quantification to evaluate pharmacokinetics of antimalarial and antituberculosis drug 
leads in mice preceded modelling evaluation, with suggestions on future improvement.  Expansion 
of pharmacokinetic methods as better screening tools for the evaluation of in-house compounds was 
successful, including capsule dosing, organ distribution studies for mechanistic pharmacokinetics, 
and simulating model results to evaluate PK/PD relationships and mouse to human translation. 
 
It was found that the implementation of simple general pharmacokinetic models with NLME aimed 
at preclinical evaluation was often straightforward. Considering the compounds analysed followed 
non-linear elimination, NLME would be more correct in interpreting clearance and volume. This 
improved half-life estimations and bioavailability due to improved calculations compared to NCA 
estimations on half-life and outdated bioavailability methods that utilise the trapezoidal rule. This is 
vital in compound screening and progression. Refining techniques to include organ distribution and 
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capsule dosing also had a positive impact and proved useful at compound screening with constructive 
feedback to improve compound optimisation that is paramount to drug discovery. 
 
6.2 Summary of compounds evaluated 
Pharmacokinetic evaluation of three benzoxazole amodiaquine analogues in mice revealed excellent 
pharmacokinetics with the best performing compound, DS23B, showing a bioavailability of 54% and 
half-life of 51 hrs. Simulated retrospective PK/PD relationships assisted by NLME modelling was 
simple and beneficial to project outcomes, guiding future compound optimisation of this series to 
improve pharmacokinetic properties for a time above IC50 drive in efficacy. Future studies should 
include pharmacokinetic sampling during efficacy assessment with the aim of including PK/PD 
analysis in one model. 
Evaluation of a cyclodextrin formulation study suggests a pH-dependent increase in solubility led to 
improved pharmacokinetic properties. NLME showed increased bioavailability and a less variable 
rate of absorption of the cyclodextrin complex that was beneficial to improving consistent compound 
exposures in mice. Still, the results displayed for both the formulation and active pharmaceutical 
ingredient mouse groups had high variability, making conclusions speculative. Suggested future 
studies should consider higher mouse numbers (n = 5) and increased sampling time points around the 
expected absorption phase. It is also recommended that capsule dosing be implemented for efficacy 
studies in the Plasmodium berghei infected mouse model, with simultaneous pharmacokinetic 
evaluation. Notwithstanding criticisms around this method, the undemanding implementation of the 
capsule dosage form will allow for advantageous PK/PD evaluation and improved accuracy and 
comparison of the results.  
Pharmacokinetic analysis of fusidic acid, its 3-ketofusidic acid metabolite and novel fusidic acid C-3 
ester prodrugs uncovered that the species-specific metabolite 3-epifusidic acid had a detrimental 
effect on compound exposure in mice. This rodent specific metabolite was retrospectively quantified, 
avoiding a repeat animal experiment. Organ distribution of the C-3 ester prodrugs showed improved 
absorption and tissue distribution of the C-3 ester prodrugs. These results support the original 
objective of the fusidic acid C-3 ester prodrugs to improve drug concentrations at the site of 
mycobacterial infection with the aim of repositioning fusidic acid for tuberculosis.  
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6.3 Non-linear mixed effects modelling compared to non-compartmental 
analysis 
It was found that implementing NLME modelling at an earlier stage in preclinical screening required 
little effort, once a standard set of pharmacokinetic models was developed. These models can be 
easily applied to future studies. Three basic models based on fundamental one-, two- and three- 
compartment models were implemented, and this model library was easily applicable to most data 
with only minor modifications necessary to some compounds. In terms of efficiency, straightforward 
compounds were faster to analyse by NLME compared to NCA, due to NLME automatically 
compiling individual profiles and analysing the data as a single set. This also had the advantage of 
increasing robustness of the data in the case where some mouse profiles were insufficient in statistical 
strength, such as the formulation study in Chapter 3, or data lacking essential elimination phase 
concentration-time points, e.g. the amodiaquine analogues presented in Chapter 2. The limitations of 
NCA became apparent when comparing bioavailability data, and 3 out of the 8 compounds studied 
showed a difference of up to 20% in bioavailability. 
This is an important consideration as preclinical screening is a process of elimination where the best 
compounds are progressed further in a resource limited screening cascade. A bioavailability estimate 
out by 20% is detrimental and could lose a potential clinical candidate to an inadequate lead.  
NLME modelling therefore added confidence in the pharmacokinetic interpretation and a level of 
decisiveness that will aid future screening.  
 
6.4 Limitations 
A concern of the results presented was the robustness of the bioanalytical methods used. In the scope 
of evaluating compounds at a preclinical level, the balance between accuracy of quantification and 
time spent on method development is shifted to be able to analyse more compounds in a short amount 
of time. The motivation behind this was that at a preclinical stage, objectives are limited to first assess 
trends and compare compounds to guide future decision-making. In hindsight, more effort could have 
been spent on the quantification methods to improve data precision. In terms of the quality of data, 
more accurate data are easier to input into NLME models with less strain on the analysis. The balance 
between time and effort of quantification methods should be reassessed in future studies. 
Modelling approaches were difficult to assess for the cyclodextrin formulation study presented in 
Chapter 3. This was a result of a minimal preliminary study design that did not provide adequate data 
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to draw concrete conclusions. Here the fundamental issue was the preclinical limitations set out in 
the original ethics protocol, with specified sampling times and animal numbers. These results will 
assist in future ethics applications to improve the animal experiment protocol. 
The tissue distribution studies were laborious and careful consideration is needed for which 
compounds to progress to tissue distribution evaluation. Since a mechanistic pharmacokinetic model 
for the fusidic acid compounds could not be implemented, the benefit of adding a modelling step at 
this stage in preclinical evaluation cannot be assessed. It was also found that the development of more 
sophisticated mechanistic models to analyse experiments can quickly become too complex and the 
additional effort could end up outweighing the advantages, especially considering potential poor 
extrapolation as in the case of the fusidic acid analogues. Future assessment should weigh the effort 
of implementation in a drug discovery screening cascade to the knowledge gained. A fully-fledged 
mechanistic model with dedicated software may prove more suitable and is likely to provide results 
that are more accurate, but it was deemed outside the scope of the current work. Future attempts 
should simplify the models with the goal that they can be easily applied to a diverse range of leads. 
 
6.5 Acknowledgment of the multidisciplinary approach 
It is fundamental to recognise that this project depended on a multidisciplinary approach that added 
strength to the results. For the benzoxazole amodiaquine study, efficacy data from the Swiss Tropical 
and Public Health Institute (Basel, Switzerland) was used retrospectively to evaluate PK/PD drivers 
and in vitro ADME results from the Drug Discovery and Development Centre (H3D), Cape Town 
(South Africa) added to the interpretation. The efforts of the Centre for Supramolecular Chemistry 
Research Centre, University of Cape Town (South Africa) aided in further formulation techniques to 
ensure uniform particle size for the cyclodextrin complex study and kinetic solubility from the ADME 
team clarified the pharmacokinetic results. The fusidic acid study had the advantage of metabolite 
identification from the Department of Chemistry, University of Cape Town (South Africa) before 
progressing to pharmacokinetic evaluation and is highly recommended. It meant knowledge was 
gained on which metabolites to expect and how to could plan accordingly with synthetic chemist to 
obtain the metabolite when compound pharmacokinetics showed it was vital to the understanding of 
the in vivo properties of fusidic acid.  
Future improvements should include an optimised screening cascade of these methods. It is suggested 
that in vitro ADME analysis precede in vivo evaluation with emphasis on adequate and consistent 
solubility as Chapter 2 and 3 showed. In vitro metabolite identification with recommendations on 
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transitions to include in the bioanalytical method is greatly supported by the findings in Chapter 4 
and will be a useful strategy for future evaluation. it is recommended that pharmacokinetics and 
pharmacodynamics of antimalarial drug leads should be evaluated simultaneously in one model with 
the aid of NLME modelling techniques. This will improve PK/PD interpretation and reduce animal 
experiments. This cascade is not advisable for antituberculosis leads due to the length of time required 
for the tuberculosis mouse model. In this case, it is recommended that pharmacokinetic evaluation 
proceed first and compounds with the most promising pharmacokinetic properties progressed to in 
vivo efficacy with additional pharmacokinetic sampling to confirm exposures. Chapter 5 suggests 
tissue distribution evaluation can be used as a problem-solving technique and the recommendation 
here is that it be reserved for compounds that have an inexplicable mismatch in pharmacokinetic and 
pharmacodynamic results. An intermediate assessment that focuses on quantifying lung and whole 
blood exposure, before evaluating other collected organs could be useful in increasing efficiency if 
bioanalytical methods are difficult to implement.  
In conclusion, the pharmacokinetic evaluation of these compounds was thoughtfully used and proved 
fundamental in asking and raising future questions about the current methods. They also proved 
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7 EXPERIMENTAL RECORDS 
7.1 Reagents and solvents 
Acetonitrile and methanol (Burdick and Jackson, LC-MS) were purchased from Honeywell 
International Inc. (Muskegon, MI, USA) and formic acid from Merck (Johannesburg, South Africa). 
Ammonium hydroxide solution, dimethyl sulfoxide (DMSO), polyethylene glycol (PEG), ethanol 
(EtOH), polypropylene glycol (PPG), hydroxypropyl methylcellulose (HPMC) were purchased from 
Sigma-Aldrich (Johannesburg, South Africa). All water used was purified by a Milli-Q reverse 
osmosis system from EMD Millipore (Microsep, Tygervalley, South Africa).  
 
7.2 Antimalarial benzoxazole amodiaquine analogues 
The experimental records for the “Chapter 2: Antimalarial benzoxazole analogues of amodiaquine” 
project (page 26) are presented in the following sections. 
 
7.2.1 LC/MS/MS Quantification 
A brief overview of the final LC/MS/MS method was presented in Chapter 2, section 2.4.2, on page 
34. Expanded sample preparation, instrumentation settings and quantification statistics are presented 
here. 
7.2.1.1 Sample preparation 
A protein precipitation method was used to extract samples at room temperature. An extraction 
volume of 20 µl of the thawed whole blood sample was precipitated with 240 µl acetonitrile solution 
containing 100 ng/ml structurally similar internal standard. The double blank samples were extracted 
with pure acetonitrile. Samples were vortexed for 1 minute and then centrifuged for 5 minutes at 10 
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000 rcf. A 200 µl volume of the resulting supernatant was transferred to a 96 well plate and dried 
under nitrogen and 100 µl of 20% acetonitrile (v/v) in 0.1% formic acid in water (v/v) added to each 
well. A 10 µl injection volume was used for LC-MS/MS quantification. 
7.2.1.2 Instrumentation 
Original LC/MS/MS analysis for DS23B, DS48B and DS50B was performed on an Agilent 1100 
series binary pump (Agilent, CA, USA) interfaced to an AB Sciex API 3200® mass spectrometer (AB 
Sciex, Ontario, Canada) with an electrospray ion (ESI) source. Subsequent 16 day repeat experiments 
of DS23B and DS50B was performed on an Agilent 1200 series binary pump (Agilent, CA, USA) 
interfaced to an AB Sciex API 4000Q® mass spectrometer (AB Sciex, Ontario, Canada) with an ESI 
source in positive mode. 
7.2.1.3 Mass spectrometer conditions 
Figure 7-1 shows the initial product ion scans (MS/MS) spectrum of the analytes and their most 




















Figure 7-1: Initial product ion scans of benzoxazole amodiaquine analogues 
The MS/MS scans of A; DS23B, B; DS48B and C; DS50B. The figure contains the compound structure and fragmentation 
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The final settings of the instrument for each of the benzoxazole analogues of amodiaquine are 
summarised in Table 7-1. 
Table 7-1: Mass spectrometer settings of benzoxazole amodiaquine analogues 
Source settings         
CUR  IS (kV) TEM (°C) GS1 GS2 
20 5500 500 60 40 
Compound settings Q1 Q3 Dwell DP EP CEP CE CXP 
  (Da) (Da) (msec) (V) (V) (V) (V) (V) 
DS23B Quant 408.182 98.0 150 45 9 25 50 1 
 Qual 408.182 337.1 150 70 12 10 50 7 
DS48B Quant 436.260 351.2 150 55 10 30 40 6 
 Qual 436.260 98.1 150 55 7 30 50 1 
DS50B Quant 382.219 72.0 150 45 11 10 45 1 
 Qual 382.219 337.0 150 65 8 10 30 7 
Note: CUR; curtain gas flow, IS; IonSpray voltage, TEM; Temperature, GS1; nebuliser gas, GS2; turbo-gas, Q1; first quadrupole, Q3; third quadrupole, 
Dwell; dwell time (time instrument records ion intensity of fragment), DP; declustering potential, EP entrance potential, CEP; collision cell exit 
potential, CE; collision energy, Quant; quantifier ion, Qual; qualifier ion. 
7.2.1.4 HPLC conditions 
Gradient chromatography shown in Table 7-2 and Table 7-3 was performed on a Waters Xterra™ 
MS C18 (2.1 x 30 mm, 3.5 µm) reverse phase column with mobile phases A; 0.03% ammonium 
hydroxide:water (v/v) and B; 0.03% ammonium hydroxide:acetonitrile (v/v). Carry over was 







Chapter 7: Experimental Records 
201 
 
Table 7-2: Gradient chromatography steps of DS23B and DS50B analogues 
Step Total Time (min) Flow Rate (µl/min) A (%) B (%) 
0 0 600 80 20 
1 1.5 600 80 20 
2 3 600 0 100 
3 4.9 600 0 100 
4 5 600 80 20 
5 10 600 80 20 
Mobile Phases A; 0.03% ammonium hydroxide:water (v/v) and B; 0.03% ammonium hydroxide:acetonitrile (v/v). 
 
Table 7-3: Gradient chromatography steps of DS48B 
Step Total Time (min) Flow Rate (µl/min) A (%) B (%) 
0 0 400 95 5 
1 0.3 400 95 5 
2 0.7 400 0 100 
3 4.0 400 0 100 
4 4.1 400 95 5 
5 7 400 95 5 
Mobile Phases A; 0.03% ammonium hydroxide:water (v/v) and B; 0.03% ammonium hydroxide:acetonitrile (v/v). 
7.2.1.5 Quantification 
Table 7-4 contains quantification statistics from the final batches analysed. 
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Table 7-4: Quantification statistics of benzoxazole amodiaquine analogues 
DS23B       
Sample Expected conc (ng/ml) Number 
Mean 





S6 9.77 2 of 2 10.1 0.189 1.87 104 
S5 39.1 2 of 2 34.3 1.73 5.06 87.6 
S4 156 2 of 2 166 2.64 1.59 107 
S3 625 2 of 2 645 21.5 3.33 103 
S2 2500 2 of 2 2460 206 8.38 98.4 
S1 5000 2 of 2 5010 65.8 1.31 100 
QC L 20 2 of 2 20 6.63 33.2 100 
QC M 2000 1 of 1 2040 N/A N/A 102 
QC H 4000 2 of 2 3910 1320 33.6 97.8 
DS48B       
S6 2 2 of 2 2.34 0.58 24.8 117 
S5 10 2 of 2 8.98 0.924 10.3 89.8 
S4 50 2 of 2 44.6 0.316 0.71 89.2 
S3 250 2 of 2 261 4.88 1.87 104 
S2 2500 2 of 2 2490 201 8.06 99.6 
S1 5000 2 of 2 5000 361 7.21 100 
QC L 10 2 of 2 11 3.07 28.0 110 
QC M 2000 2 of 2 2020 29.0 1.44 101 
QC H 4000 2 of 2 3800 304 7.99 95.1 
DS50B       
S6 9.766 1 of 1 11.2 N/A N/A 115 
S5 39.063 2 of 2 39.9 3.53 8.84 102 
S4 156.25 2 of 2 158 5.39 3.41 101 
S3 625 2 of 2 532 0.409 0.0769 85.1 
S2 2500 2 of 2 2630 231 8.79 105 
S1 5000 1 of 1 4910 N/A N/A 98.2 
QC L 19.5 1 of 1 19.8 N/A N/A 101 
QC M 2000 2 of 2 2250 67.2 2.99 113 
QC H 4000 2 of 2 3960 475 12.0 99.0 
Note: Standards S1-S6) were used for the calibration curves. Quality controls (QC) low (L), medium (M) and high (H). S.D.: Standard deviation 
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In Figure 7-2 is shown the respective calibration curves of the final analysed batches for the 
benzoxazole analogues of amodiaquine with their respective regression values. Quantification used 
quadratic regression of the analyte area/internal standard area vs concentration with 1/x weighting. 
All calibration curves showed regression above 0.990. 
 
A: DS23B 
R2 = 0.9992 
 




Figure 7-2: Calibration curves of benzoxazole amodiaquine analogues 
The calibration curve of A: DS23B, B: DS48B and C: DS50B constructed from calibration standards made in whole 
blood.  
B: DS48B 
R2 = 0.9985 
C: DS50B 
R2 = 0.9970 
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The low quality control samples of each analyte with respective internal standard is shown in Figure 
7-3. 
In Figure 7-4 is shown the blank samples injected after the highest concentration standard from the 
final batches analysed with their respective carry-over displayed. All samples showed carry-over less 
than the accepted 20% allowed. 
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C: DS50B 19.3 ng/ml 
 









Figure 7-4: Blank samples of benzoxazole amodiaquine analogues 
Integrated blank samples of A: DS23B. B: DS48B and C: DS50B. Respective carry over is shown and all fell below the accepted 20%.  
A: DS23B 
Peak area carry 
over = 12.3% 
B: DS48B 
Peak area carry 
over = 8.41% 
C: DS50B 
Peak area carry 
over = 5.30% 
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7.2.2 Animal records 
The animal experiments performed for the benzoxazole analogous of amodiaquine were described in 
Chapter 2, section 2.4.3, page 36. 
In Table 7-5 to Table 7-7 is shown the experimental record sheets of the animal experiments. They 
contain exact sampling times, summary of dosage formulations and animal weight and sex.  
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Table 7-5: DS48B 24 hr animal experiment 
Oral/IV dose - compound DS48B (24 hrs)        
Date:  24 April 2014   IV solution  Oral suspension  
Ethics no:  013/028         
Dose: Oral 20 mg/kg   Weighed: 2.48 mg Weighed: 2.52 mg 
Dose: IV 5 mg/kg   in 100 µL DMSO in 1000 µL 0.5% HPMC 
Collect 20 µL blood samples in heparin tubes, vortex, on ice 100 µL EtOH    
Freeze samples at -80°C    300 µL PEG 400    
      500 µL PPG    
Collection times          
  Mouse M1♂ IV M2♂ IV M3♂ IV M4♂ ORAL M5♂ ORAL M6♂ ORAL   
  Mass (g) 25.4 29.3 26.1 27.9 27.1 27.9   
  Volume (µL) 60 60 60 250 250 250   
  Dose time 08:31:00 08:33:00 08:35:00 08:44:00 08:45:00 08:46:00   
  5 min 08:38:00 08:40:00 08:38:00  - -  -   
  0.5 09:02:00 09:03:00 09:03:00 09:13:00 09:14:00 09:15:00   
  1 09:32:00 09:33:00 09:34:00 09:41:00 09:43:00 09:46:00   
  3 11:32:00 11:34:00 11:35:00 11:37:00 11:38:00 11:39:00   
  5 13:31:00 13:34:00 13:36:00 13:39:00 13:41:00 13:42:00   
  7 15:31:00 15:34:00 15:37:00 15:39:00 15:41:00 15:42:00   
  24 08:16:00 08:17:00 08:18:00 08:19:00 08:20:00 08:21:00   
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Table 7-6: DS23B 15 day animal experiment 
Oral/IV dose - compound DS23B (15 days)   
 Date:  18 November 2014    
 Ethics no:  013/028    
 Dose: Oral 10 mg/kg    
 Dose: IV 2.5 mg/kg    
 Collect 20 µL blood samples in heparin tubes, vortex, on ice 
 Freeze samples at -80°C    
IV solution  Oral suspension 
 Weighed: 1.27 mg Weighed: 0.82 mg 
 in 100 µL DMSO in 1000 µL 0.5% HPMC 
  100 µL EtOH     
  300 µL PEG 400    
  500 µL PPG    
 Collection times     
 M1♂ IV M2♂ IV M3♂ IV M4♀ ORAL M5♀ ORAL M6♀ ORAL 
Mass (g) 30.1 30.0 29.5 20.2 20.8 20.1 
Volume (µL)     60 60 60 150 150 150 
Dose 08:01:00 08:02:00 08:03:00 07:56:00 07:56:00 07:56:00 
5 min 08:06:00 08:07:00 08:08:00 - - - 
hr:         1 09:01:00 09:02:00 09:03:00 09:04:00 09:05:00 09:06:00 
3 11:01:00 11:02:00 11:04:00 11:05:00 11:06:00 11:07:00 
5 13:00:00 13:02:00 13:04:00 13:06:00 13:07:00 13:08:00 
8 16:01:00 16:01:00 16:04:00 16:06:00 16:07:00 16:09:00 
24 09:00:00 09:02:00 09:04:00 09:06:00 09:07:00 09:08:00 
27 12:02:00 12:03:00 12:05:00 - - - 
32 16:00:00 16:03:00 16:03:00 - - - 
48 09:00:00 09:01:00 09:02:00 09:06:00 09:10:00 09:11:00 
72 - - - 09:15:00 09:16:00 09:17:00 
96 - - - 08:13:00 08:14:00 08:15:00 
120 - - - 08:30:00 08:31:00 08:32:00 
144 - - - 09:27:00 09:28:00 09:29:00 
168 - - - 09:08:00 09:09:00 09:10:00 
192 - - - 07:32:00 07:33:00 07:34:00 
216 - - - 07:01:00 07:02:00 07:03:00 
240 - - - 10:01:00 10:02:00 10:03:00 
264 - - - 10:05:00 10:06:00 10:07:00 
288 - - - 07:03:00 07:04:00 07:05:00 
312 - - - 06:55:00 06:56:00 06:57:00 
336 - - - 07:47:00 07:48:00 07:49:00 
360 - - - 07:09:00 07:10:00 07:11:00 
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Table 7-7: DS50B 15 day animal experiment 
Oral/IV dose - compound DS50B (15 days)   
 Date:  19 November 2014   
 Ethics no:  013/028    
 Dose: Oral 10 mg/kg    
 Dose: IV 2.5 mg/kg    
 Collect 20 µL blood samples in heparin tubes, vortex, on ice 
 Freeze samples at -80°C    
IV solution  Oral suspension 
 Weighed: 1.27 mg Weighed: 1.51 mg 
 in 100 µL DMSO in 1000 µL 0.5% HPMC 
  100 µL EtOH    
  300 µL PEG 400    
  500 PPG    
 Collection times     
 M1♂ IV M2♂ IV M3♂ IV M4♀ ORAL M5♀ ORAL M6♀ ORAL 
Mass (g) 28.8 28.1 26.4 18.7 21.1 21.1 
Volume (µL)     60 60 60 150 150 150 
Dose 08:09:00 08:10:00 08:11:00 07:57:00 07:58:00 07:58:00 
5 min 08:14:00 08:15:00 08:16:00 - - - 
hr:         1 09:08:00 09:09:00 09:10:00 09:11:00 09:12:00 09:13:00 
3 11:09:00 11:11:00 11:12:00 11:13:00 11:14:00 11:15:00 
5 13:11:00 13:13:00 13:14:00 13:14:00 13:16:00 13:17:00 
8 16:13:00 16:14:00 16:15:00 16:17:00 16:18:00 16:19:00 
24 09:11:00 09:13:00 09:15:00 09:17:00 09:18:00 09:19:00 
27 12:07:00 12:08:00 12:09:00 - - - 
32 16:05:00 16:05:00 16:06:00 - - - 
48 09:04:00 09:05:00 09:06:00 09:12:00 09:13:00 09:14:00 
72 - - - 09:20:00 09:21:00 09:22:00 
96 - - - 08:20:00 08:21:00 08:22:00 
120 - - - 08:35:00 08:36:00 08:37:00 
144 - - - 09:34:00 09:35:00 09:36:00 
168 - - - 09:12:00 09:13:00 09:14:00 
192 - - - 07:40:00 07:41:00 07:42:00 
216 - - - 07:05:00 07:06:00 07:07:00 
240 - - - 10:05:00 10:06:00 10:07:00 
264 - - - 10:10:00 10:11:00 10:12:00 
288 - - - 07:10:00 07:11:00 07:12:00 
312 - - - 07:00:00 07:01:00 07:02:00 
336 - - - 07:50:00 07:51:00 07:52:00 
360 - - - 07:13:00 07:14:00 07:15:00 
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7.2.3 Individual concentration profiles & data analysis 
7.2.3.1 Non-compartmental analysis 
The summarised pharmacokinetic results of the formulation study were presented in Table 2-6 to 
Table 2-9, starting in section 2.5.3.1, page 73. The expanded individual results with individual raw 
concentration vs time data is presented below for in Table 7-8 and respective non-compartmental 
analysis results for each individual subject in Table 7-9 for DS23B, and similarly Table 7-10 and 
Table 7-11 for DS48B, and Table 7-12 and Table 7-13 for DS50B. 
Table 7-8: Individual concentrations (µM) of DS23B 
IV:          M1 M2 M3 Mean 
Time Conc (µM) Time Conc (µM) Time Conc (µM) Time (hr) Conc (µM) 
0.0833 8.43 0.0833 11.4 0.0833 9.83 0.0833 9.88 
1 3.9 1 4.09 1 3.63 1 3.87 
3 2.13 3 2.36 3.02 3.31 3.01 2.6 
4.98 0.454 5 0.588 5.02 0.569 5 0.537 
8 0.861 7.98 0.927 8.02 1.18 8 0.989 
25 0.61 25 0.726 25 1.12 25 0.82 
28 0.895 28 0.534 28 1.11 28 0.847 
32 0.517 32 0.522 32 0.64 32 0.56 
49 0.809 49 0.686 49 0.91 49 0.802 
P.O.:       M4 M5 M6 Mean 
Time Conc (µM) Time Conc (µM) Time Conc (µM) Time (hr) Conc (µM) 
1.13 1.52 1.15 4.12 1.17 1.67 1.15 2.44 
3.15 4.95 3.17 8.14 3.18 4.07 3.17 5.72 
5.17 4.56 5.18 7.7 5.2 3.29 5.18 5.18 
8.17 1.83 8.18 3.58 8.22 3.73 8.19 3.05 
25.2 1.9 25.2 2.77 25.2 1.82 25.2 2.16 
49.2 0.699 49.2 2.07 49.3 1.49 49.2 1.42 
73.3 1.39 73.3 0.682 73.4 0.895 73.3 0.988 
96.3 0.785 96.3 1.5 96.3 0.488 96.3 0.923 
121 0.287 121 0.74 121 0.319 121 0.449 
146 0.169 146 0.466 146 0.175 146 0.27 
169 0.155 169 0.192 169 0.153 169 0.167 
192 0.13 192 0.174 192 0.0907 192 0.132 
215 0.0581 215 0.166 215 0.119 215 0.114 
242 0.0657 242 0.0976 242 0.0878 242 0.0837 
266 0.0346 266 0.0951 266 0.0405 266 0.0567 
287 0.0238 287 0.0412 287 0.0419 287 0.0356 
311 0.0289 311 0.0387 311 0.0275 311 0.0317 
336 0.0179 336 0.0255 336 0.0244 336 0.0226 
359 0.0203 359 0.0225 359 0.0235 359 0.0221 
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Note: M1 represents individual mouse 1, M2 individual mouse 2 etc. M1 – M3 received intravenous (IV) doses and M4 
– M6 received oral (P.O.; per os) doses. 
Table 7-9: Non-compartmental analysis of DS23B 
IV M1 M2 M3 Mean S.E. 
Apparent half-life (h) 83.7 83.2 81.4 82.8 0.686 
Blood Clearance (ml/min/kg) 6.96 0.00233 6.57 4.51 2.26 
Vc (L/kg) 1.12 5.82 x 10-5 0.799 0.639 0.322 
Vss (L/kg) 16.6 6.67 20.3 14.5 4.08 
AUC0-inf (µM.min) 24400 7820 10000 14100 5190 
P.O. M4 M5 M6 Mean S.E. 
Apparent half-life (h) 48.1 47.2 51.3 48.9 1.27 
AUC0-inf (µM.min) 10400 17200 11400 13000 2120 
Note: IV; intravenous, P.O.; per os/oral, Vc; central volume, Vss; volume at steady state, AUC0-∞; area under the curve 
from time zero to infinity. Individual values corresponding to the same labelled raw concentration vs time data is 
represented with the calculated mean and standard error of the mean (S.E.). 
Table 7-10: Individual concentrations (µM) of DS48B 
IV:         M1 M2 M3 Mean 
Time Conc (µM) Time Conc (µM) Time Conc (µM) Time (hr) Conc (µM) 
0.117 1.68 0.117 1.72 0.05 2.29 0.0944 1.9 
0.517 0.853 0.5 0.564 0.467 0.874 0.494 0.764 
1.02 0.273 1 0.463 0.983 0.672 1 0.47 
3.02 0.404 3.02 0.346 3 0.459 3.01 0.403 
5 0.317 5.02 0.284 5.02 0.314 5.01 0.305 
7 0.236 7.02 - 7.03 0.136 7.02 0.186 
23.8 0.0849 23.7 0.0771 23.7 0.0798 23.7 0.0806 
P.O.:     M4 M5 M6 Mean 
Time Conc (µM) Time Conc (µM) Time Conc (µM) Time (hr) Conc (µM) 
0.483 0.415 0.483 0.296 0.483 0.326 0.483 0.346 
0.95 1.16 0.967 0.273 1 1.08 0.972 0.837 
2.88 1.1 2.88 0.603 2.88 1.19 2.88 0.964 
4.92 0.801 4.93 0.601 4.93 0.847 4.93 0.749 
6.92 0.764 6.93 0.541 6.93 0.75 6.93 0.685 
23.6 0.239 23.6 0.184 23.6 0.259 23.6 0.227 
Note: M1 represents individual mouse 1, M2 individual mouse 2 etc. M1 – M3 received intravenous (IV) doses and M4 
– M6 received oral (P.O.; per os) doses. 
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Table 7-11: Non-compartmental analysis of DS48B 
IV M1 M2 M3 Mean S.E. 
Apparent half-life (h) 9.72 9.21 9.59 9.51 0.153 
Blood Clearance (ml/min/kg) 32.6 28.2 32.5 31.1 1.45 
Vc (L/kg) 6.88 3.27 6.89 5.68 1.21 
Vss (L/kg) 24.3 23.9 24.2 24.2 0.122 
AUC0-inf (µM.min) 420 416 470 435 17.2 
P.O. M4 M5 M6 Mean S.E. 
Apparent half-life (h) 9.86 11.5 10.1 10.5 0.498 
AUC0-inf (µM.min) 1080 741 1120 983 122 
Note: IV; intravenous, P.O.; per os/oral, Vc; central volume, Vss; volume at steady state, AUC0-∞; area under the curve 
from time zero to infinity. Individual values corresponding to the same labelled raw concentration vs time data is 
represented with the calculated mean and standard error of the mean (S.E.). 
Table 7-12: Individual concentrations (µM) of DS50B 
IV:         M1 M2 M3 Mean 
Time Conc (µM) Time Conc (µM) Time Conc (µM) Time (hr) Conc (µM) 
0.0833 7.07 0.0833 10.2 0.0833 13.1 0.0833 10.1 
0.983 2.62 0.983 4.98 0.983 3.58 0.983 3.73 
3 2.17 3.02 3.64 3.02 2.53 3.01 2.78 
5.03 0.998 5.05 1.14 5.05 0.892 5.04 1.01 
8.07 0.903 8.07 1.03 8.07 1.05 8.07 0.996 
25 1.48 25 0.656 25.1 0.508 25 0.88 
28 0.449 28 0.416 28 0.497 28 0.454 
31.9 0.469 31.9 0.33 31.9 0.325 31.9 0.374 
48.9 0.484 48.9 0.312 48.9 0.467 48.9 0.421 
P.O.:       M4 M5 M6 Mean 
Time Conc (µM) Time Conc (µM) Time Conc (µM) Time (hr) Conc (µM) 
1.23 2.3 1.23 5.34 1.25 4.27 1.24 3.97 
3.27 3.4 3.27 4.95 3.28 6.72 3.27 5.02 
5.28 3.88 5.3 4.92 5.32 5.22 5.3 4.67 
8.33 2.61 8.33 3.12 8.35 3.8 8.34 3.18 
25.3 0.67 25.3 1.46 25.4 1.79 25.3 1.3 
49.2 0.593 49.3 0.983 49.3 0.913 49.3 0.83 
73.4 0.406 73.4 0.615 73.4 1.16 73.4 0.727 
96.4 0.213 96.4 0.523 96.4 0.336 96.4 0.357 
121 0.19 121 0.242 121 0.23 121 0.221 
146 0.0798 146 0.201 146 0.228 146 0.17 
169 0.0921 169 0.145 169 0.0936 169 0.11 
192 0.0785 192 0.0458 192 0.114 192 0.0793 
215 0.0714 215 0.0853 215 0.052 215 0.0695 
242  242 0.0331 242 0.0172 242 0.0252 
266  266 0.033 266  266 0.033 
Note: M1 represents individual mouse 1, M2 individual mouse 2 etc. M1 – M3 received intravenous (IV) doses and M4 
– M6 received oral (P.O.; per os) doses. 
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Table 7-13: Non-compartmental analysis of DS50B  
IV M1 M2 M3 Mean S.E. 
Apparent half-life (h) 36 22.2 32.1 30.1 4.12 
Blood Clearance (ml/min/kg) 1.43 1.57 0.734 1.24 0.259 
Vc (L/kg) 0.0394 0.0160 0.00296 0.0195 0.0107 
Vss (L/kg) 0.698 0.0914 0.0138 0.268 0.216 
AUC0-inf (µM.min) 4860 4530 10300 6570 1880 
P.O. M4 M5 M6 Mean S.E. 
Apparent half-life (h) 43.7 39.8 34.1 39.2 2.78 
AUC0-inf (µM.min) 6300 9790 11000 9050 1420 
Note: IV; intravenous, P.O.; per os/oral, Vc; central volume, Vss; volume at steady state, AUC0-∞; area under the curve 
from time zero to infinity. Individual values corresponding to the same labelled raw concentration vs time data is 
represented with the calculated mean and standard error of the mean (S.E.). 
7.2.3.2 Non-linear mixed effects modelling 
As described in Chapter 2, section 2.4.5, page 39 the benzoxazole analogues of amodiaquine and 
amodiaquine best fit a two-compartment model. The median values for the cohort are presented with 
their respective standard error and relative standard error determined by linearization of their Fischer 
information matrix. The fixed effects, covariate model, omega and sigma model values are shown in 
Table 7-14. 
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Table 7-14: Parameter estimations of benzoxazole amodiaquine analogues 
 DS23B DS48B DS50B Amodiaquine 
 Parameter s.e. (lin) r.s.e.(%) Parameter s.e. (lin) r.s.e.(%) Parameter s.e. (lin) r.s.e.(%) Parameter s.e. (lin) r.s.e.(%) 
Fixed effects:             
Foral 0.544 0.083 15 0.613 0.076 12 0.46 0.074 16 0.486 0.062 13 
ka (hr-1) 0.244 0.064 26 0.434 0.11 25 0.24 0.06 25 0.735 0.14 18 
V (L) 0.0179 0.003 17 0.178 0.04 22 0.0186 0.0028 15 0.11 0.015 13 
Cl (L/h) 0.00177 0.00013 7 0.0571 0.005 9 0.00251 0.00016 6 0.0838 0.0085 10 
Q (L/h) 0.00958 0.0015 16 0.317 0.079 25 0.0072 0.0017 23 0.142 0.024 17 
Vp (L) 0.0969 0.0071 7 0.533 0.073 14 0.102 0.007 7 0.239 0.032 13 
             
Covariate model:             
Beta Cl (tWEIGHT) 0.75 - - 0.75 - - 0.75 - - - - - 
Beta V (tWEIGHT) 1 - - 1 - - 1 - - - - - 
Beta Vp (tWEIGHT) 1 - - 1 - - 1 - -    
             
Parameter variability:             
Omega Foral 0.197 0.093 47 0 - - 0.253 - - 0 - - 
Omega ka 0 - - 0 - - 0.0603 0.65 1.09E+03 0 - - 
Omega V 0 - - 0 - - 0 - - 0 - - 
Omega Cl 0 - - 0 - - 0 - - 0.336 0.044 13 
Omega Q 0 - - 0 - - 0.461 - - 0 - - 
Omega Vp 0 - - 0 - - 0 - - 0 - - 
Sigma model:             
Proportional 0.335 0.026 8 0.322 0.036 11 0.308 0.0094 3 0.382 0.026 7 
Constant 0 - - 0 - - 0 - - 0 - - 
Note: Foral; bioavailability, ka; rate of absorption, V; central volume, Cl; clearance, Q; inter-compartmental clearance, Vp; peripheral volume. Standard error (s.e.) and relative standard error 
(r.s.e) expressed as a percentage of the population estimate were estimated by linearization of the Fisher information matrix. The covariate tWEIGHT is defined as the transformed log 
individual mass of each mouse, centred around the median of the cohort mass. Parameter values equal to zero are parameters that were excluded from the model based on their statistical 
insignificance as determined by -2LL. 
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Figure 7-5: Individual plots of the benzoxazole amodiaquine analogues 
The graphical diagnostic individual fit output of all individual mice for A: DS23B, B: DS48B, C: DS50B, D: 
Amodiaquine. The blue crosses represent the observed concentration data points from the experiment, the red stars 
represent the “censored” or below limit of quantification (BLQ) data and the green line represents the individual fit 
after parameter variability for respective individual mice are included. The population fit represented by the red line, 
is the median of the cohort of both the oral and intravenous groups. The individual parameters of each mice are shown 
in the yellow legend. 
 
7.3 Antimalarial aminopyridine in the form of its cyclodextrin inclusion 
complex 
The experimental records for the “Chapter 3: Aminopyridine in the form of its cyclodextrin 
inclusion complex” project (page 102) are presented in the following sections. 
 
7.3.1 LC/MS/MS 
A brief overview of the final LC/MS/MS method was presented in Chapter 3, section 3.4.2, page 
110. Expanded sample preparation, instrumentation settings and quantification statistics are 
presented below. 
7.3.1.1 Sample preparation 
A protein precipitation method was used to extract samples at room temperature. An extraction 
volume of 20 µl of the thawed whole blood sample was precipitated with 240 µl of a 100 ng/ml 
structurally similar internal standard solution in methanol, except for the double blank sample 
extracted with pure methanol. Samples were vortexed for 1 minute and then centrifuged for 5 
minutes at 10 000 rcf. A 200 µl volume of the resulting supernatant was transferred to a 96 well 
plate and dried under nitrogen and 100 µl of 5% acetonitrile (v/v) in 0.1% formic acid in water 
(v/v) added to each well. A 5 µl injection volume was used for LC-MS/MS quantification. 
7.3.1.2 Instrumentation 
LC-MS/MS analysis was performed on an Agilent 1200 series binary pump (Agilent, CA, USA) 
interfaced to an AB Sciex API 4000Q® mass spectrometer (AB Sciex, Ontario, Canada) with an 
electrospray ion (ESI) source in positive mode. 
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7.3.1.3 Mass spectrometer conditions 
Figure 7-6 shows the initial product ion scans (MS/MS) spectrum of the analyte and the most 
intense fragmentation illustrated. The settings of the apparatus are summarised in Table 7-14. 
 
 
Figure 7-6: Initial product ion scan of MMV017007 
The MS/MS scans of MMV017007. The figure contains the compound structure and fragmentation that relates to the 























Monoisotopic Mass  = 355.099061 Da
MMV017007 
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Table 7-15: Mass spectrometer settings of MMV017007 
Source settings         
CUR IS (KV) TEM (°C) GS1 GS2 
20 5500 400 60 40 
Compound settings Q1 Q3 Dwell DP EP CE CXP 
  (Da) (Da) (msec) (V) (V) (V) (V) 
007 Quant 355.983 277.0 150 116 10 49 18 
 Qual 355.983 190.0 150 116 10 87 10 
Note: CUR; curtain gas flow, IS; IonSpray voltage, TEM; Temperature, GS1; nebuliser gas, GS2; turbo-gas, Q1; first quadrupole, Q3; third 
quadrupole, Dwell; dwell time (time instrument records ion intensity of fragment), DP; declustering potential, EP entrance potential, CEP; collision 
cell exit potential, CE; collision energy, Quant; quantifier ion, Qual; qualifier ion. 
7.3.1.4 HPLC conditions 
Gradient chromatography steps shown in Table 7-16 was performed on a Phenomenex® Kinetex 
PFP (2.1 x 50 mm, 2.6 µm) reverse phase column with mobile phases A; 0.1% formic acid:water 
(v/v) and B; 0.1% formic acid:acetonitrile (v/v) at a flow rate of 200 µl/min, Table 7-16.  
Table 7-16: Gradient chromatography steps of MMV017007 
Step Total Time (min) Flow Rate (µl/min) A (%) B (%) 
0 0 200 95 5 
1 0.5 200 95 5 
2 2 200 0 100 
3 3.5 200 0 100 
4 3.6 200 95 5 
5 6.5 200 95 5 
The gradient steps used mobile phases A; 0.1% formic acid:water (v/v) and B; 0.1% formic acid:acetonitrile on a 
Phenomenex® Kinetex PFP (2.1 x 50 mm, 2.6 µm) reverse phase column. 
7.3.1.5 Quantification 
In Table 7-17 is shown the quantification statistics from the final batches measured for 
MMV017007. 
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Table 7-17: Quantification statistics of MMV017007 
MMV017007      
Sample Expected conc (ng/ml) Number 
Mean 





S7 4.12 2 of 2 4.08 0.413 10.1 99.1 
S6 12.3 2 of 2 11.5 0.185 1.61 93.4 
S5 37.0 2 of 2 42.1 0.888 2.11 114 
S4 111 2 of 2 105 7.39 7.02 94.9 
S3 333 2 of 2 325 11.4 3.50 97.7 
S2 1000 2 of 2 1010 86.4 8.54 101 
S1 3000 2 of 2 3000 117 3.90 99.9 
QC L 10 2 of 2 9.80 0.358 3.66 98.0 
QC M 2000 2 of 2 1160 56.8 4.89 96.8 
QC H 4000 2 of 2 2340 58.9 2.52 97.3 
Note: Standards (S1-S7) were used for the calibration curves. Quality controls (QC) low (L), medium (M) and high (H). 
 
The calibration curves of the final analysed batches for MMV017007 is shown in Figure 7-7. 
Quantification used quadratic regression of the analyte area/internal standard area vs concentration 
with 1/x weighting. A regression value of 0.9991 was achieved. 
 
Figure 7-7: Calibration curve of MMV017007 
MMV017007 
R2 = 0.9991 
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The blank sample injected after the highest concentration standard from the final batch analysed 
to display any signs of carry-over is shown in Figure 7-8. No carry-over was observed for the 
analyte. In Figure 7-9 is shown the integrated lowest quality control of MMV017 alongside its 
internal standard to display suitable peak to noise ratio for quantification. 
 
Figure 7-8: Blank sample of MMV017007 
MMV017007 
Peak area carry 
over = 0% 
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7.3.2 Animal experiment 
The animal experiments performed for the antimalarial aminopyridine project were described in 
Chapter 3, section 3.4.3.1, page 111. 
The experimental record sheet of the animal experiments is shown below in Table 7-18. It contains 
exact sampling times, summary of dosage formulations and animal weight and sex.  
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Table 7-18: MMV017007 formulation animal experiment 
Oral/IV dose - compound MMV017007 formulation       
Date: 29-Jul-15  IV solution   Oral capsules  
Ethics no: 013/028       Total mass of formulation   
Dose: Oral 5 mg/kg  Weighed: 1.24 mg  CapA001 543 µg 
Dose: IV 2.5 mg/kg  in 100 µL DMSO CapA002 498 µg 
     100 µL EtOH   CapA003 481 µg 
     300 µL PEG 400 CapB001 120 µg 
     500 µL PPG  CapB002 112 µg 
       CapB003 83.0 µg 
Mouse Mass (g) Dose (µg) Dose time 5 min 30 min 1 hr 3 hr 5 hr 8 hr 24 hr 
M1 IV♂ 31.3 74.4 08:07:00 08:13:00 08:37:00 09:07:00 11:06:00 13:06:00 16:05:00 07:30:00 
M2 IV♂ 31.0 74.4 08:10:00 08:14:00 08:38:00 09:09:00 11:07:00 13:08:00 16:06:00 07:32:00 
M3 IV♂ 29.0 74.4 08:11:00 08:14:00 08:39:00 09:10:00 11:09:00 13:09:00 16:07:00 07:33:00 
M4♀ Cap A 23.4 114 08:29:00 - 08:57:00 09:29:00 11:29:00 13:28:00 16:29:00 07:45:00 
M5♀ Cap A 23.0 105 08:32:00 - 08:58:00 09:31:00 11:31:00 13:29:00 16:31:00 07:46:00 
M6♀ Cap A 23.4 101 08:34:00 - 08:59:00 09:32:00 11:32:00 13:31:00 16:37:00 07:47:00 
M7♀ Cap B 23.9 120 08:48:00 - 09:18:00 09:46:00 11:48:00 13:47:00 16:34:00 07:49:00 
M8♀ Cap B 23.6 112 08:45:00 - 09:17:00 09:44:00 11:47:00 13:48:00 16:36:00 07:51:00 
M9♀ Cap B 24.5 83.0 08:47:00 - 09:18:00 09:46:00 11:49:00 13:49:00 16:36:00 07:52:00 
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7.3.3 Individual concentration profiles & data analysis 
7.3.3.1 Non-compartmental analysis 
The summarised pharmacokinetic results of the formulation study were presented in Table 3-3, 
starting in section 3.4.4, page 112. The expanded individual results with individual raw 
concentration vs time data is presented below in Table 7-19 and respective non-compartmental 
analysis results for each individual subject in Table 7-20 for both MMV017007 and its 
cyclodextrin inclusion complex, DMB·007. 
Table 7-19: Individual concentrations (µM) of 007 formulation experiment 
IV        
M1 M2 M3 Mean 
Time Conc (µM) Time Conc (µM) Time Conc (µM) Time (hr) Conc (µM) 
0.1 8.78 0.0667 7.34 0.05 9.82 0.0722 8.65 
0.5 7.03 0.467 6.42 0.467 7.43 0.478 6.96 
1 5.82 0.983 5.85 0.983 6.58 0.989 6.09 
2.98 5.77 2.95 4.98 2.97 5.26 2.97 5.34 
4.98 4.9 4.97 2.84 4.97 3.71 4.97 3.82 
7.97 2.93 7.93 1.84 7.93 2.62 7.94 2.46 
23.4 0.512 23.4 0.0554 23.4 0.195 23.4 0.254 
DMB·007       
M4 M5 M6 Mean 
Time Conc (µM) Time Conc (µM) Time Conc (µM) Time (hr) Conc (µM) 
0.467 0.0279 0.433 0.00872 0.417 0 0.439 0.0122 
1 0.0642 0.983 0.00816 0.967 0.00338 0.983 0.0252 
3 0.793 2.98 0.0146 2.97 0.298 2.98 0.369 
4.98 1.72 4.95 2.61 4.95 4.61 4.96 2.98 
8 1.34 7.98 2.61 8.05 2.95 8.01 2.3 
23.3 0.422 23.2 0.357 23.2 0.107 23.2 0.295 
007        
M7 M8 M9 Mean 
Time Conc (µM) Time Conc (µM) Time Conc (µM) Time (hr) Conc (µM) 
0.817 0.00394 0.75 0.0019 0.733 0.0112 0.767 0.00568 
1.28 0.0076 1.2 0.0022 1.2 0.00254 1.23 0.00411 
3.32 0.116 3.25 3.66 3.25 3.04 3.27 2.27 
5.3 0.712 5.27 3.1 5.25 2.58 5.27 2.13 
8.08 0.304 8.07 3.12 8.03 1.34 8.06 1.59 
23.3 0.0255 23.3 0.132 23.3 0.0257 23.3 0.061 
Note: M1 represents individual mouse 1, M2 individual mouse 2 etc. M1 – M3 received intravenous (IV) doses, M4 
to M6 received a single oral dose of DMB·007 in capsule formulation and similarly M7 to M8 received a single dose 
of MMV017007 in capsule formulation. 
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Table 7-20: Non-compartmental analysis of 007 formulation study 
IV M1 M2 M3 Mean S.E. 
Apparent half-life (h) 4.48 3.26 5.98 4.58 0.787 
Blood Clearance (ml/min/kg) 1.53 2.35 1.94 1.94 0.236 
Vd (L/kg) 0.844 0.644 0.717 0.735 0.0584 
AUC0-inf (µM.min) 4400 2870 3720 3670 443 
DMB·007 M4 M5 M6 Mean S.E. 
Apparent half-life (h) 9.45 5.58 3.34 6.12 1.79 
AUC0-inf (µM.min) 1670 2220 2490 2130 241 
007 M7 M8 M9 Mean S.E. 
Apparent half-life (h) 4.48 4.18 2.8 3.82 0.516 
AUC0-inf (µM.min) 317 2790 1530 1550 715 
Note: IV; intravenous, P.O.; per os/oral, Vc; central volume, Vss; volume at steady state, AUC0-∞; area under the curve 
from time zero to infinity. Individual values corresponding to the same labelled raw concentration vs time data is 
represented with the calculated mean and standard error of the mean (S.E.). 
7.3.3.2 Non-linear mixed effects modelling 
Table 7-21 and Table 7-22 presents the non-linear mixed effects model parameter estimates, 
typical values and variability of the random effects (on approximate %CV scale), together with 
their precision reported as standard error for separate and joint analysis of DMB·007 and 007 
respectively.  
As described in Chapter 3, section 3.4.5, page 113 several attempts to find an ideal non-linear 
mixed effects model that could describe the data were performed. The non-linear mixed model 
parameter estimates for the different approaches are presented in Table 7-21 to Table 7-22. The 
median values for the cohort are presented with their respective standard error and relative standard 
error determined by linearization of their Fischer information matrix. The fixed effects, covariate 
model, omega and sigma model values are shown in each table.  
The individual plots alongside population mean and parameter information of each subject is 
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Table 7-21: Parameter estimation of the separate data set model 
 DMB·007 007 
 Parameter s.e. (lin) r.s.e.(%) Parameter s.e. (lin) r.s.e.(%) 
Fixed effects:       
Foral 0.224 0.13 57 0.224 0.13 57 
ka (hr-1) 1.83 1.4 75 1.83 1.4 75 
V (L) 0.0266 - - 0.0266 - - 
Cl (L/h) 0.00402 - - 0.00402 - - 
Tlag (hr) 2.74 0.38 14 2.74 0.38 14 
       
Covariate Model:      
Beta Cl (tWeight) 0.75 - - 0.75 - - 
Beta V (tWeight) 1 - - 1 - - 
       
Parameter variability      
Foral 0.971 0.41 42 0.971 0.41 42 
ka 0.152 2 1.32E+03 0.152 2 1.32E+03 
V 0 - - 0 - - 
Cl 0.203 - - 0.203 - - 
Tlag 0.133 0.091 68 0.133 0.091 68 
       
Residual error (random error):     
Proportional 0.00211 0.01 481 0.00211 0.01 481 
Constant 0.201 0.031 16 0.201 0.031 16 
Note: Foral; bioavailability, ka; rate of absorption, V; central volume, Cl; clearance, Tlag; absorption delay time. 
Standard error (s.e.) and relative standard error (r.s.e) expressed as a percentage of the population estimate were 
estimated by linearization of the Fisher information matrix. The covariate tWeight is defined as the transformed log 
individual mass of each mouse centred around the median of the cohort mass. Parameter values equal to zero are 
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Table 7-22: Parameter estimation of the joint data set model 
 Parameter s.e. (lin) r.s.e.(%) p-value 
Fixed effects:     
Foral 0.249 0.11 46  
ka (hr-1) 0.815 0.23 28  
V (L) 0.0205 0.0007 3  
Cl (L/hr) 0.00351 0.00045 13  
Tlag (hr) 2.83 0.21 8  
     
Covariate Model:     
Beta Cl (tWeight) 0.75 - - - 
Beta V (tWeight) 1 - - - 
Beta Foral (formulation) -0.148 0.65 437 0.82 
Beta ka (formulation) 0.768 0.68 89 0.26 
Beta Tlag (formulation) -0.0249 0.15 589 0.87 
     
Parameter variability:     
Omega Foral 0.78 0.23 29  
Omega ka 0.0925 0.9 973  
Omega V 0 - -  
Omega Cl 0.35 0.089 25  
Omega Tlag 0.126 0.042 33  
     
Residual error:     
Proportional 0.00723 0.0046 64  
Constant 0.121 0.019 16  
     
Final experimental group parameters:    
Foral (DMB·007) 0.249 0.11 46  
Foral (007) 0.215 0.099 46  
ka (DMB·007) 0.815 0.23 28  
ka (007) 1.76 1.1 63  
Tlag (DMB·007) 2.83 0.21 8  
Tlag (007) 2.76 0.35 13  
Note: Foral; bioavailability, ka; rate of absorption, V; central volume, Cl; clearance, Tlag; absorption delay time. 
Standard error (s.e.) and relative standard error (r.s.e) expressed as a percentage of the population estimate were 
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estimated by linearization of the Fisher information matrix. The covariate tWeight is defined as the transformed log 
individual mass of each mouse centred around the median of the cohort mass. The parameters of the formulation and 
parent when modelled as categorical variables are represented in the final section of the table. Parameter values equal 
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Figure 7-10: Individual plots of the separate data model 
The graphical diagnostic individual fit output of all individual mice for the A: IV, B: DMB·007 and C: MMV017007 
API formulation. The blue crosses represent the observed concentration data points from the experiment and the green 
line represents the individual fit after parameter variability for respective individual mice are included. The population 
fit represented by the red line, is the median of the cohort of both the oral and intravenous groups. The individual 
parameters of each mice are shown in the yellow legend. 





























Preclinical pharmacokinetic evaluation of novel antimalarial and antituberculosis drug leads 
238  Natasha Strydom - April 2018 
A: IV formulation 
 
 
B: DMB·007 formulation 
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C: MMV017007 formulation 
 
 
Figure 7-11: Individual plots of joint data set model 
The graphical diagnostic individual fit output of all individual mice for the A: IV, B: DMB·007 and C: MMV017007 
API formulation. The blue crosses represent the observed concentration data points from the experiment and the green 
line represents the individual fit after parameter variability for respective individual mice are included. The population 
fit represented by the red line, is the median of the cohort of both the oral and intravenous groups. The individual 
parameters of each mice are shown in the yellow legend. 
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7.4 Fusidic acid prodrugs for potential repositioning in tuberculosis 
The experimental records for the “Chapter 4: Fusidic acid prodrugs for potential repositioning in 
tuberculosis” project (page 125) are presented in the following sections. 
 
7.4.1 LC/MS/MS 
A brief overview of the final LC/MS/MS method was presented in Chapter 4, section 4.4.2, on 
page 133. Expanded sample preparation, instrumentation settings and quantification statistics are 
presented in the sections below. 
7.4.1.1 Sample preparation 
A protein precipitation method was used to extract samples at room temperature. An extraction 
volume of 20 µl of the thawed whole blood sample was precipitated with 240 µl of a 100 ng/ml 
structurally similar internal standard solution in methanol, except for the double blank sample 
extracted with pure methanol. Samples were vortexed for 1 minute and then centrifuged for 5 
minutes at 10 000 rcf. A 200 µl volume of the resulting supernatant was transferred to a 96 well 
plate and dried under nitrogen, and 100 µl of 20% methanol (v/v) in 0.03% ammonium hydroxide 
in water (v/v) added to each well. A 5 µl injection volume was used for LC-MS/MS quantification. 
7.4.1.2 Instrumentation 
LC-MS/MS analysis was performed on an Agilent 1200 series binary pump (Agilent, CA, USA) 
interfaced to an AB Sciex API 4500® mass spectrometer (AB Sciex, Ontario, Canada) with an 
electrospray ion (ESI) source in positive mode. 
7.4.1.3 Mass spectrometer conditions 
Figure 7-12 shows the initial product ion scans (MS/MS) spectrum of the analytes and their most 
intense fragmentation illustrated. The settings of the apparatus are summarised in Table 7-23. 
Chapter 7: Experimental Records 































A: Fusidic acid 
B: 3-Ketofusidic acid 
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Figure 7-12: Initial product ion scans of fusidic acid compounds 
The MS/MS scans of A: fusidic acid, B: 3-ketofusidic acid, C: GKFA16 and D: GKFA17. The figure contains the 
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Table 7-23: Mass spectrometer settings of fusidic acid compounds 
Source settings         
CUR IS (KV) TEM (°C) GS1 GS2 
30 5500 350 30 50 
Compound settings Q1 Q3 Dwell DP EP CEP CE 
  (Da) (Da) (msec) (V) (V) (V) (V) 
Fusidic acid Quant 534.379 457.2 60 51 10 27 10 




Quant 532.323 455.2 60 86 10 17 14 
Qual 
532.323 437.2 60 86 10 27 14 
GKFA16 Quant 604.424 527.2 60 61 10 17 16 
 Qual 604.424 421.1 60 61 10 31 14 
GKFA17 Quant 618.440 541.2 60 60 10 17 16 
 Qual 618.440 421.1 60 60 10 29 14 
Note: CUR; curtain gas flow, IS; IonSpray voltage, TEM; Temperature, GS1; nebuliser gas, GS2; turbo-gas, Q1; first quadrupole, Q3; third 
quadrupole, Dwell; dwell time (time instrument records ion intensity of fragment), DP; declustering potential, EP entrance potential, CEP; collision 
cell exit potential, CE; collision energy, Quant; quantifier ion, Qual; qualifier ion. 
7.4.1.4 HPLC conditions 
Gradient chromatography shown in Table 7-24 was performed on a Phenomenex® Kinetex C18 
(2.1 x 50 mm, 2.6 µm) reverse phase column with mobile phases A; 0.03% ammonium 
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Table 7-24: Gradient chromatography steps of fusidic acid compounds 
Step Total Time (min) Flow Rate (µl/min) A (%) B (%) 
0 0 300 92 8 
1 1 300 92 8 
2 1.1 300 0 100 
3 4.5 300 0 100 
4 4.6 300 92 8 
5 11 300 92 8 
The gradient steps used mobile phases A; 0.03% ammonium hydroxide:water (v/v) and B; 0.03% ammonium 
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Table 7-25 to 7-32 presents the quantification statistics of the fusidic acid compounds. 
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Table 7-25: Quantification statistics of GKFA16 experiment 
GKFA16 experiment      
Fusidic acid      
Sample Expected conc (ng/ml) Number 
Mean 





S7 2 2 of 2 2.01 0.132 6.59 100 
S6 10 2 of 2 9.86 0.961 9.75 98.6 
S5 50 2 of 2 47 2.11 4.48 94 
S4 100 2 of 2 101 3.25 3.22 101 
S3 500 2 of 2 518 50.5 9.75 104 
S2 2500 1 of 1 2720 N/A N/A N/A 
S1 5000 2 of 2 4890 55.1 1.13 97.9 
QC L 6 1 of 1 7.35 N/A N/A 123 
QC M 2000 1 of 1 2200 N/A N/A 110 
QC H 4000 2 of 2 3740 86.6 2.32 93.5 
3-ketofusidic acid      
S7 2 2 of 2 2 0.429 21.4 100 
S6 10 1 of 1 10.1 N/A N/A 101 
S5 50 2 of 2 46.1 4.03 8.74 92.2 
S4 100 2 of 2 102 7.92 7.77 102 
S3 500 2 of 2 511 76 14.9 102 
S2 2500 1 of 1 2750 N/A N/A 110 
S1 5000 2 of 2 4880 232 4.75 97.7 
QC L 6 1 of 1 6.35 N/A N/A 106 
QC M 2000 1 of 1 2350 N/A N/A 118 
QC H 4000 2 of 2 3780 356 9.42 94.5 
GKFA16       
S7 2 2 of 2 2.03 0.417 20.5 102 
S6 10 1 of 1 8.49 N/A N/A 84.9 
S5 50 2 of 2 47.9 1.89 3.94 95.8 
S4 100 2 of 2 97.6 1.06 1.09 97.6 
S3 500 2 of 2 538 119 22.1 108 
S2 2500 1 of 1 2820 N/A N/A 113 
S1 5000 2 of 2 4860 137 2.83 97.1 
QC L 6 1 of 1 5.78 N/A N/A 96.3 
QC M 2000 1 of 1 2470 N/A N/A 123 
QC H 4000 2 of 2 4100 182 4.43 103 
Note: Standards (S1-S7) were used for the calibration curves. Quality controls (QC) low (L), medium (M) and high (H). 
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Table 7-26: Quantification statistics of GKFA17 experiment 
GKFA17 experiment      
Fusidic acid      
Sample Expected conc (ng/ml) Number 
Mean 





S7 2 2 of 2 2.01 0.404 20.1 100 
S6 10 1 of 1 9.66 N/A N/A 96.6 
S5 50 2 of 2 50.1 8.18 16.3 100 
S4 100 2 of 2 91.5 12 13.1 91.5 
S3 500 2 of 2 533 61.6 11.6 107 
S2 2500 2 of 2 2640 202 7.65 106 
S1 5000 2 of 2 4840 1180 24.4 96.8 
QC L 6 2 of 2 6.01 0.524 8.72 100 
QC M 2000 2 of 2 2240 401 17.9 112 
QC H 4000 2 of 2 4090 909 22.2 102 
3-Ketofusidic acid       
S7 2 1 of 1 1.74 N/A N/A 86.8 
S6 10 2 of 2 11.1 0.997 8.98 111 
S5 50 2 of 2 49 8.6 17.6 97.9 
S4 100 2 of 2 88.6 14 15.8 88.6 
S3 500 2 of 2 555 30.7 5.53 111 
S2 2500 2 of 2 2440 17.4 0.715 97.4 
S1 5000 1 of 1 5050 N/A N/A 101 
QC L 6 1 of 1 5.8 N/A N/A 96.7 
QC M 2000 1 of 1 1910 N/A N/A 95.6 
QC H 4000 2 of 2 3510 40.2 1.15 87.7 
GKFA17       
S7 2 2 of 2 2.11 0.0825 3.92 105 
S6 10 1 of 1 10.1 N/A N/A 101 
S5 50 2 of 2 48.8 3.67 7.52 97.6 
S4 100 2 of 2 96.7 9.24 9.55 96.7 
S3 500 2 of 2 499 0.0638 0.0128 99.8 
S2 2500 2 of 2 2510 66.2 2.64 100 
S1 5000 2 of 2 4990 339 6.79 99.9 
QC L 6 2 of 2 6.08 0.101 1.66 101 
QC M 2000 2 of 2 2220 34.4 1.55 111 
QC H 4000 2 of 2 4190 30.9 0.738 105 
Note: Standards (S1-S7) were used for the calibration curves. Quality controls (QC) low (L), medium (M) and high (H). 
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Table 7-27: Quantification statistics of fusidic acid experiment 
Fusidic acid experiment     
Fusidic acid      
Sample Expected conc (ng/ml) Number 
Mean 





S6 2 2 of 2 1.68 0.155 9.24 83.9 
S5 50 2 of 2 54.9 7.42 13.5 110 
S4 100 2 of 2 102 7.39 7.21 102 
S3 500 2 of 2 530 21.3 4.01 106 
S2 2500 2 of 2 2430 470 19.3 97.3 
S1 5000 2 of 2 5020 1760 35.1 100 
QC L 6 2 of 2 6.98 1.24 17.8 116 
QC M 2000 2 of 2 1960 599 30.5 98.2 
QC H 4000 2 of 2 3860 759 19.7 96.4 
3-ketofusidic acid      
S6 2 2 of 2 1.81 0.811 44.9 90.3 
S5 50 2 of 2 51.6 6.88 13.3 103 
S4 100 2 of 2 100 6 5.98 100 
S3 500 2 of 2 543 7.44 1.37 109 
S2 2500 2 of 2 2420 450 18.6 96.9 
S1 5000 2 of 2 5030 1500 29.8 101 
QC L 6 2 of 2 6.25 0.982 15.7 104 
QC M 2000 2 of 2 1970 639 32.5 98.5 
QC H 4000 2 of 2 3910 908 23.3 97.7 
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Table 7-28: Quantification statistics of 3-ketofusidic acid experiment 
3-Ketofusidic acid experiment    
3-Ketofusidic acid      
Sample Expected conc (ng/ml) Number 
Mean 





S7 2 2 of 2 2.01 0.123 6.09 101 
S6 10 2 of 2 9.86 2.94 29.8 98.6 
S5 50 2 of 2 44.3 9.07 20.5 88.5 
S4 100 2 of 2 98.5 2.74 2.78 98.5 
S3 500 2 of 2 552 50.2 9.1 110 
S2 2500 2 of 2 2710 392 14.5 108 
S1 5000 1 of 1 4500 N/A N/A 90 
QC L 6 2 of 2 6.19 1.1 17.8 103 
QC M 2000 2 of 2 2000 132 6.6 99.8 
QC H 4000 2 of 2 4240 524 12.4 106 
Fusidic acid      
S7 2 2 of 2 2.07 0.414 20 103 
S6 10 2 of 2 8.25 2.88 34.9 82.5 
S5 50 2 of 2 54.3 3.31 6.1 109 
S4 100 2 of 2 91.6 0.396 0.433 91.6 
S3 500 2 of 2 557 43.1 7.73 111 
S2 2500 2 of 2 2680 282 10.5 107 
S1 5000 1 of 1 4560 N/A N/A 91.2 
QC L 6 2 of 2 5.68 0.863 15.2 94.6 
QC M 2000 2 of 2 1990 138 6.93 99.4 
QC H 4000 2 of 2 4200 510 12.1 105 
Note: Standards (S1-S7) were used for the calibration curves. Quality controls (QC) low (L), medium (M) and high (H). 
 
In Figure 7-13 is shown the respective calibration curves of the final analysed batches for the 
fusidic acid compounds with their respective regression values. Quantification used quadratic 
regression of the analyte area/internal standard area vs concentration with specified weighting. 
All calibration curves showed regression above 0.98. 
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Figure 7-13: Calibration curves of fusidic acid analogues 
The calibration curve of A: Fusidic acid, B: 3-Keto-fusidic acid, C: GKFA16 and D: GKFA17 constructed from 
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The low quality control samples of each analyte with respective internal standard is shown in 
Figure 7-14. 
In Figure 7-15 is shown the blank samples injected after the highest concentration standard from 
the final batches analysed with their respective carry-over displayed. All samples showed carry-
over below the accepted 20% allowed. 
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C: GKFA16 (6 ng/ml) 
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D: GKFA17 (6 ng/ml) 
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Fusidic acid 
Peak area carry 
over = 0% 
3-Ketofusidic acid 
Peak area carry 
over = 0% 
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Figure 7-15: Blank samples of fusidic acid compound evaluation. 
 
GKFA16 
Peak area carry 
over = 0% 
GKFA17 
Peak area carry 
over = 0% 
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7.4.2 Animal experiment 
The animal experiments performed for the fusidic acid analogues were described in Chapter 4, section 
4.4.3.1, page 135. 
In Table 7-29 to Table 7-32 are shown the experimental record sheets of the animal experiments. 
They contain exact sampling times, summary of dosage formulations and animal weight and sex.  
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Table 7-29: Fusidic acid animal experiment 
Oral/IV dose - compound fusidic acid      
Date:   3 June 2014   IV solution  Oral suspension 
Ethics no: 013/032        
Dose: Oral 25 mg/kg Weighed: 1.25 mg Weighed: 2.35 mg 
Dose: IV 2.5 mg/kg  100 µL DMSO  1000 µL 0.5% HPMC 
    100 µL EtOH    
    300 µL PEG 400    
    500 µL PPG    
   Dose: 60 µL   Dose: 250 µL 
Mouse Weight (g) Dose time 5 min 30 min 1 3 5 7 
M1♂ IV 28.3 08:04:00 08:09:00 08:34:00 09:04:00 11:04:00 13:02:00 15:04:00 
M2♂ IV 29.2 08:05:00 08:10:00 08:36:00 09:05:00 11:08:00 13:05:00 15:10:00 
M3♂ IV 31.6 08:06:00 08:10:00 08:36:00 09:06:00 11:11:00 13:06:00 15:11:00 
M4♂ ORAL 26.4 08:17:00 - 08:47:00 09:17:00 11:14:00 13:17:00 15:17:00 
M5♂ ORAL 27.2 08:18:00 - 08:48:00 09:18:00 11:15:00 13:18:00 15:18:00 
M6♂ ORAL 25.4 08:19:00 - 08:49:00 09:19:00 11:16:00 13:19:00 15:19:00 
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Table 7-30: 3-Ketofusidic acid animal experiment 
Oral/IV dose – compound 3-ketofusidic acid      
Date:   30 Oct 2014   IV solution  Oral suspension  
Ethics no: 013/032         
Dose: Oral 20 mg/kg Weighed: 2.48 mg Weighed: 2.45 mg  
Dose: IV 5 mg/kg  100 µL DMSO  1000 µL 0.5% HPMC  
    100 µL EtOH     
    300 µL PEG 400     
    500 µL PPG     
   Dose: 60 µL   Dose: 180 µL  
Mouse Weight (g) Dose time 5 min 30 min 1 3 5 7 24 
M1♂ IV 28.1 08:04:00 07:13:00 07:18:00 07:44:00 08:14:00 10:14:00 12:14:00 15:11:00 
M2♂ IV 30.6 08:05:00 07:15:00 07:19:00 07:45:00 08:16:00 10:16:00 12:15:00 15:12:00 
M3♂ IV 29.1 08:06:00 07:16:00 07:20:00 07:46:00 08:18:00 10:18:00 12:16:00 15:14:00 
M4♀ ORAL 22.2 08:17:00 07:10:00 - 07:40:00 08:11:00 10:06:00 12:10:00 15:06:00 
M5♀ ORAL 21.8 08:18:00 07:10:00 - 07:41:00 08:12:00 10:08:00 12:11:00 15:08:00 
M6♀ ORAL 21.1 08:19:00 07:10:00 - 07:42:00 08:13:00 10:10:00 12:12:00 15:10:00 
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Table 7-31: GKFA16 animal experiment 
Oral/IV dose - compound GKFA16      
Date:   18 June 2014   IV solution  Oral suspension 
Ethics no: 013/032        
Dose: Oral 25 mg/kg Weighed: 1.25 mg Weighed: 2.47 mg 
Dose: IV 3 mg/kg  100 µL DMSO  1000 µL 0.5% HPMC 
    100 µL EtOH    
    300 µL PEG 400    
    500 µL PPG    
   Dose: 60 µL   Dose: 250 µL 
Mouse Weight (g) Dose time 5 min 30 min 1 3 5 7 
M1♂ IV 28.1 07:50:00 07:55:00 08:20:00 08:55:00 10:52:00 12:54:00 14:55:00 
M2♂ IV 26.4 07:51:00 07:56:00 08:21:00 09:27:00 10:53:00 12:55:00 14:58:00 
M3♂ IV 26.4 07:52:00 07:57:00 08:22:00 08:58:00 10:54:00 12:56:00 15:00:00 
M4♂ ORAL 24.3 07:44:00 - 08:14:00 08:44:00 10:48:00 12:48:00 14:51:00 
M5♂ ORAL 25.7 07:45:00 - 08:15:00 08:44:00 10:49:00 12:50:00 14:53:00 
M6♂ ORAL 26.4 07:45:00 - 08:16:00 08:46:00 10:50:00 12:52:00 14:54:00 
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Table 7-32: GKFA17 animal experiment 
Oral/IV dose - compound GKFA17      
Date:   18 June 2014   IV solution  Oral suspension 
Ethics no: 013/032        
Dose: Oral 25 mg/kg Weighed: 1.47 mg Weighed: 2.38 mg 
Dose: IV 3 mg/kg  100 µL DMSO  1000 µL 0.5% HPMC 
    100 µL EtOH    
    300 µL PEG 400    
    500 µL PPG    
   Dose: 60 µL   Dose: 250 µL 
Mouse Weight (g) Dose time 5 min 30 min 1 3 5 7 
M1♂ IV 27.8 08:47:00 08:52:00 09:18:00 09:47:00 11:44:00 13:48:00 15:46:00 
M2♂ IV 28.2 08:48:00 08:53:00 09:19:00 09:48:00 11:46:00 13:50:00 15:47:00 
M3♂ IV 25.6 08:49:00 08:54:00 09:20:00 09:48:00 11:47:00 13:52:00 15:48:00 
M4♂ ORAL 24.2 08:39:00 - 09:14:00 09:39:00 11:39:00 13:41:00 15:42:00 
M5♂ ORAL 21.6 08:40:00 - 09:15:00 09:40:00 11:41:00 13:43:00 15:43:00 
M6♂ ORAL 26.1 08:40:00 - 09:17:00 09:40:00 11:42:00 13:45:00 15:44:00 
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7.4.3 Individual concentration profiles & data analysis 
7.4.3.1 Non-compartmental analysis 
The summarised pharmacokinetic results of the formulation study were presented in Table 4-4 to 
Table 4-7, starting in section 4.5.3.1, page 144. The expanded individual results with individual raw 
concentration vs time data is presented below in   
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Table 7-33 to Table 7-40 for fusidic acid, 3-ketofusidic acid, GKFA16 and GKFA17 respectively. 
Similarly non-compartmental analysis results by compound are presented in Table 7-37 to Table 
7-40. 
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Table 7-33: Individual concentrations (µM) of fusidic acid experiment 
IV        
M1 Time (hr) 0.0833 0.5 1 3 4.97 7 
 Conc FA (µM) 3.51 0.804 0.372 - - - 
Conc k-FA (µM) 0.0146 0.0241 0.0309 - - - 
Conc e-FA (µM) 3.55 0.0605 0.0574 - - - 
M2 Time (hr) 0.0833 0.517 1 3.05 5 7.08 
Conc FA (µM) 1.66 0.539 0.304 0.161 0.0129 0.00448 
Conc k-FA(µM) 0.0103 0.01 0.00907 0.0458 0.0192 - 
Conc e-FA(µM) 1.68 0.0205 0.055 0.045 - 0.00322 
M3 Time (hr) 0.0667 0.5 1 3.08 5 7.08 
Conc FA(µM) 1.11 0.709 0.552 0.256 0.0351 0.0198 
Conc k-FA(µM) 0.00746 0.0245 0.0262 0.00174 0.0311 0.00614 
Conc e-FA(µM) 1.13 0.0874 0.0891 0.063 0.0432 - 
Mean Time (hr) 0.0778 0.506 1 3.04 4.99 7.06 
Conc FA(µM) 2.09 0.684 0.41 0.209 0.024 0.0121 
Conc k-FA(µM) 0.0108 0.0195 0.0221 0.0238 0.0251 0.00307 
Conc e-FA(µM) 2.12 0.0561 0.0672 0.054 0.0432 0.00161 
P.O        
M4 Time (hr)  0.5 1 2.95 5 7 
Conc FA(µM)  1.3 0.725 0.189 0.0758 0.0581 
Conc k-FA(µM)  0.229 0.189 0.0452 0.0532 0.0416 
Conc e-FA(µM)  5.1 0.924 0.0938 0.0886 0.0349 
M5 Time (hr)  0.5 1 2.95 5 7 
Conc FA(µM)  0.711 0.467 0.0328 0.0183 0.0191 
Conc k-FA(µM)  0.237 0.239 0.0252 0.0425 0.0249 
Conc e-FA(µM)  1.01 0.711 0.0256 0.0572 0.179 
M6 Time (hr)  0.5 1 2.95 5 7 
Conc FA(µM)  1.62 1.12 0.0537 0.0328 0.031 
Conc k-FA(µM)  0.272 0.305 0.0276 0.0829 0.0639 
Conc e-FA(µM)  1.7 1.52 0.045 0.0601 0.112 
Mean Time (hr)  0.5 1 2.95 5 7 
Conc FA(µM)  1.21 0.769 0.0917 0.0423 0.0361 
Conc k-FA(µM)  0.246 0.244 0.0327 0.0595 0.0434 
Conc e-FA(µM)  2.6 1.05 0.0548 0.0686 0.109 
Note: M1 represents individual mouse 1, M2 individual mouse 2 etc. M1 – M3 received intravenous (IV) doses and M4 
– M6 received oral (P.O.; per os) doses. 
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Table 7-34: Individual concentration (µM) of 3-ketofusidic acid experiment 
IV         
M1 Time (hr) 0.0833 0.517 1.02 3.02 5.02 7.97 24 
Conc k-FA(µM) 2.42 0.543 0.161 0.0132 0.00605 0.0103 0.00018 
Conc FA(µM) 0.0375 0.0097 0.00815 0.00517 0.00017 0.00325 - 
Conc e-FA(µM) 14.6 8.01 2.82 0.0957 0.0211 0.122 - 
M2 Time(hr) 0.0667 0.5 1.02 3.02 5 7.95 24 
Conc k-FA(µM) 1.9 0.471 0.121 0.0146 0.0299 0.0146 0.00035 
Conc FA(µM) 0.0163 0.00726 0.00879 0.00406 - 0.00071 - 
Conc e-FA(µM) 11.9 4.85 1.65 0.0726 0.138 0.154 - 
M3 Time (hr) 0.0667 0.5 1.03 3.03 5 7.97 24 
Conc k-FA(µM) 3.03 0.776 0.233 0.0256 0.0115 0.0359 0.00055 
Conc FA(µM) 0.042 0.0103 0.00623 0.00284 0.00023 0.0213 - 
Conc e-FA(µM) 16.4 8.99 2.31 0.174 0.027 0.128 0.0307 
Mean Time (hr) 0.0722 0.506 1.02 3.02 5.01 7.96 24 
Conc k-FA(µM) 2.45 0.597 0.172 0.0178 0.0158 0.0202 0.00036 
Conc FA(µM) 0.032 0.00909 0.00772 0.00403 0.00013 0.00842 - 
Conc e-FA(µM) 14.3 7.29 2.26 0.114 0.0619 0.135 0.0102 
P.O.         
M4 Time (hr)  0.5 1.02 2.93 5 7.93 24 
Conc k-FA(µM)  1.43 0.572 0.347 0.271 0.743 0.00152 
Conc FA(µM)  0.0221 0.00552 0.00515 0.00439 0.00915 - 
Conc e-FA(µM)  0.948 0.28 0.268 0.199 0.637 - 
M5 Time (hr)  0.517 1.03 2.97 5.02 7.97 24 
Conc k-FA(µM)  3.99 2.93 1.29 0.593 0.287 0.00206 
Conc FA(µM)  0.0656 0.0439 0.0107 0.00704 0.00447 - 
Conc e-FA(µM)  5.56 3 1.65 0.654 0.623 - 
M6 Time (hr)  0.533 1.05 3 5.03 8 24 
Conc k-FA(µM)  5 1.81 1.17 0.723 0.655 0.00764 
Conc FA(µM)  0.0884 0.0308 0.00952 0.009 0.0116 0.00025 
Conc e-FA(µM)  3.06 0.895 0.708 0.454 0.481 0.00058 
Mean Time (hr)  0.517 1.03 2.97 5.02 7.97 24 
Conc k-FA(µM)  3.47 1.77 0.935 0.529 0.562 0.00374 
Conc FA(µM)  0.0587 0.0267 0.00845 0.00681 0.0084 8.4E-05 
Conc e-FA  5.31 1.79 0.292 0.204 0.252 0.00019 
Note: M1 represents individual mouse 1, M2 individual mouse 2 etc. M1 – M3 received intravenous (IV) doses and M4 
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Table 7-35: Individual concentrations (µM) of GKFA16 experiment 
IV        
M1 Time (hr) 0.0833 0.517 1 2.95 5.02 6.98 
Conc(µM) GKFA16 2.45 1.05 0.813 0.153 0 0 
Conc(µM) FA 0.628 0.349 0.496 0.109 0.00698 0.00897 
Conc(µM) k-FA 0.00973 0.0109 0.0181 0.0214 0.00439 0.013 
Conc(µM) e-FA 0 0 0 0 0 0 
M2 Time (hr) 0.0833 0.517 1 2.97 5.03 6.98 
Conc(µM) GKFA16 3.08 0.998 0.608 0.107 - - 
Conc(µM) FA 0.721 0.378 0.372 0.229 0.00795 0.0215 
Conc(µM) k-FA 0.0204 0.0129 0.0225 0.0249 0.00472 0.00998 
Conc(µM) e-FA - - - 0.0168 - - 
M3  Time (hr) 0.0833 0.517 0.983 2.97 5.05 6.98 
Conc(µM) GKFA16 3.64 0.816 0.389 0.0662 - - 
Conc(µM) FA 0.44 0.19 0.136 0.194 0.0112 - 
Conc(µM) k-FA 0.00868 0.00806 0.0111 0.0245 0.00581 0.00305 
Conc(µM) e-FA - - - 0.0231 - - 
Mean Time 0.0833 0.517 0.994 2.96 5.03 6.98 
Conc(µM) GKFA16 3.06 0.953 0.603 0.108 - - 
Conc(µM) FA 0.596 0.306 0.335 0.177 0.00872 0.0102 
Conc(µM) k-FA 0.0129 0.0106 0.0172 0.0236 0.00497 0.00867 
Conc(µM) e-FA - - - 0.0133 - - 
P.O.        
M4 Time (hr)  0.583 1 3 5.03 7.05 
Conc(µM) GKFA16  3.7 1.13 0.0543 0.112 - 
Conc(µM) FA  1.26 0.316 0.0246 0.0386 0.0127 
Conc(µM) k-FA  0.19 0.105 0.0256 0.0835 0.0414 
Conc(µM) e-FA  1.13 0.3 0.00591 0.0236 0.00876 
M5 Time (hr)  0.583 1 3.02 5.05 7.05 
Conc(µM) GKFA16  4.01 1.79 0.059 0.0545 0.0273 
Conc(µM) FA  1.01 0.444 0.0164 0.00998 - 
Conc(µM) k-FA  0.118 0.125 0.0101 0.0268 0.0254 
Conc(µM) e-FA  0.488 0.444 - - 0.00517 
M6 Time (hr)  0.617 1 3.03 5.08 7.07 
Conc(µM) GKFA16  8.83 7.51 0.161 0.102 0.0487 
Conc(µM) FA  2.93 2.33 0.0359 0.0266 0.0172 
Conc(µM) k-FA  0.264 0.499 0.0208 0.0278 0.0342 
Conc(µM) e-FA  2.07 3.8 0.0122 0.00953 0.0103 
Mean Time (hr)  0.594 1 3.02 5.06 7.06 
Conc(µM) GKFA16  5.51 3.48 0.0915 0.0897 0.0253 
Conc(µM) FA  1.73 1.03 0.0256 0.025 0.00996 
Conc(µM) k-FA  0.191 0.243 0.0188 0.046 0.0337 
Conc(µM) e-FA  1.23 1.51 0.00602 0.0111 0.00809 
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Table 7-36: Individual concentrations (µM) of GKFA17 
IV        
M1 Time(hr) 0.0833 0.517 1 2.95 5.02 6.98 
Conc(µM) GKFA17 0.906 0.263 0.193 0.0526 0.00585 - 
Conc(µM) FA 0.572 0.215 0.185 0.134 0.00886 - 
Conc(µM) k-FA 0.00332 0.00365 0.00089 0.0162 - 0.00109 
Conc(µM) e-FA 0 0 0 0 0 0 
M2 Time(hr) 0.0833 0.517 1 2.97 5.03 6.98 
Conc(µM) GKFA17 0.821 0.207 0.232 0.0422 0.0113 - 
Conc(µM) FA 0.537 0.17 0.146 0.0808 0.0152 0.00812 
Conc(µM) k-FA 0.00109 - - 0.0109 0.0052 0.00114 
Conc(µM) e-FA - - - 0.0324 - - 
M3 Time(hr) 0.0833 0.517 0.983 2.97 5.05 6.98 
Conc(µM) GKFA17 1.04 0.197 0.215 0.0371 0.00812 - 
Conc(µM) FA 0.709 0.177 0.18 0.0868 0.0173 0.00959 
Conc(µM) k-FA 0.00402 0.00039 0.00305 0.0157 0.00437 0.00014 
Conc(µM) e-FA - - - 0.0446 0.0105 - 
Mean Time(hr) 0.0833 0.517 0.994 2.96 5.03 6.98 
Conc(µM) GKFA17 0.923 0.222 0.214 0.044 0.00842 - 
Conc(µM) FA 0.606 0.187 0.17 0.101 0.0138 0.0059 
Conc(µM) k-FA 0.00281 0.00135 0.00131 0.0143 0.00319 0.00079 
Conc(µM) e-FA - - - 0.0444 0.00351 - 
P.O.        
M4 Time(hr)  0.583 1 3 5.03 7.05 
Conc(µM) GKFA17  1.5 1.26 0.045 0.0116 - 
Conc(µM) FA  3.06 1.56 0.0422 0.0242 0.0112 
Conc(µM) k-FA  0.841 0.672 0.0359 0.0736 0.026 
Conc(µM) e-FA  10.5 5.66 0.0914 0.228 0.0464 
M5 Time(hr)  0.583 1 3.02 5.05 7.05 
Conc(µM) GKFA17  3.52 0.508 0.021 - - 
Conc(µM) FA  4.88 0.771 0.0271 0.0182 0.0225 
Conc(µM) k-FA  2.82 0.722 0.032 0.0487 0.0757 
Conc(µM) e-FA  19.3 3.78 0.0553 0.0727 0.165 
M6 Time(hr)  0.617 1 3.03 5.08 7.07 
Conc(µM) GKFA17  1.73 0.561 0.0726 - 0.0124 
Conc(µM) FA  2.34 0.473 0.1 0.0168 0.0145 
Conc(µM) k-FA  0.777 0.243 0.0652 0.0827 0.0522 
Conc(µM) e-FA  8.91 1.68 0.269 0.259 0.148 
Mean Time(hr)  0.594 1 3.02 5.06 7.06 
Conc(µM) GKFA17  2.25 0.776 0.0462 0.00387 0.00414 
Conc(µM) FA  3.43 0.935 0.0566 0.0197 0.016 
Conc(µM) k-FA  1.48 0.546 0.0444 0.0683 0.0513 
Conc(µM) e-FA  12.9 3.71 0.138 0.187 0.12 
Note: M1 represents individual mouse 1, M2 individual mouse 2 etc. M1 – M3 received intravenous (IV) doses and M4 
– M6 received oral (P.O.; per os) doses. 
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Table 7-37: Non-compartmental analysis of fusidic acid parent 
IV M1 M2 M3 Mean S.E. 
Apparent half-life (h) 1.1 0.286 1.07 0.819 0.267 
Blood Clearance 
(ml/min/kg)  53.1 42.8 47.9 4.22 
Vc (L/kg)  2.17 3.81 2.99 0.817 
Vss (L/kg)  7.22 5.54 6.38 0.686 
AUC0-inf (µM.min)  91.9 109 101 7.02 
P.O. M4 M5 M6 Mean S.E. 
Apparent half-life (h) 1.46 1.23 1.1 1.27 0.106 
AUC0-inf (µM.min) 135 66 146 116 25.1 
Note: IV; intravenous, P.O.; per os/oral, Vc; central volume, Vss; volume at steady state, AUC0-inf; area under the curve 
from time zero to infinity. Individual values corresponding to the same labelled raw concentration vs time data is 
represented with the calculated mean and standard error of the mean (S.E.). 
 
Table 7-38: Non-compartmental analysis of 3-ketofusidic acid parent 
IV M1 M2 M3 Mean S.E. 
Apparent half-life (h) 3.35 3.44 3.57 3.45 0.0636 
Blood Clearance 
(ml/min/kg) 125 138 83.4 116 16.6 
Vc (L/kg) 3.17 3.84 3.52 3.51 0.192 
Vss (L/kg) 45.3 36.7 32.4 38.1 3.79 
AUC0-inf (µM.min) 82 68.2 119 89.7 15.1 
P.O. M4 M5 M6 Mean S.E. 
Apparent half-life (h) 2.49 2.29 2.74 2.51 0.129 
AUC0-inf (µM.min) 591 747 918 752 94.3 
Note: IV; intravenous, P.O.; per os/oral, Vc; central volume, Vss; volume at steady state, AUC0-inf; area under the curve 
from time zero to infinity. Individual values corresponding to the same labelled raw concentration vs time data is 
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Table 7-39: Non-compartmental analysis of GKFA16 parent 
IV M1 M2 M3 Mean S.E. 
Apparent half-life (h) 0.627 0.681 0.925 0.744 0.0916 
Blood Clearance 
(ml/min/kg) 24 29.6 3.93 19.2 7.78 
Vc (L/kg) 0.257 0.689 0.886 0.611 0.186 
Vss (L/kg) 0.273 1.43 2.14 1.28 0.545 
AUC0-inf (µM.min) 196 169 133 166 18.2 
P.O. M4 M5 M6 Mean S.E. 
Apparent half-life (h) 0.415 1.12 0.907 0.814 0.209 
AUC0-inf (µM.min) 218 280 893 464 215 
Note: IV; intravenous, P.O.; per os/oral, Vc; central volume, Vss; volume at steady state, AUC0-inf; area under the curve 
from time zero to infinity. Individual values corresponding to the same labelled raw concentration vs time data is 
represented with the calculated mean and standard error of the mean (S.E.). 
Table 7-40: Non-compartmental analysis of GKFA17 parent 
IV M1 M2 M3 Mean S.E. 
Apparent half-life (h) 0.62 0.882 0.494 0.665 0.114 
Blood Clearance 
(ml/min/kg) 75.5 99.7 39.5 71.6 17.5 
Vc (L/kg) 0.55 2.01 0.14 0.903 0.566 
Vss (L/kg) 0.569 5.57 0.145 2.1 1.74 
AUC0-inf (µM.min) 64.5 48.2 136 82.9 26.9 
P.O. M4 M5 M6 Mean S.E. 
Apparent half-life (h) 0.935 1.52 1.58 1.34 0.206 
AUC0-inf (µM.min) 144 147 109 133 12.2 
Note: IV; intravenous, P.O.; per os/oral, Vc; central volume, Vss; volume at steady state, AUC0-inf; area under the curve 
from time zero to infinity. Individual values corresponding to the same labelled raw concentration vs time data is 
represented with the calculated mean and standard error of the mean (S.E.). 
7.4.3.2 Non-linear mixed effects modelling 
Expanded from the summarised results shown in Chapter 4, section 4.5.3, page 144, Table 7-41 
presents the non-linear mixed effects model parameter estimates.  
The median values for the cohort are presented with their respective standard error and relative 
standard error determined by linearization of their Fischer information matrix. The fixed effects, 
covariate model, omega and sigma model values are shown.  
. 
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Table 7-41: Parameter estimation of fusidic acid compounds 
 Fusidic acid 3-Ketofusidic acid GKFA16 GKFA17 
 Parameter s.e. (lin) r.s.e.(%) Parameter s.e. (lin) r.s.e.(%) Parameter s.e. (lin) r.s.e.(%) Parameter s.e. (lin) r.s.e.(%) 
Fixed Effects:             
Foral 0.124 0.032 26 3.03 0.68 22 0.435 0.15 35 0.445 0.064 14 
ka (hr-1) 2.58 1.4 54 0.408 0.079 19 18 25 138 3 - - 
V (L) 0.0529 0.014 26 0.0898 0.027 30 0.0334 0.0063 19 0.0969 0.016 16 
Cl (L/h) 0.0871 0.0098 11 0.232 0.039 17 0.0604 0.0066 11 0.201 0.017 9 
Q (L/h) 0.0505 0.017 34 0.0898 0.033 37 0.0216 0.015 71 0.0676 0.052 77 
Vp (L) 0.0748 0.017 22 0.248 0.073 29 0.0242 0.007 29 0.112 0.023 21 
Covariate model:             
Beta V(t_WT) 1 - - 1 - - 1 - - 1 - - 
Beta Cl (tWT) 0.75 - - 0.75 - - 0.75 - - 0.75 - - 
Beta Vp(t_WT) 1 - - 1 - - 1 - - 1 - - 
Parameter variability:            
Omega Foral 0.351 0.19 53 0 - - 0.547 0.27 50 0.0411 0.39 961 
Omega ka 0.0996 2.6 2.6E+03 0.165 0.19 116 1.06 1.2 110 0.19 0.31 164 
Omega V 0 - - 0 - - 0.0898 0.44 494 0 - - 
Omega Cl 0 - - 0.131 0.071 54 0.0877 0.13 144 0 - - 
Omega Q 0 - - 0 - - 1.48 0.58 39 1.71 0.66 39 
Omega Vp 0 - - 0 - - 0.156 1.5 979 0 - - 
Sigma model:             
Proportional 0.00345 0.0033 96 0 - - 0.00979 0.0076 78 0 - - 
Constant 0.405 0.069 17 0.498 0.063 13 0.322 0.11 35 0.303 0.034 11 
Note: Foral; bioavailability, ka; rate of absorption, V; central volume, Cl; clearance, Q; inter-compartmental clearance, Vp; peripheral volume. Standard error (s.e.) and relative standard error 
(r.s.e) expressed as a percentage of the population estimate were estimated by linearization of the Fisher information matrix. The covariate tWT is defined as the transformed log individual 
mass of each mouse, centred around the median of the cohort mass. Parameter values equal to zero are parameters that were excluded from the model based on their statistical insignificance 
as determined by -2LL. 
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In Figure 7-16, shown below, is the individual plots and parameter information of each subject. 
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Figure 7-16: Individual plots of fusidic acid compounds 
The graphical diagnostic individual fit output of all individual mice for A: fusidic acid, B: 3-keto-fusidic acid, C: 
GKFA16, D: GKFA17. The blue crosses represent the observed concentration data points from the experiment, the red 
stars represent the “censored” or below limit of quantification (BLQ) data and the green line represents the individual fit 
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after parameter variability for respective individual mice are included. The population fit represented by the red line, is 
the median of the cohort of both the oral and intravenous groups. The individual parameters of each mice are shown in 
the yellow legend. 
 
7.5 Organ distribution of fusidic acid prodrugs 
7.5.1 LC/MS/MS 
7.5.1.1 Sample preparation 
A liquid-liquid method was used to extract homogenized organ and whole blood samples on ice. A 
20 µl volume of 250 ng/ml structurally similar internal standard solution in pH 3 universal buffer was 
added to the thawed sample except for the double blank sample that did not contain any internal 
standard in the buffer added, and briefly vortexed. An extraction volume of 250 µl ethyl acetate was 
added and samples were vortexed for 1 minute to allow analytes to move into the organic phase and 
then centrifuged for 5 minutes at 10 000 rcf. A 200 µl volume of the resulting ethyl acetate organic 
layer was transferred to a 96 well plate and dried under nitrogen and 100 µl of 20% methanol (v/v) 
in 0.03% ammonium hydroxide in water (v/v) added to each well. A 5 µl injection volume was used 
for LC-MS/MS quantification. 
 
7.5.1.2 Mass spectrometer conditions and instrumentation 
Same as previously described in Section 7.4.1.1. 
7.5.1.3 HPLC conditions 
Gradient chromatography shown in Table 7-42 was performed on a Phenomenex® Kinetex C18 (2.1 
x 50 mm, 2.6 µm) reverse phase column with mobile phases A; 0.03% ammonium hydroxide:water 
(v/v) and B; 0.03% ammonium hydroxide:acetonitrile (v/v) at a flow rate of 400 µl/min. The resulting 
chromatogram in Figure 7-17 shows a representative chromatogram of a medium quality control 
spleen sample of the fusidic acid compounds.  
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Figure 7-17: Representative chromatogram of an organ sample 
Table 7-42: Gradient chromatography steps used for organ samples 
Step Total Time (min) Flow Rate (µl/min) A (%) B (%) 
1 0.0 400 80 20 
2 0.70 400 80 20 
3 1.00 400 0 100 
4 3.50 400 0 100 
5 3.60 400 95 5 
6 7.00 400 95 5 
XIC of +MRM (10 pairs): 534.379/457.200 Da ID: GKFA from Sample 59 (SYS) of 01052015_spleen_kinetixC18_001.wiff (Turbo Spray) Max. 2.4e6 cps.






























Retention time: 2.23 min 
3-Ketofusidic acid 
 Retention time: 2.04 min 
 
GKFA16 Retention time: 3.00 min 
 
   
GKFA17 Retention time: 3.04 min 
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G: Brain 10 ng/ml 
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7.5.1.4 Quantification 
Table 7-43 to Table 7-48 contains the quantification statistics of the organ assays, and shows 
representative calibration curves and blank samples from the final batches used for pharmacokinetic 
calculation. The low quality control samples of each analyte with respective internal standard is 
shown in Figure 7-14. 
 













FA       
S4 50 2 of 2 47.1 7.84 16.6 94.2 
S3 100 2 of 2 107 6.75 6.33 107 
S2 500 2 of 2 495 139 28.1 99 
S1 2500 2 of 2 2500 407 16.3 99.8 
k-FA       
S4 50 2 of 2 53.6 12.4 23.1 107 
S3 100 2 of 2 91.8 18.3 19.9 91.8 
S2 500 2 of 2 504 166 32.8 101 
S1 2500 2 of 2 2500 363 14.5 99.8 
GKFA16       
S4 50 2 of 2 57.3 3.32 5.78 115 
S3 100 2 of 2 83.5 3.29 3.94 83.5 
S2 500 2 of 2 508 126 24.8 102 
S1 2500 2 of 2 2490 284 11.4 99.8 
GKFA17       
S4 50 2 of 2 48.1 0.44 0.916 96.1 
S3 100 2 of 2 104 7.15 6.86 104 
S2 500 2 of 2 497 50.2 10.1 99.5 
S1 2500 2 of 2 2490 353 14.2 99.7 
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FA       
S5 10 2 of 2 9.16 2.42 26.4 91.6 
S4 50 2 of 2 57.9 0.339 0.585 116 
S3 100 2 of 2 92.4 6.45 6.98 92.4 
S2 500 2 of 2 500 46.1 9.22 100 
S1 2500 2 of 2 2500 250 10 99.8 
k-FA       
S5 10 2 of 2 9.69 2.63 27.2 96.9 
S4 50 2 of 2 58.3 0.648 1.11 117 
S3 100 2 of 2 85.1 8.57 10.1 85.1 
S2 500 2 of 2 506 71.6 14.2 101 
S1 2500 2 of 2 2500 227 9.09 99.8 
GKFA16       
S5 10 2 of 2 7.51 3.16 42 75.1 
S4 50 2 of 2 60.5 7.53 12.4 121 
S3 100 2 of 2 106 22.2 20.9 106 
S2 500 2 of 2 486 79.7 16.4 97.2 
S1 2500 2 of 2 2500 161 6.43 100 
GKFA17       
S5 10 2 of 2 8.77 1.32 15.1 87.7 
S4 50 2 of 2 60.3 5 8.29 121 
S3 100 2 of 2 91.6 6.8 7.42 91.6 
S2 500 2 of 2 499 66.8 13.4 99.7 
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FA       
S5 10 2 of 2 11 1.86 16.9 110 
S4 50 2 of 2 45.1 6.86 15.2 90.3 
S3 100 2 of 2 68.6 9.76 14.2 91.4 
S2 500 2 of 2 521 41.6 7.99 104 
S1 2500 2 of 2 2480 147 5.93 99.3 
k-FA       
S5 10 2 of 2 2.2 1.87 84.8 22 
S4 50 2 of 2 38.7 8.94 23.1 77.4 
S3 100 2 of 2 60.8 11.7 19.3 81.1 
S2 500 2 of 2 523 31 5.93 105 
S1 2500 2 of 2 2530 74.6 2.95 101 
GKFA16       
S5 10 2 of 2 1.93 1.54 80.1 19.3 
S4 50 2 of 2 39.9 8.37 21 79.9 
S3 100 2 of 2 66.9 12 18 89.2 
S2 500 2 of 2 571 20.8 3.64 114 
S1 2500 2 of 2 2370 62.3 2.63 94.8 
GKFA17       
S5 10 2 of 2 1.25 1.75 140 12.5 
S4 50 2 of 2 38.3 7.11 18.6 76.6 
S3 100 2 of 2 63.1 8.86 14 84.2 
S2 500 2 of 2 559 15.1 2.7 112 
S1 2500 2 of 2 2440 158 6.49 97.5 
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FA       
S5 10 2 of 2 9.38 0.665 7.09 93.8 
S4 50 2 of 2 53.7 16.1 29.9 107 
S3 75 2 of 2 74.5 1.91 2.56 99.4 
S2 500 2 of 2 497 99.9 20.1 99.3 
S1 2500 2 of 2 2480 665 26.8 99.4 
k-FA       
S5 10 2 of 2 9.62 0.16 1.66 96.2 
S4 50 2 of 2 53.6 18.2 33.9 107 
S3 75 2 of 2 72.6 0.446 0.614 96.8 
S2 500 2 of 2 499 95.7 19.2 99.7 
S1 2500 2 of 2 2490 726 29.2 99.4 
GKFA16       
S5 10 2 of 2 9.41 0.547 5.81 94.1 
S4 50 2 of 2 55.4 16.3 29.4 111 
S3 75 2 of 2 71.4 5.09 7.12 95.3 
S2 500 2 of 2 498 94.8 19 99.6 
S1 2500 2 of 2 2500 450 18 99.8 
GKFA17       
S5 10 2 of 2 9.51 2.03 21.3 95.1 
S4 50 2 of 2 56.7 27.3 48.2 113 
S3 75 2 of 2 68.4 2.33 3.4 91.3 
S2 500 2 of 2 500 55.8 11.2 100 
S1 2500 2 of 2 2490 501 20.1 99.7 
 
 
Preclinical pharmacokinetic evaluation of novel antimalarial and antituberculosis drug leads 
290  Natasha Strydom - April 2018 













FA       
S5 10 2 of 2 10.2 1.55 15.2 102 
S4 50 2 of 2 47 3.34 7.1 94 
S3 100 2 of 2 92.5 4.2 4.54 92.5 
S2 500 2 of 2 575 33 5.73 115 
S1 2500 2 of 2 2440 830 34 97.7 
k-FA       
S5 10 2 of 2 10.1 1.54 15.2 101 
S4 50 2 of 2 47.5 3.91 8.22 95.1 
S3 100 2 of 2 94.8 1.96 2.07 94.8 
S2 500 2 of 2 555 6.35 1.14 111 
S1 2500 2 of 2 2460 892 36.2 98.5 
GKFA16       
S5 10 2 of 2 10.2 0.295 2.9 102 
S4 50 2 of 2 46.2 1.58 3.41 92.4 
S3 100 2 of 2 95.8 3.71 3.87 95.8 
S2 500 2 of 2 563 39.1 6.94 113 
S1 2500 2 of 2 2450 763 31.2 97.9 
GKFA17       
S5 10 2 of 2 10.1 0.961 9.48 101 
S4 50 2 of 2 46.9 2.52 5.38 93.9 
S3 100 2 of 2 96.5 8.55 8.86 96.5 
S2 500 2 of 2 553 22.6 4.09 111 
S1 2500 2 of 2 2450 568 23.1 98.1 
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FA       
S4 10 2 of 2 11.1 3.24 29.3 111 
S3 50 2 of 2 44 9.57 21.7 88 
S2 500 2 of 2 505 127 25.1 101 
S1 2500 2 of 2 2490 504 20.2 99.7 
k-FA       
S4 10 2 of 2 10.8 2.88 26.7 108 
S3 50 2 of 2 45.7 7.44 16.3 91.4 
S2 500 2 of 2 504 85.4 17 101 
S1 2500 2 of 2 2490 443 17.8 99.8 
GKFA16       
S4 10 2 of 2 11.5 4.88 42.3 115 
S3 50 2 of 2 41.7 13.4 32.3 83.3 
S2 500 2 of 2 506 211 41.8 101 
S1 2500 2 of 2 2490 611 24.6 99.5 
GKFA17       
S4 10 2 of 2 11.6 4.91 42.2 116 
S3 50 2 of 2 41 13.8 33.6 82 
S2 500 2 of 2 506 212 41.9 101 
S1 2500 2 of 2 2480 740 29.8 99.3 
 
In Figure 7-19 is shown the respective calibration curves of the lung batch for the fusidic acid 
compounds with their respective regression values as example. Quantification used quadratic 
regression of the analyte area/internal standard area vs concentration with 1/x weighting. All 
calibration curves showed regression above 0.990. 
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The low quality control samples of fusidic acid for each batch with respective internal standard is 
shown in Figure 7-20. 
In Figure 7-21 is shown the blank samples injected after the highest concentration standard from the 
final batches analysed with their respective carry-over displayed. All samples showed carry-over 
below the accepted 20% allowed. 
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G: Brain 10 ng/ml 
 





Preclinical pharmacokinetic evaluation of novel antimalarial and antituberculosis drug leads 
302  Natasha Strydom - April 2018 
Fusidic acid 
Peak area carry 
over = 2.1% 
3-Ketofusidic acid 
Peak area carry 
over = 1.2% 
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Figure 7-21: Representative blank samples of organ distribution. 
GKFA16 
Peak area carry 
over = 1.3% 
GKFA17 
Peak area carry 
over = 3.0% 
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7.5.1.5 Individual concentrations 
Table 7-49: Mean concentration-time (nmol/mg) values of organ distribution experiments 
FA experiment   GKFA16 experiment   GKFA17 experiment   
Blood    Blood     Blood     
Time FA k-FA e-FA Time FA16 FA k-FA e-FA Time FA17 FA k-FA e-FA 
1.5 0.286 0.399 0.813 1.42 0.253 0.109 0.144 1.04 6.87 - 0.0101 0.0441 0.293 
3.64 0.238 0.199 0.583 3.47 0.0266 0.0429 0.175 1.76 5.25 0.00414 0.0128 0.15 0.779 
5.6 0.0634 0.0625 0.0747 5.19 0.0126 0.0162 0.0414 0.597 3.52 0.00814 0.0349 0.297 2.05 
6.95 0.0459 0.0266 0.155 7.35 0.014 0.0314 0.0355 0.167 1.7 0.0951 0.376 0.18 2 
              
Liver    Liver     Liver     
Time FA k-FA e-FA Time FA16 FA k-FA e-FA Time FA17 FA k-FA e-FA 
1.5 4.81 7.78 11.7 1.42 0.465 9.5 3.23 8.41 6.87 0.123 1.02 1.56 5.35 
3.64 6.19 6.65 10.9 3.47 0.245 1.87 2.06 7.18 5.25 0.758 2.58 6.98 10.1 
5.6 1.56 1.51 4.94 5.19 0.341 1.67 1.53 5.83 3.52 1.77 5.4 5.15 12.4 
6.95 0.348 0.68 2.84 7.35 0.0248 0.729 0.305 1.44 1.7 6.24 15 5.07 12.2 
              
Lungs    Lungs     Lungs     
Time FA k-FA e-FA Time FA16 FA k-FA e-FA Time FA17 FA k-FA e-FA 
1.5 0.222 0.0626 0.694 1.42 0.0456 0.0909 0.0184 0.226 1.7 0.0897 0.322 0.258 2.16 
3.64 0.0914 0.0412 0.363 3.47 0.391 0.0516 0.0219 0.466 3.52 0.0109 0.0471 0.0656 0.712 
5.6 0.0473 0.0261 0.217 5.19 - 0.0145 0.00965 0.112 5.25 0.00578 0.0302 0.0266 0.217 
6.95 0.0715 0.0682 0.114 7.35 0.00073 0.011 - 0.039 6.87 0.00733 0.0326 0.0151 0.089 
Chapter 7: Experimental Records 
Natasha Strydom - April 2018   305 
 
Kidneys    
 
Kidneys     
 
Kidneys     
Time FA k-FA e-FA Time FA16 FA k-FA e-FA Time FA17 FA k-FA e-FA 
1.5 0.268 0.0742 2.01 1.42 - 0.307 0.0673 0.847 6.87 0.0155 0.0324 0.0289 0.28 
3.64 0.0971 0.0487 0.879 3.47 - 0.148 0.102 1.02 5.25 0.0179 0.0431 0.045 0.95 
5.6 0.0481 0.0316 0.404 5.19 0.00066 0.0562 0.0427 0.333 3.52 0.0263 0.076 0.0601 1.55 
6.95 0.0303 0.0316 0.284 7.35 - 0.0323 0.0251 0.107 1.7 0.138 0.437 0.0803 2.69 
              
Brain    Brain     Brain     
Time FA k-FA e-FA Time FA16 FA k-FA e-FA Time FA17 FA k-FA e-FA 
1.5 0.0283 0.0113 0.0572 1.42 0.0402 0.0248 - 0.00901 6.87 0.00932 0.00696 - - 
3.64 0.0103 0.0064 0.0147 3.47 0.0371 0.0101 - 0.0224 5.25 0.00989 0.00437 0.0016 0.00413 
5.6 0.0126 - 0.0157 5.19 0.0143 0.0145 0.0011 0.0254 3.52 0.0122 0.0158 0.00807 0.0185 
6.95 0.0172 - 0.0135 7.35 0.00509 0.0124 - 0.0028 1.7 0.0408 0.014 0.00473 0.028 
              
Spleen    Spleen     Spleen     
Time FA k-FA e-FA Time FA16 FA k-FA e-FA Time FA17 FA k-FA e-FA 
1.5 0.162 0.122 0.359 1.42 0.0767 0.108 0.0402 0.27 6.87 - 0.0397 0.095 0.265 
3.64 0.108 0.119 0.295 3.47 0.0481 0.0339 0.0371 0.263 5.25 0.0116 0.0403 0.0596 0.218 
5.6 0.0941 0.0854 0.235 5.19 0.0418 0.015 0.0143 0.0834 3.52 0.167 0.247 0.553 1.79 
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Time FA k-FA e-FA Time FA16 FA k-FA e-FA Time FA17 FA k-FA e-FA 
1.5 0.295 0.305 1.61 1.42 0.386 0.144 0.0767 1.16 6.87 0.0219 0.0365 0.06 0.227 
3.64 0.0899 0.14 0.694 3.47 0.044 0.0348 0.0481 0.728 5.25 0.027 0.0327 0.098 0.591 
5.6 0.086 0.114 0.567 5.19 0.0317 0.0398 0.0418 0.449 3.52 0.0428 0.0549 0.213 1.78 
6.95 0.0322 0.0523 0.201 7.35 0.0214 0.0301 0.0274 0.0895 1.7 0.532 0.275 0.198 2.62 
Note: All concentration values expressed as nmol/mg and time in hrs  
 
Table 7-50: AUC∞ values (min.nmol/mg) of organ distribution studies 
FA experiment GKFA16 experiment GKFA17 experiment 
 FA k-FA e-FA  FA16 FA k-FA e-FA  FA17 FA k-FA e-FA 
Blood 85.1 96.8 234 Blood 46.6 24 72.1 405 Blood 11.4 49.1 71.4 551 
Liver 1850 2520 4240 Liver 119 1550 791 2590 Liver 936 2570 1960 4700 
Lungs 83.5 16.7 207 Lungs 49.3 22.9 5.52 96.6 Lungs 12.3 43.7 40.2 340 
Kidneys 88 41.6 627 Kidneys 38.6 84.2 34.1 682 Kidneys 34.1 79 30.2 645 
Brain 12.6 2.34 13 Brain 30.9 4.67 1.77 6.1 Brain 7.83 4.37 1.69 5.94 
Spleen 48.8 55.8 177 Spleen 45.3 390 93.4 376 Spleen 44.3 56.3 87.5 359 
Heart 69.2 107 433 Heart 57.3 39.4 28.5 268 Heart 74.8 7.41 68.2 560 
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